PAR DRUGS AND CHEMICALS LIMITED

Registered Office :
815, Nilamber Triumph, Gotri-Vasna Road, Vadodara - 390 007. Gujarat (INDIA).
Ph. : +91-265-2991021 / 2991022

Email : admin@pardrugs.com **CIN No. :** L24117GJ1999PLC035512

www.pardrugs.com

PAR/CS/NSE/2026-27/18

Date: 03/09/2026

To,
The Manager
Listing department,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra (E),
Mumbai- 400 051
Maharashtra

Subject: Annual Report for the Financial Year 2025-26 and Notice convening the 27th Annual General Meeting

Ref.: Symbol- PAR, ISIN: INE04LG01015

Dear Sir/Madam,

Pursuant to Regulation 30, Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Annual Report of the Company for the Financial Year 2025-26 along with Notice convening the 27th Annual General Meeting, scheduled to be held on Saturday, 26th Day of September, 2026 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India. The Company has sent the AGM Notice & Annual Report on September 03, 2026 through electronic mode to the members whose email addresses are registered with the Company/Depositories/Share Transfer Agent and whose name available in the register of members of the Company as on Friday, August 21, 2026 in accordance with regulation 36 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in compliance with the applicable provisions of the Companies Act, 2013 as amended time to time. The Annual Report for the F.Y. 2025-26 is also available on the Company's website at www.pardrugs.com

Kindly take on the record and acknowledge the receipt.

Yours Faithfully,
For PAR DRUGS AND CHEMICALS LIMITED

SANKET BHUPENDRA BHAI TRIVEDI
Digitally signed by SANKET BHUPENDRABHAI TRIVEDI
Date: 2026.09.03 15:04:35 +05'30'

PAR DRUGS AND CHEMICALS LIMITED GUJARAT

(Sanket B. Trivedi)
Company Secretary & Compliance Officer
Encl: As above

Guided by Responsibility

DRUGS AND CHEMICALS LIMITED

CIN: L24117GJ1999PLC035512

Annual Report 2025-26

Table of Contents

Corporate Information

Board of Directors

Mr. Falgun Vallabhbhai Savani
Chairman & Managing Director

Mr. Jignesh Vallabhbhai Savani
Executive Director & CEO

Mr. Pravin Manjibhai Bhayani
Independent Director

Mrs. Krishna Mitulbhai Shah
Independent Director

Mrs. Kajal Chintanbhai Vaghani
Independent Director

Mrs. Bintal Bhaveshkumar Shah
Independent Director

Key Managerial Personnel

Mr. Chintan P. Chauhan
Chief Financial Officer
(E-mail: cfo.par@pardrugs.com)

Mr. Sanket B. Trivedi
Company Secretary & Compliance Officer
(E-mail: cs.sanket@pardrugs.com)

Registered Office

815, Nilamber Triumph,
Gotri Vasna Road,
Vadodara-390007,
Gujarat, India.
Phone: 0265-2991021 / 0265-2991022.
E-mail: investors@pardrugs.com.
Website: www.pardrugs.com

Factory Unit
333/1, G.I.D.C. Industrial Estate, Phase-II, Chitra,
Bhavnagar-364004.
Phone: 0278-2447013

Statutory Auditor

Sarupria Somani & Associates, Chartered Accountants
602, Victoria Corporate, Opp. Gulista Ground, Sony Show Room Lane, Vadodariya Park, Bhavnagar.
Gujarat-364001,
Email : somanibvn@gmail.com

Secretarial Auditor

DG Patel & Associates
Practicing Company Secretaries,
204, Imperial Arc, Opp. University Gate, Waghawadi Road,
Bhavnagar-364002, Gujarat.

Banker

Kotak Mahindra Bank Limited
21, Vicenza House,
Friends Co-operative Housing Society, Alkapuri, Vadodara-390007,
Gujarat.
Phone no.: +91 9687659842

ICICI Bank Limited
Shop No. 1 & 2, Ground Floor,
Tilak Complex, Jetalpur Road,
Prakash Colony,
Vadodara, - 390 007. Gujarat,
Phone no.: +91 9271855257

Registrar & Share Transfer Agent

MUFG Intime India Private Limited
(erstwhile Link Intime India Private Limited),
5th Floor, 506 to 508,
Amarnath Business Centre-1 (ABC-1), Beside Gala Business Centre, Nr. St. Xavier's College Corner, Off C G Road, Ellisbridge,
Ahmedabad-380006.
(SEBI Registration Number:- INR000004058)
Tel : 079 - 2646 5179
Website: www.in.mpms.mufg.com / https://in.mpms.mufg.com/
Contact link:
https://web.in.mpms.mufg.com/contact-us.html
Email: rnt.helpdesk@in.mpms.mufg.com, ahmedabad@in.mpms.mufg.com, investor.helpdesk@in.mpms.mufg.com

General Information

The Company's equity shares are listed on the National Stock Exchange of India Limited (Symbol: PAR). The shares are mandated for trading in demat mode. ISIN: INE04LG01015.

About The Company

Par Drugs and Chemicals Limited traces its origins to 1982, when it was established by our Honorary Director, Late Shri Vallabhbhai J. Savani. The legacy is carried forward by the second generation, Mr. Falgun V. Savani and Mr. Jignesh V. Savani.

Over more than four decades of operations, the Company has built an established operating platform, manufacturing capabilities, customer relationships and industry experience, supported by a consistent emphasis on quality, financial discipline and stakeholder trust.

The Company remained profitable during FY2025-26. Revenue from operations for the year stood at ₹103.66 crore, profit before tax at ₹17.30 crore and profit after tax at ₹13.11 crore. The Company remained debt-free during the year, with no current or non-current borrowings as at March 31, 2026, and maintained a strong liquidity position throughout the year.

FY2025-26: The Year in Context

FY2025-26 was shaped by three distinct dynamics: the performance of the Company's existing operations; a highly competitive demand environment that weighed on margins; and certain regulatory developments concerning a proposed transaction involving the Company.

The Company remained profitable and maintained a strong financial position through the year. At the same time, competitive pressures and margin dynamics underscored the importance of continuously reassessing business economics, risk-return trade-offs, and capital allocation priorities. Management will continue to evaluate the options available to the Company, without presupposing any particular direction or outcome.

Throughout this process, the Company remains guided by applicable laws, governance processes, and regulatory requirements, and by the directions of competent authorities — while extending full cooperation in connection with the ongoing regulatory process.

Our Guiding Approach

In the context of the current business environment, the management's approach is guided by the following three principles:

Evaluate

The management will continue to evaluate the operating environment and opportunities available to the Company, taking into consideration the relevant risks, capital requirements, business considerations and potential returns. Such evaluation is an ongoing management process and should not be construed as indicating or committing to any specific future course of action in relation to the Company's existing operations or any potential business opportunity.

Comply

Any decision or action arising from such evaluation will be undertaken strictly in accordance with applicable laws, regulatory requirements, corporate governance processes and the directions of the competent authorities.

No Presupposition of Outcomes

The Company will not presume, anticipate or indicate any particular strategic outcome while matters relating to any proposed transaction remain subject to the applicable regulatory and approval processes. Any future course of action, if considered appropriate, will be determined based on the outcome of such processes and the interests of the Company and its stakeholders.

Our Value Proposition

- **Legacy of Trust** — More than four decades of operating experience, credibility and enduring stakeholder relationships.
- **Established Operating Platform** — Established manufacturing capabilities, customer relationships, technical expertise and industry experience developed over the years.
- **Financial Strength and Discipline** — A debt-free balance sheet, healthy liquidity position and prudent management of financial resources provide the Company with financial flexibility.
- **Governance and Transparency** — Business decisions are guided by sound governance practices, applicable disclosure requirements, regulatory compliance and accountability to stakeholders.
- **Stakeholder-Centric Approach** — The Company remains committed to considering the interests of its investors, customers, employees, business partners and other stakeholders while conducting its affairs.

The Company's financial strength and liquidity provide it with a meaningful degree of financial flexibility. However, financial capacity alone does not determine the Company's future allocation of capital. Management will continue to evaluate available opportunities, risks and strategic alternatives prudently, having regard to the Company's long-term interests and within the applicable legal, regulatory and governance framework.

Message from the Chairman & Managing Director

Navigating an Evolving Environment

Dear Stakeholders,

FY 2025-26 was a year that called for measured decision-making, financial discipline and a continued focus on the fundamentals of our business.

The industries in which we operate continue to experience changing market dynamics, competitive pricing, movements in input costs and evolving customer requirements. Against this backdrop, our operations remained profitable during the year. These conditions also reinforce the importance of maintaining operational discipline and continuously assessing margins, risks, capital requirements and potential returns.

On a standalone basis, the Company reported total income of ₹107.66 crore in FY 2025-26, compared with ₹103.12 crore in the previous year. Profit before tax stood at ₹17.30 crore, compared with ₹17.92 crore, while profit after tax stood at ₹13.11 crore, compared with ₹13.36 crore in the previous year. The Company remained debt-free throughout the year and closed FY 2025-26 with cash and cash equivalents of approximately ₹41.84 crore, reflecting a sound liquidity position.

As custodians of shareholder capital, we believe that responsible management requires us to look beyond short-term financial performance and periodically evaluate the opportunities and alternatives available to the Company. Accordingly, our approach remains one of careful evaluation, financial prudence and responsible decision-making. We will continue to assess the operating environment, business opportunities, risks and potential returns without presupposing or indicating any particular future course of action or outcome.

During the year, there were also certain regulatory developments in relation to a proposed transaction involving the Company. We respect the regulatory framework and remain committed to providing all necessary cooperation and information to the competent regulatory authorities. The Company will continue to conduct its affairs in accordance with applicable laws, regulations, governance requirements and directions of the competent authorities.

As the regulatory process remains ongoing, it would not be appropriate to anticipate or comment on its eventual outcome. Any matter requiring consideration by the Company will be evaluated objectively and dealt with through the appropriate governance and regulatory processes, keeping in view the interests of the Company and its stakeholders.

Our responsibility remains clear: to preserve financial discipline, evaluate opportunities prudently, uphold appropriate standards of governance and transparency, and take decisions with due regard to the long-term interests of the Company and all its stakeholders.

I would like to express my sincere gratitude to our shareholders, employees, customers, business partners and other stakeholders for their continued trust, confidence and support. Your continued faith in the Company remains an important source of strength as we navigate an evolving business environment.

With gratitude,

Sincerely,

Mr. Falgun V. Savani
Chairman & Managing Director

Review by the Executive Director & CEO

Dear Stakeholders,

The year under review required the Company to remain focused on multiple priorities simultaneously — maintaining the steady conduct of its operations, navigating a challenging margin environment and responding appropriately to regulatory developments concerning a proposed transaction involving the Company.

Our operations continued steadily through FY 2025-26. Revenue from operations stood at ₹103.66 crore, compared with ₹100.97 crore in the previous year. While the Company recorded growth in turnover, operating performance continued to be influenced by movements in input costs, competitive pricing and prevailing market conditions. Profit before tax stood at ₹17.30 crore, while profit after tax stood at ₹13.11 crore for the year. The Company's profitability was also supported by other income of approximately ₹4 crore during the year, which contributed meaningfully to the overall financial performance, primarily arising from investment activities during the year.

Maintaining the quality and strength of the balance sheet remained an important priority. The Company generated approximately ₹16.43 crore of net cash from operating activities during the year, had no borrowings as at March 31, 2026, and with cash and cash equivalents at the end of the year approximately ₹41.84 crore. Working capital continued to be managed prudently, with a focus on maintaining liquidity and efficient utilisation of resources.

The markets in which we operate remain subject to competitive intensity, pricing pressures, changing customer requirements, movements in input costs, regulatory requirements and evolving supply-demand conditions. These factors can have a direct bearing on margins and the returns generated from the deployment of capital. Accordingly, management evaluates performance not merely in terms of revenue growth and absolute profitability, but also with regard to the sustainability of margins, efficient utilisation of capital, associated risks and potential returns.

With regard to the regulatory process concerning the proposed transaction, the Company has extended and will continue to extend its full cooperation to the competent regulatory authorities. The Company remains committed to complying with applicable laws, regulations, governance requirements and directions issued by the competent authorities.

Management will continue to evaluate the operating environment and the possibilities available to the Company through appropriate governance processes and with due consideration to the interests of the Company and its stakeholders. Such evaluation should not be construed as indicating, anticipating or presupposing any particular course of action or outcome.

The year called for patience, prudence and discipline. I would like to express my sincere appreciation to our employees, customers, business partners and shareholders for their continued support, confidence and commitment.

Sincerely,



Mr. Jignesh Vallabhbhai Savani
Executive Director & CEO

Milestones

1982
Foundation and Early Growth

Established as M/s PAR INORGANICS by Mr. V. J. Savani.

1999
Foundation and Early Growth

Incorporated as Par Drugs and Chemicals Limited.

2002
Technological Advancements

Introduced Drying Technology Upgradation (spin flash dryer) in India, marking a pioneering stride in the product segment.

2005
Expansion and Certification

Established second manufacturing facility within Asia's largest chemicals corridor, GIDC Ankleshwar.

2009
Technological Advancements

Implemented Fuel Technology modification—changed from furnace oil to Coal Fired Hot Air Generators, improving cost efficiency and profitability.

2010
Foundation and Early Growth

Received Good Manufacturing Practice (GMP) Certification from the World Health Organisation (WHO) for Bhavnagar manufacturing facility.

2012
Foundation and Early Growth

Added two manufacturing blocks in Bhavnagar—one for fine chemicals and another for magnesium hydroxide.

2015
Product Development and Sustainability

Introduced Sucralfate API, becoming its sole manufacturer in India.

2017
Product Development and Sustainability

Installed a 120 kW Solar Power Generation Plant, reducing carbon emissions by 154,000 kgs annually.

2018
Corporate Development

Converted to a Public Limited Company.

2019
Corporate Development

Launched IPO and listed on NSE SME EMERGE platform.

2021
Corporate Development

Migrated equity shares from SME EMERGE to Main Board Platform, effective September 16, 2021.

2025
Strategic Diversification

Initiated plans to enter the real estate and construction sector through a dedicated subsidiary and began exploring a clean and renewable energy venture to broaden revenue streams and enhance long-term value creation.

2026
Regulatory Developments

Certain regulatory developments arose in relation to the proposed transaction. The Company is extending the necessary cooperation and acting in accordance with the directions of the competent authorities.

Corporate Governance

At Par Drugs and Chemicals Limited, we believe that strong corporate governance is fundamental to maintaining stakeholder confidence and creating sustainable long-term value. Our governance framework is built around the principles of transparency, accountability, fairness, integrity and responsible decision-making, and is intended to support effective oversight of the Company's affairs.

Governance Framework

Board of Directors — A Board comprising experienced professionals who provide strategic oversight, constructive guidance and independent judgment in accordance with their respective roles and responsibilities.

Committees of the Board — Board committees, including the Audit Committee, Nomination and Remuneration Committee, Stakeholders' Relationship Committee and Corporate Social Responsibility Committee, provide focused oversight in their respective areas.

Compliance and Risk Management — Processes and controls designed to support compliance with applicable statutory and regulatory requirements, identify material risks and facilitate their appropriate monitoring and mitigation.

Ethics and Integrity — A commitment to conducting business with integrity, maintaining appropriate standards of ethical conduct and ensuring transparent and responsible disclosures.

Stakeholder Engagement — Appropriate channels of communication and engagement to understand and address the interests and concerns of shareholders, customers, employees, business partners and other stakeholders.

Our Commitment

During FY 2025-26, the Company placed particular emphasis on maintaining appropriate governance standards, complying with applicable regulatory requirements and extending the necessary cooperation to the competent regulatory authorities in connection with the ongoing regulatory process.

The Company remains committed to continuously strengthening its governance framework, internal processes and compliance practices in line with applicable laws, regulatory requirements and evolving standards of corporate governance. We believe that sound governance is an ongoing responsibility and an essential foundation for protecting stakeholder interests and supporting the Company's long-term sustainability.

Board of Directors

Mr. Falgun Vallabhbhai Savani
Chairman & Managing Director

A founding member of the Company with over two decades of industry experience, he holds a degree in Pharmacy and plays a pivotal role in overseeing organisational management and governance. He holds no directorship in any other entity.

AC

Mr. Jignesh Vallabhbhai Savani
Executive Director & CEO

A founding team member with extensive industry experience, he is responsible for overseeing sales, administration and finance while managing day-to-day operations. He holds no directorship in any other entity.

SRC

Mr. Pravin M. Bhayani
Independent Director

A Chartered Accountant with over two decades of professional expertise encompassing audit, accounts, taxation and systems implementation, he contributes deep financial acumen and governance oversight to the Board, supporting compliance, risk management and fiscal discipline. He holds no directorship in any other entity.

AC C SRC C NRC C CSR C

Mrs. Krishna Mitulbhai Shah
Independent Director

A Commerce graduate and certified Independent Director with strong governance proficiency, she brings valuable perspectives on compliance, corporate responsibility and policy oversight to the Board. She holds no directorship in any other entity.

AC SRC NRC CSR

Mrs. Kajal Chintanbhai Vaghani
Independent Director

A Commerce graduate and certified Independent Director, she brings cross-sector insights to the Board and supports effective planning and decision-making, strengthening the Company's governance framework. She holds no directorship in any other entity.

AC

Mrs. Bintal Bhaveshkumar Shah
Independent Director

A Commerce graduate and certified Independent Director with a strong understanding of governance frameworks, she offers balanced perspectives on stakeholder relationships and organisational ethics. She holds no directorship in any other entity.

NRC CSR

Senior Management Personnel

Mr. Ghanshyam Bhagvanbhai Savani

Production Head

Mr. Ghanshayambhai Bhagvanbhai Savani is the Production Head of the Company and is actively involved in overseeing and managing the production activities of the Company. He brings with him more than three decades of extensive experience in the Active Pharmaceutical Ingredients (API) industry. With his rich industry knowledge, technical expertise and professional acumen, he has been instrumental in strengthening the Company's production capabilities and supporting its sustainable growth. His experience and contribution continue to add significant value to the Company's operations and overall development.

Mr. Chintan Pratapbhai Chauhan

Chief Financial Officer- KMP

Mr. Chintan Pratapbhai Chauhan is the Chief Financial Officer of the Company, appointed with effect from November 26, 2018. He holds a Bachelor's degree in Commerce from M. J. College of Commerce, Bhavnagar, affiliated with Bhavnagar University. He has an experience of about 21 years in the finance field. He is responsible for the financial operations of the Company.

Mr. Sanket Bhupendrabhai Trivedi

Company Secretary and Compliance Officer – KMP

Mr. Sanket Bhupendrabhai Trivedi is a qualified Company Secretary and Fellow Member of the Institute of Company Secretaries of India (ICSI) with 9 years of wide experience and expertise in corporate secretarial, legal, and compliance matters. Since his appointment on September 6, 2018, he has been responsible for overseeing the Company's corporate secretarial functions, ensuring adherence to regulatory requirements and supporting effective governance practices. He holds a Bachelor's degree in Commerce from B. J. Vanijya Mahavidyalaya, affiliated with Sardar Patel University, and a Bachelor of Legislative Law (LLB) from Sheth H. J. Law College, affiliated with Maharaja Krishnakumarsinhji Bhavnagar University.

Committee Role

Acts as the Secretary for all Committees of the Company

Mr. Harshadbhai Jayantilal Rajyaguru

QC & QA Head

Mr. Harshadbhai Jayantilal Rajyaguru holds a Bachelor of Science (B.Sc.) degree from Sir P. P. College, Bhavnagar University. He is a results-oriented Quality Control and Quality Assurance professional with over 25 years of experience in the Active Pharmaceutical Ingredients (API) and pharmaceutical formulation industries. He has extensive experience in managing QC and QA functions across the pharmaceutical quality lifecycle, including testing and approval of incoming raw materials, in-process quality control, analytical testing, finished product testing and release, and ensuring quality assurance compliance throughout manufacturing and operations. His strong technical knowledge, leadership capabilities and understanding of pharmaceutical quality systems make him a valuable professional in the field of QC and QA.

Mr. Jayeshbhai Jayantibhai Rajyaguru

Export, Sales & Marketing Head

Mr. Jayeshkumar Jayantilal Rajyaguru, holds a Bachelor of Commerce (B.Com.) degree from M.J. Commerce College, Bhavnagar University. He is a results-oriented Export, Sales & Marketing professional with over 20 years of experience in the Active Pharmaceutical Ingredients (API) industry. He has extensive experience in driving business growth across domestic and international markets through strategic sales, customer relationship management and market expansion. His expertise includes export sales and business development, identifying new opportunities, developing distributor and customer networks, negotiating commercial agreements and managing key client relationships. He is also well-versed in international trade regulations, export documentation and regulatory compliance, ensuring smooth global business operations and sustainable long-term growth in the pharmaceutical API sector.

Board Committees

AC	Audit Committee
SRC	Stakeholder Relationship Committee
NRC	Nomination and Remuneration Committee
CSR	Corporate Social Responsibility Committee
C	Chairman

Our Operating Platform

The Company's approach rests on operational discipline, financial prudence and governance. The existing business has provided the Company with an established operating platform, manufacturing capabilities, customer relationships and industry experience.

Operational Reliability

manufacturing operations conducted with a consistent emphasis on quality and regulatory compliance.

Financial Prudence

a debt-free balance sheet, disciplined working-capital management and healthy cash generation.

Governance

decision-making conducted through Board and committee processes and in accordance with applicable laws and regulations.

Relationships

long-standing associations with customers, vendors, employees and other stakeholders.

At the same time, management recognises that the economics of a business cannot be viewed independently of changes in its operating environment. Competitive pricing, fluctuations in input costs, changing customer expectations and other industry dynamics have created pressure on margins across parts of the operating landscape. This has reinforced the importance of periodically evaluating the economics of the business and the return profile associated with incremental capital deployment.

Such evaluation should not be interpreted as an indication regarding the continuation, discontinuation, disposal, expansion or restructuring of any particular business. It represents a normal process through which management assesses the environment in which the Company operates and considers the possibilities available to it.

How We Create Value

Value creation at Par Drugs and Chemicals Limited is anchored in the disciplined conduct of the business and the responsible stewardship of the Company's resources. During FY2025-26, this was reflected in the following enablers:

Operational Continuity

the Company's operations continued through the year and remained profitable.

Prudent Resource Management

resources were managed with due regard to liquidity, risk and return, and the Company remained free of borrowings.

Governance and Compliance

business conducted through appropriate governance processes and in accordance with applicable laws, regulations and directions of competent authorities.

Stakeholder Relationships

continued engagement with investors, customers, employees and business associates.

Responsible Practices

community initiatives undertaken under the Company's CSR framework.

Value Creation Framework

Inputs

- Financial Capital — a strong balance sheet with no borrowings and healthy liquidity.
- Human Capital — an experienced leadership team and skilled workforce.
- Intellectual Capital — more than four decades of operational expertise and industry know-how.
- Stakeholder Capital — trust and support of investors, partners and customers.

Process

- Conducting operations with discipline and quality focus.
- Evaluating the operating environment, business economics and the possibilities available to the Company on an ongoing basis.
- Maintaining governance, compliance and disclosure standards.
- Engaging with stakeholders and regulatory authorities as required.

Outcomes Delivered in FY2025-26

- Revenue from operations of ₹103.66 crore and profit after tax of ₹13.11 crore.
- Net cash from operating activities of approximately ₹16.43 crore.
- A debt-free balance sheet with total equity of approximately ₹111.98 crore as at March 31, 2026.
- Cash and cash equivalents of approximately ₹41.84 crore as at March 31, 2026.
- Continued community impact through CSR initiatives.

Review of the Year and Strategic Evaluation

During the year, management continued its ongoing review of the Company's operations and the environment in which they are conducted.

Performance Beyond Revenue

Revenue from operations exceeded ₹100 crore during FY2025-26 and the Company remained profitable. However, management increasingly evaluates performance through the quality of returns rather than revenue alone. Industry economics require consideration of several interconnected factors:

• sustainability of margins; • the pricing environment; • input-cost dynamics; • competitive intensity; • capital requirements; • operating risks; • potential return on incremental investment; and • changing market opportunities.

A Changing Economic Equation

The Company's operations are conducted within markets influenced by competitive intensity, pricing, customer requirements, input-cost movements, regulatory requirements and changing supply-demand conditions. These factors can influence margins and the returns generated from incremental deployment of capital. The margin environment remains demanding across parts of the operating landscape.

Evaluating Possibilities

The operating environment has reinforced the importance of maintaining an open and considered approach towards the possibilities available to the Company. Management will continue to assess the business environment, opportunities, risks, capital utilisation and requirements, and potential returns associated with such possibilities.

Regulatory Developments During the Year

During FY2025-26, certain regulatory developments arose in relation to a proposed transaction concerning the Company's business undertaking, which had earlier been considered through the applicable Board and shareholder processes. Certain interim directions were issued in the matter by the competent regulatory authority during the year and were subsequently confirmed. The proposed transaction has not been given effect to and remains subject to the directions issued and the ongoing regulatory process.

The Company respects the regulatory process and remains committed to extending the necessary cooperation to the regulatory authorities. The Company will continue to act in accordance with applicable laws, regulations and directions issued by the competent authorities from time to time. Requisite disclosures in relation to the matter have been made to the stock exchange from time to time in accordance with applicable regulations.

In view of the ongoing regulatory process, the Company considers it inappropriate to anticipate or comment upon the eventual outcome of the matter, and nothing in this Annual Report should be construed as a characterisation of the matters involved or their eventual outcome.

Progress and Outcomes

The year under review called for steadiness, discipline and careful attention to the Company's obligations. Key outcomes of FY2025-26 were as follows:

- Operational Continuity — the Company's operations continued through the year, with earning revenue from operations of ₹103.66 crore.
- Profitability Maintained — profit before tax of ₹17.30 crore and profit after tax of ₹13.11 crore, notwithstanding a demanding margin environment.
- Balance-Sheet Strength — no borrowings as at March 31, 2026, cash and cash equivalents of approximately ₹41.84 crore and total equity of approximately ₹111.98 crore.
- Regulatory Compliance and Cooperation — the Company acted in accordance with the directions of the competent authorities and extended the necessary cooperation in connection with the regulatory process.
- Audit Outcome — the statutory auditors expressed an unmodified opinion on the audited financial results for the year ended March 31, 2026.
- Governance Maintained — Board and committee processes functioned through the year, and investor queries and complaints were addressed within prescribed timelines.

Human Capital

Our people remain central to the conduct of the Company's operations. Over more than four decades, our workforce has contributed to building the operational reliability, trust and credibility that define the Company.

Skill and Safety

Continued attention to training, safe working practices and the well-being of employees at our facilities.

Engagement

A culture of collaboration, accountability and open communication.

Fair Practices

Equal opportunity and a workplace guided by ethics and mutual respect.

Management acknowledges with gratitude the commitment shown by employees at all levels during a year that required patience and discipline. Industrial relations remained cordial throughout the year.

Corporate Social Responsibility (CSR)

At Par Drugs and Chemicals Limited, Corporate Social Responsibility is a commitment to responsible governance and social well-being. Our CSR philosophy focuses on initiatives that address fundamental community needs and create tangible value for the communities around us.

The Company remains committed to fulfilling its Corporate Social Responsibility ("CSR") objectives through initiatives that create meaningful and sustainable impact in the areas of environmental protection, animal welfare, education and community development. The Company's CSR activities are implemented in partnership with established institutions having domain expertise, and are carried out in accordance with the Company's CSR Policy and the applicable provisions of the Companies Act, 2013 and the rules framed thereunder. During the year under review, the Company undertook the following three CSR initiatives:

SWARGA SPARSH – Climate Friendly Cremation System (Environmental Sustainability)

Under the "SWARGA SPARSH" initiative, implemented in partnership with the Society for Research and Initiatives for Sustainable Technologies and Institutions (SRISTI), the Company supported the installation of the "SWARGAROHAN – Climate Friendly Cremation System" at Chitra Smashan, GIDC, Chitra, Bhavnagar 364001, Gujarat.

The initiative addresses the air pollution, smoke and consumption of firewood associated with traditional open pyre cremation. The system enables the last rites to be completed in a substantially shorter time and with a significantly lower quantity of firewood, while all the religious customs and rituals associated with agni sanskar continue to be observed in full. The facility also reduces the cost of a cremation for families from economically weaker sections and helps keep the cremation premises clean and safe for the community.

SWARGAROHAN Climate Friendly Cremation System installed at Chitra Smashan, GIDC, Bhavnagar

GAU SNEH – Animal Welfare and Cow Care

Under the "GAU SNEH" initiative, implemented in partnership with Shree Sarveshwar Gau Dham Trust, Kobdi, the Company supported animal welfare activities at Shree Nilkanth Mahadev Ashram, Kobadi, District Bhavnagar, Gujarat, with a focus on the supply of nutritious cattle feed and the provision of necessary veterinary care for cows sheltered at the facility.

The initiative is aimed at improving the health, wellbeing and quality of life of the cattle through adequate and appropriate nutrition, supported by regular medical attention. Particular attention is given to elderly and disabled cows, for whom care and dietary support are provided as per their specific requirements. Through this initiative, the Company seeks to promote compassionate animal care as part of its responsible and inclusive CSR practices.

Cattle feeding and cattle feed and necessary medical care for cows. supported at Shree Nilkanth Mahadev Ashram, Kobadi, Bhavnagar

PRAGATI PATH – Supporting Education and Student Welfare

Under the "PRAGATI PATH" initiative, implemented in partnership with Gohilwad Leauva Patidar Kelavani Mandal, the Company supported the development of hostel infrastructure at Bhavnagar. The support covered the construction of three hostel rooms together with the associated supporting infrastructure, with the objective of creating safe, functional and durable accommodation for students.



The initiative is aligned with the Company's CSR objectives of promoting education, supporting the development of young talent and contributing to lasting community infrastructure. The improved hostel facilities provide students with a conducive living and learning environment and thereby support their educational pursuits and overall wellbeing.

The above initiatives have been undertaken in the areas specified in Schedule VII to the Companies Act, 2013, and the details of the CSR expenditure incurred during the year are set out in the Annual Report on CSR Activities annexed to this Report.

Management Discussion and Analysis

Industry Structure and Operating Environment

The Company operates within a dynamic environment shaped by competitive intensity, pricing movements, input-cost variations, regulatory requirements and changing customer expectations. These factors can influence operating margins and the return profile associated with incremental capital deployment.

During FY2025-26, the Company continued to evaluate these dynamics closely. While the business remained profitable, management recognises the importance of assessing performance not only through revenue and absolute profitability but also through the sustainability of margins, capital requirements, associated risks and potential returns.

Financial Performance

The audited standalone financial results for the year ended March 31, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 14, 2026. The statutory auditors have expressed an unmodified opinion on the financial results. A summary is set out below:

Revenue from operations (₹ crore)



Other income (₹ crore)



Total income (₹ crore)



Total expenses (₹ crore)



Profit before tax (₹ crore)



Profit after tax (₹ crore)



Earnings per share (₹)

Revenue from operations grew modestly during the year, while profitability reflected a moderation in margins attributable to input-cost and pricing dynamics. Other income for the year stood at ₹4.00 crore as against ₹2.15 crore in the previous year.

The Company's financial position as at March 31, 2026 remained strong. equity share capital stood at ₹12.30 crore and other equity at ₹99.68 crore, resulting in total shareholders' equity of approximately ₹111.98 crore. The Company remained debt-free, with no current or non-current borrowings as at the year-end. The Company had liquidity of approximately ₹68.98 crore, comprising cash and cash equivalents of ₹41.84 crore and non-current investments of ₹27.14 crore. The Company generated net cash of approximately ₹16.43 crore from operating activities during the year.

The financial position provides the Company with a significant degree of financial flexibility. The management recognises the importance of disciplined capital allocation and will continue to evaluate the possibilities available to the Company having regard to risk, return, liquidity, regulatory requirements and stakeholder interests. Any material capital allocation decision will be considered through the appropriate governance processes and in accordance with applicable regulatory requirements.

Product wise performance:

Review of Sales and Product Portfolio during FY 25-26 are as under:





Financial Highlights

Revenue

(₹ in Lakhs)



EBITDA

(₹ in Lakhs)



EBITDA Margin

(%)



PBT

(₹ in Lakhs)



PAT

(₹ in Lakhs)



PAT Margin

(%)



EPS
(₹)



Net Worth
(₹ in Lakhs)



ROE
(%)



ROCE
(%)



Significant changes in key financial ratios

Particulars	2025-26	2024-25	Variance (%)	Reasons for Variance
(i) Debtors Turnover (Sales / Debtors)	8.62	6.04	42.65%	The improvement in the ratio is primarily attributable to better management of receivables and a reduction in the average level of trade receivables during the year.
(ii) Inventory Turnover (Sales / Inventory)	19.29	16.54	16.66%	The improvement in the ratio is primarily attributable to more efficient inventory management and a reduction in the average level of inventory during the year.
(iii) Interest Coverage Ratio	0	0	0.00%	Not applicable, as the Company had no interest-bearing borrowings during the year.
(iv) Current Ratio (Current Assets / Current Liabilities)	4.68	3.31	41.35%	The improvement in the ratio is primarily attributable to an increase in cash and cash equivalents and a reduction in current liabilities during the year.
(v) Debt-Equity Ratio	0	0	0.00%	Not applicable, as the Company had no debt during the year.
(vi) Operating Profit Margin (%)	16.53%	19.31%	-14.42%	The decrease in the ratio is primarily attributable to an increase in the cost of materials and other operating costs, resulting in moderation of operating margins.
(vii) Net Profit Margin (%) (Profit Before Tax / Revenue from Operations)	16.69%	17.75%	-5.96%	The decrease in the ratio is primarily attributable to moderation in operating profitability during the year.
(viii) Return on Net Worth (%) (Net Profit / Net Worth)	11.71%	13.50%	-13.27%	The decrease in the ratio is primarily attributable to an increase in net worth coupled with a moderation in profit during the year.

Discussion on financial performance with respect to operational performance.

The Company's financial performance during FY 2025-26 remained resilient despite a competitive operating environment and continued pressure on margins.

Operationally, the Company continued to focus on maintaining product quality, customer relationships, production efficiency and prudent working-capital management. The improvement in debtor and inventory turnover ratios indicates better management of receivables and inventory during the year.

Overall, the Company's finance performance reflects modest growth in revenue, sustained profitability and a strong liquidity position notwithstanding the moderation in operating margins. Going forward, management will continue to focus on strengthening sales and marketing, improving operational efficiency, managing costs, maintaining customer relationships and deploying capital prudently, while taking into consideration prevailing market conditions, associated risks and potential returns.

Segment Information

The Company's operations constitute a single business segment in terms of Ind AS 108 on Operating Segments. Accordingly, there are no separate reportable segments. The product-wise performance of the Company's API and Fine Chemicals businesses has been stated above.

Opportunities and Threats

Opportunities

The Company operates in sectors supported by established customer relationships, manufacturing capabilities and accumulated industry experience. The management believes that the Company's financial strength, debt-free position and healthy liquidity provide a degree of flexibility to evaluate opportunities for sustainable growth and efficient deployment of capital.

Key opportunities include:

- Operational Optimisation — Improving manufacturing efficiency, productivity and cost management to support sustainable margins.
- Customer and Market Development — Strengthening existing customer relationships and exploring opportunities to expand the Company's presence across existing and potential markets.
- Product and Business Diversification — Evaluating opportunities to broaden the Company's product portfolio and business activities, subject to commercial viability and applicable regulatory requirements.
- Prudent Capital Deployment — The Company's debt-free balance sheet and healthy liquidity provide flexibility to evaluate investments and other opportunities based on risk, capital requirements and potential returns.
- Long-Term Value Creation — Continued focus on operational efficiency, financial discipline, governance and responsible capital allocation can support sustainable value creation for stakeholders.

Threats

The Company's performance may be influenced by factors beyond its direct control. Key risks and challenges include:

Competitive Pressure — Increasing competition and pricing pressure may affect revenue growth and operating margins.

Input Cost Volatility — Changes in the prices and availability of key raw materials, utilities and other inputs may impact profitability.

Market and Demand Conditions — Changes in customer requirements, industry demand and supply-demand dynamics may affect volumes and margins.

Regulatory Environment — Changes in applicable laws, regulations, regulatory requirements or directions of competent authorities may affect the Company's operations and strategic alternatives.

Execution and Capital Allocation Risks — New business initiatives, diversification or deployment of capital may involve execution risks and may not generate the anticipated returns.

Macroeconomic and Geopolitical Factors — Broader economic conditions, trade policies, foreign exchange movements and geopolitical developments may influence market conditions and business performance.

Management Approach

The Company continues to adopt a measured and disciplined approach towards its operations, opportunities and risks. Management recognises that the operating environment remains dynamic and may be influenced by competitive conditions, pricing, input costs, customer requirements, regulatory developments and broader market factors.

Management will continue to evaluate the possibilities available to the Company with due regard to their commercial rationale, associated risks, capital requirements, resource utilisation and potential returns. Such evaluation is an ongoing management process and does not represent a commitment to, or indication of, any particular future course of action.

The Company remains focused on maintaining operational and financial discipline, efficient utilisation of resources, prudent capital allocation and appropriate risk management. At the same time, the Company will continue to uphold its governance and compliance responsibilities and conduct its affairs in accordance with applicable laws, regulations and directions of the competent authorities.

With respect to the regulatory developments concerning the proposed transaction, the Company respects the ongoing regulatory process and remains committed to extending the necessary cooperation to the competent authorities and complying with the directions issued from time to time. In view of the ongoing nature of the regulatory process, management does not consider it appropriate to anticipate or indicate any particular outcome.

Any matter requiring consideration will be evaluated objectively, at the appropriate time, through the applicable governance processes and within the prevailing legal and regulatory framework, having regard to the interests of the Company and its stakeholders.

The Company remains committed to evaluating these opportunities and risks on an ongoing basis. Management will continue to adopt a measured approach, balancing growth opportunities with financial discipline, risk assessment, regulatory compliance and the efficient utilisation of capital.

Regulatory Proceedings

The Company is mindful of the regulatory developments concerning a proposed transaction of the Company, broadly described in the section titled 'Regulatory Developments During the Year'. The Company respects the regulatory process and remains committed to extending the necessary cooperation to the regulatory authorities and complying with applicable laws, regulations and directions. Given the ongoing nature of the regulatory process, the Company considers it appropriate not to anticipate its outcome. Any matter requiring consideration will be approached through the appropriate governance and regulatory processes.

Risks and Concerns

- Market and Margin Risk — competitive intensity, pricing movements and input-cost variations can influence operating margins and returns.
- Customer and Demand Risk — changing customer requirements and supply-demand conditions can affect volumes and realisations.
- Regulatory and Compliance Risk — the Company operates within regulatory frameworks applicable to its operations and to it as a listed entity; the regulatory proceedings described elsewhere in this report remain a relevant consideration, and their eventual outcome cannot be anticipated.
- Concentration Risk — the Company operates in a single reportable business segment.

Management monitors these risks on an ongoing basis and addresses them through operational discipline, financial prudence and adherence to governance and compliance processes.

Internal Control Systems and Their Adequacy

The Company has internal control systems commensurate with its size and the nature of its operations, directed at safeguarding assets, ensuring the reliability of financial reporting and ensuring compliance with applicable laws and regulations. The Audit Committee periodically reviews the adequacy and effectiveness of internal controls.

Human Resources

The Company continued to maintain cordial industrial relations during the year. Attention was given to training, safety and employee well-being across the organisation.

Outlook

The operating environment continues to evolve, requiring businesses to remain attentive to market conditions, competitive dynamics, input costs, margins and capital efficiency.

Against this backdrop, management will continue to evaluate the environment and the possibilities available to the Company, taking into consideration the associated opportunities, risks, capital requirements and potential returns.

The Company remains mindful of the regulatory developments concerning it and will continue to comply with applicable laws, regulations and directions of the competent authorities and extend the necessary cooperation in connection with the regulatory process.

Given the circumstances, management does not consider it appropriate to anticipate any particular strategic outcome. Any proposal or course of action that may require consideration will be evaluated at the appropriate time, through the applicable governance processes and subject to the prevailing regulatory framework.

Cautionary Statement

Statements in this Annual Report describing the Company's position, performance and perceptions are based on information available as on the date of this report and on the current operating environment. This report does not contain, and should not be read as containing, any commitment, assurance, projection or indication regarding any future course of action of the Company, including in relation to its existing operations, the proposed transaction or any other business opportunity. References to the evaluation of possibilities are descriptions of an ongoing management process and do not indicate any particular outcome. Matters concerning the regulatory proceedings described in this report remain subject to the ongoing regulatory process, and nothing contained herein should be construed as anticipating or commenting upon the outcome of such proceedings.

Actual developments may differ materially from those expressed or implied, on account of factors beyond the Company's control, including economic conditions, market dynamics, input costs, and regulatory and legal developments.



Par Drugs And Chemicals Limited

CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph, Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0278-2447013
Website: www.pardrugs.com Email: investors@pardrugs.com

NOTICE OF 27TH ANNUAL GENERAL MEETING TO MEMBERS

Notice is hereby given that the Twenty Seventh (27th) Annual General Meeting ("AGM") of the Members of **PAR DRUGS AND CHEMICALS LIMITED** ("the Company") will be held on **Saturday, 26th Day of September, 2026 at 11:00 A.M.** at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India to transact the following business:

Ordinary Business:

Item No.1: To receive, consider and adopt the Audited Standalone Financial Statements of the company for the financial year ended on 31st March, 2026 together with the report of the Board of Directors and Auditors thereon.

Item No.2: To appoint a Director in place of Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203), who retires by rotation and being eligible offer himself for re-appointment.

Item No.3: To re-appoint statutory auditors of the Company and to fix their remuneration and in this regard to consider and if thought fit, to pass, with or without modification(s), the following resolution as an Ordinary resolution:

"**RESOLVED THAT** pursuant to the provisions of Section 139 and all other applicable provisions, if any, of the Companies Act, 2013 and the Rules made thereunder, **M/s. Sarupria Somani & Associates, Chartered Accountants (Firm Registration No.: 010674C)** be and are hereby re-appointed as the Statutory Auditors of the Company from the conclusion of this 27th Annual General Meeting till the conclusion of the next 28th Annual General Meeting of the Company to be held for the F.Y. 2026-27 at an annual remuneration / fees of ₹ 2,25,000/- (Rupees Two Lakh Twenty Five Thousand Only) plus out of pocket expenses and taxes as applicable from time to time with the power to the Board/Audit Committee to alter and vary the terms and conditions of re-appointment, revision including upward revision in the remuneration during the remaining tenure."

"**RESOLVED FURTHER THAT** for the purpose of giving effect to the above resolution, the Board be and is hereby authorized to do all such acts, deeds, matters and things and take all such steps as may be necessary, proper or expedient for implementation of the above resolution and matters connected therewith or incidental thereto including but not limited to delegation of all or any of the powers herein conferred to any Committee or any director(s) or any other officer(s) of the Company, or to settle any questions, difficulties or doubts that may arise with regard to the above resolution, without being required to seek any further clarification, consent or approval of the Members.**"**

Special Business:

Item No.4: To approve the remuneration payable to Mr. Pravin Manjibhai Bhayani (DIN: 08332851) as an Independent Director of the Company and in this regard to consider and if thought fit, to pass, with or without modification (s), the following resolution as a Special resolution:

"**RESOLVED FURTHER THAT** pursuant to the provisions of Section 149(9), 197(3) and 198 read with Schedule V and other applicable provisions, if any, of the Companies Act, 2013, Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and Regulation 17(6)(ca) and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any amendment/modification or re-enactment thereof) and pursuant to the recommendation and approval of the Nomination and Remuneration Committee and Audit Committee and the approval of the Board of Directors of the Company, consent of the Members of the Company be and is hereby accorded to for payment of remuneration to **Mr. Pravin Manjibhai Bhayani (DIN: 08332851),** Independent Director of the Company, amounting to ₹ 24 Lakhs (Rupees Twenty-Four Lakhs Only) for the period of one year w.e.f. 1st October, 2026 to 30th September, 2027, payable on a monthly, quarterly, half yearly or yearly basis, as decided by the Board of Directors of the Company.

"**RESOLVED FURTHER THAT** the Board of Directors of the Company may pay the remuneration to Mr. Pravin Manjibhai Bhayani, Independent Director, DIN: 08332851 whether by way of remuneration, Commission or any other way and/ or any combination of the same as mutually agreed by the Board and Mr. Pravin Manjibhai Bhayani.

"**RESOLVED FURTHER THAT** such remuneration shall exclude all the fees payable to Mr. Pravin Manjibhai Bhayani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, the Committees, Shareholders and such other meetings as organized by the Company from time to time.

"**RESOLVED FURTHER THAT** any present Directors of the company be and are hereby authorized to do sign/ digitally sign all such necessary forms, documents, papers, and to do all such acts, matters, deeds as may be required under the Companies Act, 2013 and rules made there under to give effect to the aforesaid resolution and any matters consequential thereto."

Item No.5: Ratification of Remuneration of Cost Auditors and in this regard to consider and if thought fit, to pass, with or without modification (s), the following resolution as an Ordinary resolution:

"**RESOLVED THAT** pursuant to the provision of Section 148(3) and all other applicable provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force) and the Companies (Audit and Auditors) Rules, 2014, as amended from time to time, the Company hereby ratifies the remuneration of ₹ 60,000 (Rupees Sixty Thousand Only) plus applicable taxes and reimbursement of out-of-pocket expenses payable to **M/s Maulin Shah & Associates, Cost Accountants, Proprietor (Firm Registration Number 101527),** who based on the recommendation(s) of the Audit Committee, have been appointed by the Board of Directors of the Company ('Board'), as the Cost Auditors of the Company, to conduct the audit of the cost records maintained by the Company for the Financial Year ending March 31, 2027.

"**RESOLVED FURTHER THAT** the Board and/or any person authorised by the Board, be and is hereby authorised severally to settle any question, difficulty or doubt, that may arise in giving effect to this resolution and to do all such acts, deeds and things as may be necessary, expedient or desirable for the purpose of giving effect to this resolution."

Item No.6: To increase Remuneration payable to Mr. Falgun Vallabhbhai Savani (DIN: 00198236) as a Managing Director of the Company and to consider and if thought fit, to pass with or without modification(s) the following Resolution as a Special Resolution:

"**RESOLVED THAT** pursuant to the provisions of Sections 196, 197, 198, 203 and any other applicable provisions, if any, read along with Schedule V of the Companies Act, 2013 ("Act") and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s)or enactment thereof for the time being in force); Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and pursuant to the approval and recommendation of the Nomination & Remuneration Committee and approval of Audit Committee and the approval of the Board of Directors of the Company, the consent of the Members be and is hereby accorded to increase remuneration payable to **Mr. Falgun Vallabhbhai Savani (DIN: 00198236) as a Managing Director (MD)** of the Company, amounting to ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum including Salary, perquisites and allowances for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028, on the terms and conditions as set out in the Explanatory Statement annexed to the Notice convening this Meeting, with liberty to the Board of Directors to alter and vary the terms and conditions of remuneration as it may deem fit and in such manner as may be agreed to between the Board and Mr. Falgun Vallabhbhai Savani."

"**RESOLVED FURTHER THAT** the Board of Directors of the Company may pay the remuneration to Mr. Falgun Vallabhbhai Savani, MD, whether by way of Salary, Commission, Perquisites and/ or any combination of the same as mutually agreed by the Board and Mr. Falgun Vallabhbhai Savani."

"**RESOLVED FURTHER THAT** the Board of Directors of the Company be and is hereby authorised to vary and/or modify the terms and conditions of remuneration payable to the said MD in such manner as may be mutually agreed between the Board and Mr. Falgun Vallabhbhai Savani within the limits as prescribed in Section 197 read Schedule V of the Companies Act, 2013, including any amendment, modification, variation or re-enactment thereof."

"**RESOLVED FURTHER THAT** in the event of loss or inadequacy of profits in any financial year, Mr. Falgun Vallabhbhai Savani shall be paid salary, perquisites and other allowances as set out in explanatory statement as the minimum remuneration, subject to ceiling as specified in Section 197 read Schedule V of the Companies Act, 2013 from time to time and subject to the approval of the Central Government, if so required, in accordance with the provisions of the Companies Act, 2013."

"**RESOLVED FURTHER THAT** for the purpose of giving effect to the above resolution, the Board be and is hereby authorized to do all such acts, deeds, matters and things and take all such steps as may be necessary, proper or expedient for implementation of the above resolution and matters connected therewith or incidental thereto including but not limited to delegation of all or any of the powers herein conferred to any Committee or any director(s) or any other officer(s) of the Company, or to settle any questions, difficulties or doubts that may arise with regard to the above resolution, without being required to seek any further clarification, consent or approval of the Members.**"**

Item No. 7: To increase Remuneration payable to Mr. Jignesh Vallabhbhai Savani (DIN: 00198203) as a CEO of the Company and to consider and if thought fit, to pass with or without modification(s) the following Resolution as a Special Resolution:

"RESOLVED THAT pursuant to the provisions of Sections 196, 197, 198, 203 and any other applicable provisions, if any, read along with Schedule V of the Companies Act, 2013 ("Act") and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 (including any statutory modification(s)or enactment thereof for the time being in force); Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and pursuant to the approval and recommendation of the Nomination & Remuneration Committee and approval of Audit Committee and the approval of the Board of Directors of the Company, the consent of the Members be and is hereby accorded to increase remuneration payable to **Mr. Jignesh Vallabhbhai Savani (DIN: 00198203)** as a Chief Executive Officer (CEO) the Company, amounting to ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum including Salary, perquisites and allowances for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028, on the terms and conditions as set out in the Explanatory Statement annexed to the Notice convening this Meeting, with liberty to the Board of Directors to alter and vary the terms and conditions of remuneration as it may deem fit and in such manner as may be agreed to between the Board and Mr. Jignesh Vallabhbhai Savani."

"RESOLVED FURTHER THAT the Board of Directors of the Company may pay the remuneration to Mr. Jignesh Vallabhbhai Savani, CEO & Director, whether by way of Salary, Commission, Perquisites and/ or any combination of the same as mutually agreed by the Board and Mr. Jignesh Vallabhbhai Savani."

"RESOLVED FURTHER THAT the Board of Directors of the Company be and is hereby authorised to vary and/ or modify the terms and conditions of remuneration payable to the said CEO in such manner as may be mutually agreed between the Board and Mr. Jignesh Vallabhbhai Savani within the limits as prescribed in Section 197 read Schedule V of the Companies Act, 2013, including any amendment, modification, variation or re-enactment thereof."

"RESOLVED FURTHER THAT in the event of loss or inadequacy of profits in any financial year, Mr. Jignesh Vallabhbhai Savani shall be paid salary, perquisites and other allowances as set out in explanatory statement as the minimum remuneration, subject to ceiling as specified in Section 197 read Schedule V of the Companies Act, 2013 from time to time and subject to the approval of the Central Government, if so required, in accordance with the provisions of the Companies Act, 2013."

"RESOLVED FURTHER THAT for the purpose of giving effect to the above resolution, the Board be and is hereby authorized to do all such acts, deeds, matters and things and take all such steps as may be necessary, proper or expedient for implementation of the above resolution and matters connected therewith or incidental thereto including but not limited to delegation of all or any of the powers herein conferred to any Committee or any director(s) or any other officer(s) of the Company, or to settle any questions, difficulties or doubts that may arise with regard to the above resolution, without being required to seek any further clarification, consent or approval of the Members.**"**

By Order of the Board of Directors
For Par Drugs and Chemicals Limited

Sd/-
Mr. Sanket B. Trivedi
Company Secretary & Compliance Officer
(Membership No: FCS: 13800)

Place: Bhavnagar
Date: August 22, 2026

Par Drugs And Chemicals Limited
CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph,
Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0278-2447013
Website: www.pardrugs.com Email: investors@pardrugs.com

NOTES

1. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF/HERSELF AND PROXY NEED NOT BE A MEMBER OF THE COMPANY.**

   THE ENCLOSED PROXY FORM, IF INTENDED TO BE USED, MUST BE RECEIVED BY THE COMPANY, DULY FILLED, STAMPED AND SIGNED, AT ITS REGISTERED OFFICE NOT LESS THAN 48 HOURS BEFORE THE SCHEDULED TIME OF THE MEETING.

   Proxies submitted on behalf of limited companies, societies, etc., must be supported by appropriate resolutions/authority, as applicable, issued on behalf of the nominating organization.

2. A person can act as proxy on behalf of Members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. In case a proxy is proposed to be appointed by a Member holding more than ten percent of the total share capital of the Company carrying voting rights, then such proxy shall not act as a proxy for any other person or Member.

3. Corporate members intending to send their authorized representatives to attend the Meeting are requested to send to the Company a certified copy of the Board Resolution authorizing their representative to attend and vote on their behalf at the Meeting.

4. The Explanatory Statement, pursuant to Section 102 of the Companies Act, 2013 setting out facts concerning the business under Item No. 3 to 7 of the Notice is annexed hereto.

5. Brief Profile of Directors seeking appointment / re-appointment at the Annual General Meeting is provided at **Annexure-A** to this Notice as prescribed under regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India.

6. In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

7. As per amended regulation 40 of the Listing Regulations pursuant to which requests for effecting transfer of securities shall not be processed unless the securities are held in the dematerialized form. Members holding the shares in physical form are requested to dematerialize their holdings at the earliest as it will not be possible to transfer shares held in physical mode.

8. Members are requested to bring their attendance slip along with their copy of annual report to the Meeting.

9. Members who hold shares in de-materialization form are requested to bring their demat/depository account number for identification/ Client Master Report.

10. In case of joint holders attending the Meeting only such joint holder who is higher in the order of names will be entitled to vote.

11. All the Relevant documents referred to in the accompanying notice are open for inspection by the members at the registered office of the Company on all working days, between 11:00 a.m. to 5:00 p.m. up to the date of meeting and shall be available at the website of our Company at www.pardrugs.com and during the AGM.

12. Members desirous of obtaining any information concerning accounts or operations of the Company are requested to address their questions in writing to the Company at least 7 days before the date of the Meeting through email on investors@pardrugs.com so that the information required may be made available at the AGM and the same will be replied by the Company suitably.

13. Members holding shares in dematerialized mode are requested to intimate all changes with respect to their change of address, e-mail address, change in name etc. to their respective Depository Participant. These changes will be automatically reflected in the Company's records which will help the Company to provide efficient and better service to the members.

14. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participants with whom they are maintaining their Demat accounts. Members holding shares in physical form can submit their PAN to the Company / MUFG INTIME INDIA PRIVATE LIMITED (Erstwhile known as Link Intime India Private Limited) ("RTA" of the Company).

15. Members holding shares in single name and physical form are advised to make nomination in respect of their shareholding in the Company. The Nomination Form-SH 13 prescribed by the Government can be obtained from the Share Transfer Agent or may be downloaded from the website of the Ministry of Company Affairs.

16. Members who hold shares in physical form in multiple folios in identical names or joint holding in the same order of names are requested to send the share certificates to MUFG INTIME INDIA PRIVATE LIMITED, for consolidation into a single folio.

17. Non-Resident Indian Members are requested to inform MUFG INTIME INDIA PRIVATE LIMITED, immediately of:

a) Change in their residential status on return to India for permanent settlement.

b) Particulars of their bank account maintained in India with complete name, branch, account type, account number and address of the bank with pin code number, if not furnished earlier.

18. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with MUFG INTIME INDIA PRIVATE LIMITED (RTA) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system will be provided by RTA.

19. Pursuant to Sections 124 of the Companies Act, 2013, the amount of dividend remaining unpaid or unclaimed for a period of seven years from the date of its transfer to the Unpaid Dividend Account of the Company is required to be transferred to Investor Education and Protection Fund ("IEPF") established by the Central Government. The shareholders who have not claimed their dividend for in the earlier years are requested to approach the Company for the payment thereof as the same will be transferred to the Investor Education and Protection Fund after the period of seven years and no claim shall lay against the Company for the said amount of unclaimed dividend so transferred. The details of unclaimed dividends are available on the Company's website at www.pardrugs.com

Further, pursuant to the provisions of Section 124 of the Act and Investor Education and Protection Fund Authority Rules, 2016 ("IEPF Rules"), all shares on which dividend has not been paid or claimed for seven consecutive years or more are required to be transferred to Demat Account of IEPF. Accordingly, Shares of those Shareholders who have not encashed their Interim Dividend declared during the financial year 2019-2020 for seven consecutive years will be transferred to the IEPF Authority if the said dividend for the financial year 2019-2020 are not claimed by the concerned shareholder(s).The Company timely sent individual intimation to all such shareholders. All such Shareholders are requested to claim their Unclaimed Dividend expeditiously failing which their shares shall be transferred to Demat Account of IEPF and no claim shall lay against the Company. The Shareholders thereafter need to claim their shares from IEPF Authority by filing Web IEPF-5 Form and by following such procedures as prescribed in the IEPF Rules (as may be amended from time to time).

20. To support the "Green Initiative in Corporate Governance" taken by the Ministry of Corporate Affairs by allowing paperless compliance and stating that service of notices / documents including Annual Report can be effected by sending the same through electronic mode to the registered e-mail addresses of the shareholders.

The notice of the 27^{th} AGM along with the Annual Report 2025-26 are being sent only by electronic mode to those Members whose e-mail addresses are registered with the Company/Depositories. Members may please note that this Notice and Annual Report 2025-26 will also be available on the Company's website at www.pardrugs.com, websites of the Stock Exchange i.e. National Stock Exchange of India Limited at www.nseindia.com and on the website of RTA at https://instavote.linkintime.co.in/. Members who would like to receive such notices / documents in electronic mode in lieu of physical copy and who have not registered their e-mail addresses so far or who would like to update their e-mail addresses already registered, are requested to register/update their e-mail addresses:

- In respect of electronic shareholding- through their respective Depository Participants;
- In respect of physical shareholding- by sending a request to the Company's Share Transfer Agent, mentioning therein their folio number and e-mail address.
- **For Permanent Registration for Demat shareholders:**

It is clarified that for permanent registration of e-mail address, the Members are requested to register their e-mail address, in respect of demat holdings with the respective Depository Participant (DP) by following the procedure prescribed by the Depository Participant or via email to RTA at ahmedabad@in.mpms.mufg.com or at investors@pardurgs.com

21. The route map showing directions to reach the venue of the 27^{th} AGM is annexed.

E–VOTING (VOTING THROUGH ELECTRONIC MEANS):

1) In compliance with the provisions of section 108 of the Act read with the Companies (Management and Administration) Rules, 2014 as amended from time to time, Standard 8 of the Secretarial Standards on General Meetings and in compliance with Regulation 44 of the SEBI Listing Regulations, the Company is pleased to offer the facility of voting through electronic means. The Company has made necessary arrangements with MUFG INTIME INDIA PRIVATE LIMITED (RTA) to facilitate the members to cast their votes electronically, ("remote e–voting").

2) A person whose name is recorded in the register of members or in the register of beneficial owners

maintained by the depositories as on the **cut-off date Friday, September 18, 2026,** shall be entitled to avail the facility of remote e–voting. Persons who are not members as on the cut–off date should treat this notice for information purpose only.

3) **Remote e-voting will commence at 9:00 A.M. IST on Tuesday, 22nd September, 2026 and will end at 5:00 P.M. IST on Friday, 25th September, 2026,** then remote e-voting will be blocked by RTA.

4) Any person who has acquired shares of the company and becomes member of the company after the dispatch of the Annual Report and holding shares as on the cut-off date may obtain the User Id and Password by referring e-voting instructions given in the notice which is uploaded on our website at www.pardrugs.com and RTA website https://in.mpms.mufg.com/

5) Once the vote on a resolution is cast by the member, he/she shall not be allowed to change it subsequently or cast the vote again.

6) The voting rights of the members shall be in proportion to their share in the paid up equity share capital of the Company as on the Cut-off date.

7) The Company has appointed CS Dip G. Patel, Proprietor of DG Patel & Associates, Practicing Company Secretary (Membership No. FCS: 10533; COP No: 13774), to act as the Scrutinizer to scrutinize the voting during the AGM and remote e-voting process in a fair and transparent manner.

The Scrutinizer shall, immediately after the conclusion of voting at the AGM, first count the votes cast during the AGM, thereafter unblock the votes cast through remote e-voting and make, not later than 48 hours of conclusion of the AGM submit a consolidated Scrutinizer's Report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same.

The result of the voting on the Resolutions shall be announced by the Chairman or any other person authorized by him immediately after the results are declared.

The results declared along with the Scrutinizer's Report, will be posted on the website of the Company www.pardrugs.com and on the website of the RTA https://instavote.linkintime.co.in/ and will be displayed on the Notice Board of the Company at its Registered Office immediately after the declaration of the results by the Chairman or any other person authorized by him and will also be communicated to the National Stock Exchange.

REMOTE E-VOTING INSTRUCTIONS FOR SHAREHOLDERS:

In terms of SEBI circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 / HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants.

Shareholders are advised to update their mobile number and email Id correctly in their demat accounts to access remote e-Voting facility.

Login method for Individual shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode with NSDL

METHOD 1 - NSDL OTP based login

a) Visit URL: https://eservices.nsdl.com/SecureWeb/evoting/evotinglogin.jsp

b) Enter your 8 - character DP ID, 8 - digit Client Id, PAN, Verification code and generate OTP.

c) Enter the OTP received on your registered email ID/mobile number and click on login.

d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services.

e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

METHOD 2 - NSDL IDeAS facility

Shareholders registered for IDeAS facility:

a) Visit URL: https://eservices.nsdl.com and click on "Beneficial Owner" icon under "IDeAS Login Section".

b) Enter IDeAS User ID, Password, Verification code & click on "Log-in".

c) Post successful authentication, you will be able to see e-Voting services under Value added services section. Click on "Access to e-Voting" under e-Voting services.

d) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Shareholders not registered for IDeAS facility:

a) To register, visit URL: https://eservices.nsdl.com and select "Register Online for IDeAS Portal" or click on https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp

b) Enter 8-character DP ID, 8-digit Client ID, Mobile no, Verification code & click on "Submit".

c) Enter the last 4 digits of your bank account / generate 'OTP'

d) Post successful registration, user will be provided with Login ID and password.

e) Follow steps given above in points (a-d).

"Shareholders/Members can also download NSDL Mobile App "NSDL Speede" facility by scanning the QR code mentioned below for seamless voting experience."

App Store Google Play

METHOD 3 - NSDL e-voting website

a) Visit URL: https://www.evoting.nsdl.com

b) Click on the "Login" tab available under 'Shareholder/ Member' section.

c) Enter User ID (i.e., your 16-digit demat account no. held with NSDL), Password/OTP and a Verification Code as shown on the screen & click on "Login".

d) Post successful authentication, you will be re-directed to NSDL depository website wherein you will be able to see e-Voting services under Value added services. Click on "Access to e-Voting" under e-Voting services.

e) Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Individual Shareholders holding securities in demat mode with CDSL

METHOD 1 - CDSL e-voting page

a) Visit URL: https://www.cdslindia.com.

b) Go to e-voting tab.

c) Enter 16-digit Demat Account Number (BO ID) and PAN No. and click on "Submit".

d) System will authenticate the user by sending OTP on registered Mobile and Email as recorded in Demat Account

e) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

METHOD 2 - CDSL Easi/ Easiest facility:

Shareholders registered for Easi/ Easiest facility:

a) Visit URL: https://web.cdslindia.com/myeasitoken/Home/Login or Visit URL: www.cdslindia.com, click on "Login" and select "My Easi New (Token)".

b) Enter existing username, Password & click on "Login".

c) Post successful authentication, user will be able to see e-voting option. The evoting option will have links of e-voting service providers i.e., MUFG InTime. Click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Shareholders not registered for Easi/ Easiest facility:

a) To register, visit URL: https://web.cdslindia.com/myeasitoken/Home/EasiRegistration / https://web.cdslindia.com/myeasitoken/Home/EasiestRegistration.

b) Proceed with updating the required fields for registration.

c) Post successful registration, user will be provided username and password on the registered email id. Follow steps given above in points (a-c).

Individual Shareholders holding securities in demat mode with Depository Participant

Individual shareholders can also login using the login credentials of your demat account through your depository participant registered with NSDL / CDSL for e-voting facility.

a) Login to DP website

b) After Successful login, user shall navigate through "e-voting" option.

c) Click on e-voting option, user will be redirected to NSDL / CDSL Depository website after successful authentication, wherein user can see e-voting feature.

d) Post successful authentication, click on "MUFG InTime" or "evoting link displayed alongside Company's Name" and you will be redirected to InstaVote website for casting the vote during the remote e-voting period.

Login method for shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode.

Shareholders holding shares in physical mode / Non-Individual Shareholders holding securities in demat mode as on the cut-off date for e-voting may register and vote on InstaVote as under:

STEP 1: LOGIN / SIGNUP on InstaVote

Shareholders registered for INSTAVOTE facility:

a) Visit URL: https://instavote.linkintime.co.in & click on **"Login"** under 'SHARE HOLDER' tab.

b) Enter details as under:

InstaVote User ID		
	NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g. IN123456) and 8 digit Client ID (eg. 12345678).
	CDSL	User ID is 16 Digit Beneficiary ID.
	Shares hold in physical form	User ID is Event No + Folio no. registered with the Company

1. User ID: Enter User ID
2. Password: Enter existing Password
3. Enter Image Verification (CAPTCHA) Code
4. Click "Submit".

   (Home page of e-voting will open. Follow the process given under "Steps to cast vote for Resolutions")

Shareholders not registered for INSTAVOTE facility:

a) Visit URL: https://instavote.linkintime.co.in & click on **"Sign Up"** under 'SHARE HOLDER' tab & register with details as under:

InstaVote User ID		
	NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g. IN123456) and 8 digit Client ID (eg. 12345678).
	CDSL	User ID is 16 Digit Beneficiary ID.
	Shares hold in physical form	User ID is Event No + Folio no. registered with the Company

1. User ID: Enter User ID
2. PAN: Enter your 10-digit Permanent Account Number (PAN) (Shareholders who have not updated their PAN with the Depository Participant (DP)/ Company shall use the sequence number provided to you, if applicable.
3. DOB/DOI: Enter the Date of Birth (DOB) / Date of Incorporation (DOI) (As recorded with your DP/ Company - in DD/MM/YYYY format)
4. Bank Account Number: Enter your Bank Account Number (last four digits), as recorded with your DP/Company.
   - o Shareholders, holding shares in **NSDL form**, shall provide 'point 4' above.
   - o Shareholders, holding shares in **CDSL form**, shall provide 'point 3' or 'point 4' above.
   - o Shareholders, holding shares in **physical form** but have not recorded 'point 3' and 'point 4', shall provide their Folio number in 'point 4' above
5. Set the password of your choice.

   (The password should contain minimum 8 characters, at least one special Character (!#$&*), at least one numeral, at least one alphabet and at least one capital letter).
6. Enter Image Verification (CAPTCHA) Code.
7. Click "Submit" (You have now registered on InstaVote).

Post successful registration, click on **"Login"** under 'SHARE HOLDER' tab & follow steps given above in points (a-b).

STEP 2: Steps to cast vote for Resolutions through InstaVote

A. Post successful authentication and redirection to InstaVote inbox page, you will be able to see the "Notification for e-voting".

B. Select 'View' icon. E-voting page will appear.

C. Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link).

D. After selecting the desired option i.e. Favour / Against, click on 'Submit'.

E. A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

NOTE: Shareholders may click on "Vote as per Proxy Advisor's Recommendation" option and view proxy advisor recommendations for each resolution before casting vote. "Vote as per Proxy Advisor's Recommendation" option provides access to expert insights during the e-Voting process. Shareholders may modify their vote before final submission.

Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently.

Non-Individual Body corporate shareholders shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at registered email address.

Guidelines for Institutional shareholders ("Custodian / Corporate Body/ Mutual Fund")

STEP 1 – Custodian / Corporate Body/ Mutual Fund Registration

A. Visit URL: https://instavote.linkintime.co.in

B. Click on "Sign Up" under "Custodian / Corporate Body/ Mutual Fund"

C. Fill up your entity details and submit the form.

D. A declaration form and organization ID is generated and sent to the Primary contact person email ID (which is filled at the time of sign up). The said form is to be signed by the Authorised Signatory, Director, Company Secretary of the entity & stamped and sent to insta.vote@linkintime.co.in.

E. Thereafter, Login credentials (User ID; Organisation ID; Password) is sent to Primary contact person's email ID. (You have now registered on InstaVote)

STEP 2 – Investor Mapping

A. Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

B. Click on "Investor Mapping" tab under the Menu section

C. Map the Investor with the following details:

   1) 'Investor ID' – Investor ID for NSDL demat account is 8 Character DP ID followed by 8 Digit Client ID i.e., IN00000012345678; Investor ID for CDSL demat account is 16 Digit Beneficiary ID.

   2) 'Investor's Name - Enter Investor's Name as updated with DP.

   3) 'Investor PAN' - Enter your 10-digit PAN.

   4) 'Power of Attorney' - Attach Board resolution or Power of Attorney.

      NOTE: File Name for the Board resolution/ Power of Attorney shall be – DP ID and Client ID or 16 Digit Beneficiary ID.

   Further, Custodians and Mutual Funds shall also upload specimen signatures.

D. Click on Submit button. (The investor is now mapped with the Custodian / Corporate Body/ Mutual Fund Entity). The same can be viewed under the "Report section".

STEP 3 – Steps to cast vote for Resolutions through InstaVote

The corporate shareholder can vote by two methods, during the remote e-voting period.

METHOD 1 - VOTES ENTRY

a) Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

b) Click on "Votes Entry" tab under the Menu section.

c) Enter the "Event No." for which you want to cast vote.

   Event No. can be viewed on the home page of InstaVote under "On-going Events".

d) Enter "16-digit Demat Account No.".

e) Refer the Resolution description and cast your vote by selecting your desired option 'Favour / Against' (If you wish to view the entire Resolution details, click on the 'View Resolution' file link). After selecting the desired option i.e. Favour / Against, click on 'Submit'.

f) A confirmation box will be displayed. If you wish to confirm your vote, click on 'Yes', else to change your vote, click on 'No' and accordingly modify your vote.

   (Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

METHOD 2 - VOTES UPLOAD

a) Visit URL: https://instavote.linkintime.co.in and login with InstaVote Login credentials.

b) After successful login, you will see "Notification for e-voting".

c) Select "View" icon for "Company's Name / Event number".

d) E-voting page will appear.

e) Download sample vote file from "Download Sample Vote File" tab.

f) Cast your vote by selecting your desired option 'Favour / Against' in the sample vote file and upload the same under "Upload Vote File" option.

g) Click on 'Submit'. 'Data uploaded successfully' message will be displayed.

   (Once you cast your vote on the resolution, you will not be allowed to modify or change it subsequently).

NOTE: **Non-Individual Body corporate shareholders** shall send a scanned copy of the board resolution authorising its representative to vote, to the scrutinizer at registered email address with a copy marked to RTA at enotices@in.mpms.mufg.com and the company at registered email address.

HELPDESK:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode facing any technical issue in login may contact INSTAVOTE helpdesk by sending a request at enotices@in.mpms.mufg.com or contact on: - Tel: 022 – 4918 6000.

Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in demat mode may contact the respective helpdesk for any technical issues related to login through Depository i.e., NSDL and CDSL.

Login type	Helpdesk details
Individual Shareholders holding securities in demat mode with NSDL	Members facing any technical issue in login can contact NSDL helpdesk by sending request at evoting@nsdl.co.in or call at: 022 - 4886 7000
Individual Shareholders holding securities in demat mode with CDSL	Members facing any technical issue in login can contact CDSL helpdesk by sending request at helpdesk.evoting@cdslindia.com or contact at toll free no. 1800 22 55 33

Forgot Password:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode:

Individual Shareholders holding securities in physical mode / Non-Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

InstaVote User ID		
	NSDL	User ID is 8 Character DP ID followed by 8 Digit Client ID (e.g. IN123456) and 8 digit Client ID (eg. 12345678).
	CDSL	User ID is 16 Digit Beneficiary ID.
	Shares hold in physical form	User ID is Event No + Folio no. registered with the Company

- Click on **"Login"** under 'SHARE HOLDER' tab.
- Further Click on **"forgot password?"**
- Enter User ID, select Mode and Enter Image Verification code (CAPTCHA).
- Click on "SUBMIT".

In case Custodian / Corporate Body/ Mutual Fund has forgotten the USER ID [Login ID] or Password or both then the shareholder can use the "Forgot Password" option available on: https://instavote.linkintime.co.in

- Click on 'Login' under "Custodian / Corporate Body/ Mutual Fund" tab
- Further Click on **"forgot password?"**
- Enter User ID, Organization ID and Enter Image Verification code (CAPTCHA).
- Click on "SUBMIT".

In case shareholders have a valid email address, Password will be sent to his / her registered e-mail address. Shareholders can set the password of his/her choice by providing information about the particulars of the Security Question and Answer, PAN, DOB/DOI etc. The password should contain a minimum of 8 characters, at least one special character (!#$&), at least one numeral, at least one alphabet and at least one capital letter.*

Individual Shareholders holding securities in demat mode with NSDL/ CDSL has forgotten the password:

Individual Shareholders holding securities in demat mode have forgotten the USER ID [Login ID] or Password or both, then the Shareholders are advised to use Forget User ID and Forget Password option available at above mentioned depository/ depository participants website.

General Instructions - Shareholders

- It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- For shareholders/ members holding shares in physical form, the details can be used only for voting on the resolutions contained in this Notice.
- During the voting period, shareholders/ members can login any number of time till they have voted on the resolution(s) for a particular "Event".

By Order of the Board of Directors
For Par Drugs and Chemicals Limited

Sd/-
Mr. Sanket B. Trivedi
Company Secretary & Compliance Officer
(Membership No: FCS: 13800)

Place: Bhavnagar
Date: August 22, 2026

Par Drugs And Chemicals Limited
CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph,
Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0278-2447013
Website: www.pardrugs.com Email: investors@pardrugs.com

EXPLANATORY STATEMENT PURSUANT TO SECTION 102(1) OF THE COMPANIES ACT, 2013

ITEM NO. 3: TO RE-APPOINT STATUTORY AUDITORS OF THE COMPANY AND TO FIX THEIR REMUNERATION.

The Board of Directors of the Company ('the Board'), on the recommendation of the Audit Committee ('the Committee'), recommended for the approval of the Members, the re-appointment of **M/s. Sarupria Somani & Associates, Chartered Accountants (Firm Registration No.: 010674C)**, as the Auditors of the Company for a period of one year from the conclusion of this AGM till the conclusion of the next AGM at an annual remuneration / fees of ₹ **2,25,000/- (Rupees Two Lakh Twenty Five Thousand only).** On the recommendation of the committee, the Board also recommended for the approval of the Members, the remuneration of **M/s. Sarupria Somani & Associates**, Chartered Accountants for the financial year 2026-27 as set out in the Resolution relating to their re-appointment.

The Committee considered various parameters like capability to serve a diverse and complex business landscapes that of the Company, audit experience in the Company's operating segment, market standing of the firm, clientele served, technical knowledge etc., and found **M/s. Sarupria Somani & Associates** to be best suited to handle the scale, diversity and complexity associated with the audit of the financial statements of the Company.

M/s. Sarupria Somani & Associates have given their consent to act as the Auditors of the Company and have confirmed that the said re-appointment, if made, will be in accordance with the conditions prescribed under Sections 139 and 141 of the Companies Act, 2013.

Disclosure under Regulation 36(5) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Category of the Auditor	Statutory Auditors
Name of Auditor or Auditor's Firm	Sarupria Somani & Associates, Chartered Accountants
Firm Registration No.	010674C
Number of Financial Year(s) to which re-appointment relates	One (1) Year
Period of account for which re-appointed	F.Y. 2026-27
Date of re-appointment made by Board of Directors	August 22, 2026
Proposed fees payable to proposed Statutory Auditor for the F.Y. 2026-27	₹ 2,25,000/- (Rupees Two Lakh Twenty Five Thousand only).
Any material change in the fee payable to such auditor from that paid to the outgoing auditor along with the rationale for such change	Not Applicable
Basis of recommendation and Auditor Credentials	The recommendations are based on the fulfilment of the eligibility criteria prescribed by the Act, with regard to the full-time partners, audit experience of the firms, capability, independence assessment, and audit experience Brief Profile The firm has standing of more than 36 years and the firm is having sufficient work force and is capable of employing more staff as per the need of assignment. The firm has tie up across India for rendering services on PAN India basis. The firm has rich experience in the field of Bank Audits, Accounting, Auditing, Taxation, Company Law, Finance and Management Consultancy. Further, you can find the detailed profile from the outcome of the Company dated 22.08.2026

The Board recommends the Ordinary Resolution set out at Item No. 3 for approval of the Members.

None of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in this Resolution except to the extent of their respective shareholding in the Company to the same extent as that of every other member of the Company.

ITEM NO. 4: TO APPROVE THE REMUNERATION PAYABLE TO MR. PRAVIN MANJIBHAI BHAYANI (DIN: 08332851) AS AN INDEPENDENT DIRECTOR OF THE COMPANY:

Mr. Pravin Manjibhai Bhayani (DIN: 08332851) was first appointed as an Independent Director of the company pursuant to Section 149 of the Companies Act, 2013 and Rules made thereunder on 17th January, 2019 and then reappointed for a second term of five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029 not liable to retire by rotation.

Brief profile of the above Independent Director is as under:

Name of Director	Pravin Manjibhai Bhayani
Date of Birth	22/09/1971
Date of Appointment on the Board	17/01/2019
Expertise in specific functional area	He has 27 years of vast experience in the field of Audit, Accounts, System Implementation, Cost Review, Income-tax, GST and Finance.
Qualifications	FCA (Chartered Accountant), DISA (ICAI), B.Com
Directorships in Public Limited Companies	NIL
Shareholding of Director in the Company	NIL

Membership of Committees in Public Limited Companies:

Audit Committee	NIL
CSR Committee	NIL
Nomination and remuneration committee	NIL

Mr. Pravin Manjibhai Bhayani, aged 54 years, is a Qualified Chartered Accountant and a Fellow Member of The Institute of Chartered Accountants of India and also holds Certificate of Practice of The Institute of Chartered Accountants of India. He completed his commerce graduation i.e. B. Com. from Gujarat University. He also holds Post Qualification degree in Information System Audit (DISA) from ICAI. He has 27 years of vast experience in the field of Audit, Accounts, System Implementation, Cost Review, Income-tax, GST and Finance.

Mr. Pravin Manjibhai Bhayani has confirmed that he is in compliance with Rules 6(1) and 6(2) of the Companies (Appointment and Qualifications of Directors) Rules, 2014, with respect to his registration with the data bank of Independent Directors maintained by the Indian Institute of Corporate Affairs ('IICA'). Mr. Pravin Manjibhai Bhayani is exempt from the requirement to undertake online proficiency self-assessment test conducted by IICA.

In terms of Regulation 25(8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations), Mr. Pravin Manjibhai Bhayani has confirmed that he is not aware of any circumstance or situation which exists or may be reasonably anticipated that could impair or impact his ability to discharge his duties. Mr. Pravin Manjibhai Bhayani has also confirmed that he is not debarred from holding the office of Director by virtue of any SEBI Order or any such authority pursuant to circular dated June 20, 2018 issued by the National Stock Exchange of India Limited pertaining to enforcement of SEBI Orders.

In the opinion of the Board, Mr. Pravin Manjibhai Bhayani fulfils the all the conditions specified in the Companies Act, 2013 and rules made thereunder and the SEBI Listing Regulations as an Independent Director of the Company and that the director is independent of the management.

Section 197 of the Companies Act, 2013 ("Act"), as amended, permits payment of remuneration to Director(s) who is neither Managing Director nor Whole-time Director, in excess of 1% of the net profits of a company, if there is a managing or whole-time director or manager; and in excess of 3% of the net profits of a company, if there is no managing or whole-time director or manager, by obtaining approval of the Shareholders in general meeting by passing a special resolution. Further, the Companies (Amendment) Act, 2020 effective March 18, 2021 inter alia provides that if, in any financial year, a company has no profits or its profits are inadequate, the company shall not pay to its Non-Executive Directors, including an Independent Director, any remuneration except in accordance with the provisions of Schedule V of the Act. The remuneration thresholds as prescribed in Schedule V of the Act can be exceeded by passing a special resolution by the Members of the Company.

Regulation 17(6) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, inter alia provides that the Board shall recommend to the Members for their approval all fees or compensation, if any, paid to Non-Executive Directors, including Independent Directors.

Pursuant to Regulation 17(6)(ca) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the SEBI Listing Regulations"), the approval of the Members by special resolution is required to be obtained every financial year, in which the annual remuneration payable to a single non-executive director exceeds fifty per cent of the total annual remuneration payable to all non-executive directors, giving details of the remuneration thereof. The remuneration payable to Mr.

Pravin Manjibhai Bhayani for the period of one year from 1st October 2026 to 30th September 2027 will exceed 50% of the total remuneration payable to all the Non-Executive Directors of the Company for the said period, considering that no remuneration shall be payable to any other Non-Executive Directors or Independent Directors of the Company.

Mr. Pravin Manjibhai Bhayani plays an important role in overseeing the governance, performance and sustainable growth of the Company. Mr. Pravin Manjibhai Bhayani contributes his wealth of knowledge, skills, expertise, independent perspective, strategies and experience to the business of the Company and provide required diversity in Board's decision-making process. With the enhanced corporate governance requirements, increased responsibilities and duties of the Independent Directors under the Act, the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and the competitive business environment, the role of the Independent Directors, has become more onerous, requiring enhanced level of decision making ability, greater time commitments with high level of oversight.

In view of the above and in appreciation to the contribution and services Mr. Pravin Manjibhai Bhayani has rendered and continue to render to the Company, the Board, on the basis of the recommendation and approval of the Nomination and Remuneration Committee ("NRC") and approval of Audit Committee ("AC"), at their meeting held on **August 22, 2026,** have approved payment of remuneration to Mr. Pravin Manjibhai Bhayani amounting to ₹ 24,00,000/- (Rupees Twenty Four Lakhs Only), per annum **for the period of one year w.e.f. 1st October, 2026 to 30th September, 2027**, payable on a monthly, quarterly, half yearly or yearly basis, as decided by the Board of Directors of the Company.

The aforesaid remuneration shall exclude all the fees payable to Mr. Pravin Manjibhai Bhayani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, Committees, Shareholders and such other meetings as organized by the Company from time to time.

The remuneration may exceed the statutory limits prescribed under Section 197 of the Act but shall be subject to a maximum limit of ₹ 24,00,000/- (Rupees Twenty Four Lakhs Only) per annum. Further, in case of loss or inadequacy of profits, the said amount would be paid as minimum remuneration in accordance with Schedule V of the Act, with requisite approvals.

The Company has not defaulted in payment of dues to any bank or public financial institution or any other secured creditors. The Company have not issued any debentures.

Statement pursuant to Clause (iv) of Section II of Part-II of schedule V of the Companies Act, 2013:

I. GENERAL INFORMATION:

1.	Nature of Industry.	Active Pharma Ingredients & Fine Chemicals		
2.	Date or Expected Date of Commencement of Commercial Production.	Company is already engaged in manufacturing activities.		
3.	In case of New Companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus.	Not applicable.		
4.	Financial performance based on given indicators	**Particulars**	**2025-26 (Rs. in Lacs except EPS)**	**2024-25 (Rs. in Lacs except EPS)**
		Revenue from operations	10365.56	10097.35
		Profit before Tax	1730.16	1792.29
		Profit After Tax	1310.86	1335.79
		EPS	10.65	10.86
5.	Foreign Investments or Collaborators, if any.	At present, the Company does not have any foreign investments or collaborations.		

II. INFORMATION ABOUT THE APPOINTEE:

1. Background Details:

Mr. Pravin Manjibhai Bhayani (DIN: 08332851) was first appointed as an Independent Director of the company pursuant to Section 149 of the Companies Act, 2013 and Rules made thereunder on 17th January, 2019 and then reappointed for a second term of five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029 not liable to retire by rotation.

He is a Qualified Chartered Accountant and a Fellow Member of The Institute of Chartered Accountants of India and also holds Certificate of Practice of The Institute of Chartered Accountants of India. He completed his commerce graduation i.e. B. Com. from Gujarat University. He also holds Post Qualification degree in Information System Audit (DISA) from ICAI. He has 27 years of vast experience in the field of Audit, Accounts, System Implementation, Cost Review, Income-tax, GST and Finance.

2. **Past Remuneration:**

Period	Remuneration paid (₹ in Lakhs)
2023-24	Remuneration: 12.00 (Paid for the period 1st October, 2023 to 31st March, 2024) Sitting Fees: 0.90
2024-25	Remuneration: 24.00 Sitting Fees: 1.00
2025-26	Remuneration: 24.00 Sitting Fees: 0.75

3. **Recognition or awards:**

Mr. Pravin Manjibhai Bhayani plays an important role in overseeing the governance, performance and sustainable growth of the Company. Mr. Pravin Manjibhai Bhayani contributes his wealth of knowledge, skills, expertise, independent perspective, strategies and experience to the business of the Company and provide required diversity in Board's decision-making process.

4. **Job Profile and his suitability:**

In the capacity of Independent Director of the Company Mr. Pravin Manjibhai Bhayani shall be responsible for ensuring adoption of good governance practices and provide his professional expertise and rich experience and knowledge in the filed of finance, accounts business strategy, finance, Information Technology etc.

5. **Remuneration proposed:**

₹ 24,00,000/- (Rupees Twenty Four Lakhs Only), per annum **for the period of one year w.e.f. 1st October, 2026 to 30th September, 2027**, payable on a monthly, quarterly, half yearly or yearly basis, as decided by the Board of Directors of the Company.

The aforesaid remuneration shall exclude all the fees payable to Mr. Pravin Manjibhai Bhayani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, Committees, Shareholders and such other meetings as organized by the Company from time to time.

6. **Comparative remuneration profile with respect to industry, size of the company, profile of the position and person.**

Considering the specialised nature of the Company's business, which encompasses the manufacturing of Active Pharmaceutical Ingredients (APIs) and Fine Chemicals, the remuneration payable has been considered with reference to the size and scale of the Company's operations, the complexity and nature of its business, the responsibilities attached to the respective positions, the experience and qualifications of Pravin Manjibhai Bhayani, and the level of involvement required in managing the Company's operations and affairs.

Given the specialised nature of the Company's business, it is not considered appropriate or meaningful to directly compare the proposed remuneration with that of companies operating in similar industries, as there may be significant differences in the nature and scale of operations, the positions and responsibilities involved, and the qualifications, experience and profiles of the respective managerial personnel. Accordingly, such industry comparison may not be feasible and may not provide a meaningful benchmark or basis for determining comparable remuneration payable for any particular year.

The proposed remuneration of ₹ 2.00 Lakh per month has been considered having regard to his professional qualifications as a Chartered Accountant, more than two decades of experience in audit, taxation, finance and systems, and his role in providing independent financial, governance and risk oversight to the Company for more than 5 years.

7. **Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any.**

Mr. Pravin Manjibhai Bhayani is not holding any the equity share capital of the company. However, his Spouse is holding 6000 equity shares in the company. Apart form this, he is not having pecuniary relation, directly and indirectly, with the company.

III. OTHER INFORMATION:

1. **Reasons of Loss or Inadequate Profits:**

The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Fine Chemicals. The business operates in a competitive environment and is subject to pricing pressures, fluctuations in input costs, changing customer requirements, regulatory requirements and prevailing market conditions. These factors may impact operating margins and profitability from time to time.

2. **Steps taken or proposed to be taken for improvement:**

   The Company continues to focus on strengthening its sales and marketing initiatives, expanding customer relationships and improving market penetration with a view to increasing sales and improving operating performance. Simultaneously, continued emphasis is being placed on cost optimisation, operational efficiency, prudent working-capital management and effective utilisation of resources. These measures are expected to support sustainable improvement in margins and profitability.

3. **Expected increase in productivity and profits in measurable terms:**

   Given the nature of the Company's business and the various external factors influencing its operations, including competitive intensity, market conditions, input-cost fluctuations, customer requirements and regulatory developments, the precise impact of the above measures on productivity and profitability cannot be determined with certainty. Nevertheless, management expects that the continued focus on sales growth, operational efficiency, cost optimisation and prudent resource utilisation will contribute to improvement in productivity and profitability over the medium to long term.

IV. REASONS AND JUSTIFICATION FOR PAYMENT BEYOND LIMITS SPECIFIED IN SCHEDULE.

Mr. Pravin Manjibhai Bhayani is a Qualified Chartered Accountant and a Fellow Member of The Institute of Chartered Accountants of India and also holds Certificate of Practice of The Institute of Chartered Accountants of India. He completed his commerce graduation i.e. B. Com. from Gujarat University. He also holds Post Qualification degree in Information System Audit (DISA) from ICAI. He has 27 years of vast experience in the field of Audit, Accounts, System Implementation, Cost Review, Income-tax, GST and Finance.

Mr. Pravin Manjibhai Bhayani plays an important role in overseeing the governance, performance and sustainable growth of the Company. Mr. Pravin Manjibhai Bhayani contributes his wealth of knowledge, skills, expertise, independent perspective, strategies and experience to the business of the Company and provide required diversity in Board's decision-making process. In the capacity of Independent Director of the Company Mr. Pravin Manjibhai Bhayani shall be responsible for ensuring adoption of good governance practices and provide his professional expertise and rich experience and knowledge in the filed of Audit, Accounts, System Implementation, Cost Review, Income-tax, GST and Finance. Looking to his expertise and experience, it is proposed to approve remuneration beyond the Limits.

Pursuant to the provisions of Sections 197 and other applicable provisions read along with Schedule V of the Companies Act, 2013 and applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 payment of remuneration to Mr. Pravin Manjibhai Bhayani required to be approved by the members of the company by Special Resolution.

The Board commends the Special Resolution set out at Item No. 4 of the Notice for approval by the members.

Except Mr. Pravin Manjibhai Bhayani, none of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in this Resolution except to the extent of their respective shareholding in the Company to the same extent as that of every other member of the Company.

ITEM NO. 5: Ratification of Remuneration of Cost Auditors:

In terms of Section 148 of the Act read with the Companies (Cost Records and Audit) Rules, 2014 ('Rules'), each as amended from time to time, the Company is required to undertake the audit of its cost records for products covered under the Rules. Such cost audit shall be conducted by a cost accountant in practice.

The Audit Committee of the Company considered and recommended to the Board, the appointment of **Maulin Shah & Associates, Cost Accountants** (Firm Registration Number - 101527), as the Cost Auditors of the Company for F.Y. 2026-27, for a remuneration of ₹ 60,000/- plus applicable taxes and reimbursement of out-of-pocket expenses.

Based on the recommendation of the Audit Committee, the Board at its meeting held on August 22, 2026, approved the appointment of **Maulin Shah & Associates, Cost Accountants** (Firm Registration Number - 101527), as the Cost Auditors of the Company for F.Y. 2026-27 at a remuneration of ₹ 60,000/- plus applicable taxes and reimbursement of out-of-pocket expenses, payable to Cost Auditors. In accordance with the provisions of Section 148(3) of the Act read with Rule 14 of the Companies (Audit and Auditors) Rules, 2014, as amended, the remuneration payable to the Cost Auditors, as recommended by the Audit Committee and approved by the Board, must be ratified by the Members of the Company.

The consent of the Members is sought for passing an Ordinary Resolution as set out at Item No. 5 of the Notice for ratification of the remuneration payable to the Cost Auditor of the Company for the Financial Year ending March 31, 2027.

The Board recommends the Ordinary Resolution set forth in Item No. 5 for the approval of the Members.

None of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in this Resolution except to the extent of their respective shareholding in the Company to the same extent as that of every other member of the Company.

Item No.6: To increase Remuneration payable to Mr. Falgun Vallabhbhai Savani (DIN: 00198236) as a Managing Director of the company:

Falgun Vallabhbhai Savani has been the Director of our Company since inception and was subsequently designated as Chairman and Managing Director of the Company w.e.f. November 26, 2018. He holds Bachelor's degree in Pharmacy from B. K. Modi Government Pharmacy Collage, Rajkot affiliated with Saurashtra University. He has more than two decades of experience in API Industry. He is playing vital role in formulating business strategies and effective implementation of the same. He is responsible for expansion, growth and overall management of the business of our Company. His leadership abilities have been instrumental in leading the core team of our Company.

Considering his contribution and progress made by the company under his leadership and guidance and as per the recommendations and approval of Nomination and Remuneration Committee and Audit Committee, the Board at its meeting held on 22nd August, 2026 approved to increase the remuneration payable to **Mr. Falgun Vallabhbhai Savani (DIN: 00198236)** as a Managing Director of the company amounting to ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028 on terms and conditions mentioned hereinafter.

The aforesaid remuneration shall exclude all the fees payable to Mr. Falgun Vallabhbhai Savani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, Committees, Shareholders and such other meetings as organized by the Company from time to time.

The remuneration may exceed the statutory limits prescribed under Section 197 of the Act but shall be subject to a maximum limit of ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum. Further, in case of loss or inadequacy of profits, the said amount would be paid as minimum remuneration in accordance with Schedule V of the Act, with requisite approvals.

The Company has not defaulted in payment of dues to any bank or public financial institution or any other secured creditors. The Company have not issued any debentures.

The main terms and conditions of remuneration of Mr. Falgun Vallabhbhai Savani are furnished below:

1) **Salary, perquisites and allowances:**

Salary including Perquisites and allowances at the rate of ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028.

The aforesaid remuneration shall exclude all the fees payable to Mr. Falgun Vallabhbhai Savani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, Committees, Shareholders and such other meetings as organized by the Company from time to time.

Perquisites and allowances:

Perquisites and allowances shall include -

A. **Car with driver:** Managing Director will be provided a Car with driver for use on Company's business. All the expenses for maintenance and running of the same including salary of the driver to be borne by the company.

B. **Medical reimbursement / allowance:** As per the rules of the Company.

C. **Personal accident insurance:** As per the rules of the Company.

D. The Company shall reimburse actual entertainment and travelling expenses incurred by the Managing Director in connection with the Company's business.

Provided Salary, perquisites and allowances may be revised periodically by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee and Audit Committee within the limits as prescribed in Section 197 read Schedule V of the Companies Act, 2013, including any amendment, modification, variation or re-enactment thereof and subject to the condition that the value of any increment in the annual Salary, perquisites and allowances payable to Managing Director shall not exceed 3% of the Annual Net Profit of the company as per the latest audited financial statements of the company.

2) **Sitting Fees:**

Sitting fees at the rate of Rs. 5,000/- (Rupees Five Thousands Only) per meeting of Board of Directors and its committees attended which may be revised by the Board of director as per requirement.

3) **Perquisites as per the Section IV of the Schedule V of the Act as provided below:**

A. The Board has considered the relation of the Managing Director in terms of his involved in the management of the company through his substantial interest in the company and based on that, it is duly considered that there is no employer and employee relation between the company and Managing Director on his appointment but the same is an agency relationship. Hence, the remuneration as mentioned in point no. 1 above shall not be subject to the provisions of any Provident Fund or ESI under the respective Act(s) and/or Rules framed thereunder and no provisions under the aforesaid Act(s) shall be made over and above of the remuneration payable to the Managing Director.

B. Encashment of leave at the end of tenure as per rules of the company.

C. Gratuity computed as per the provisions of the Gratuity Act shall be payable on retirement of the director from the Company.

It is clarified that employees stock options as might be granted to Mr. Falgun Vallabhbhai Savani, from time to time, shall not be considered as a part of perquisites mentioned above and that the perquisite value of stock options exercised shall be in addition to the remuneration under point no. 1 above.

Statement pursuant to Clause (iv) of Section II of Part-II of schedule V of the Companies Act, 2013:

I. GENERAL INFORMATION:

1.	Nature of Industry.	Active Pharma Ingredients & Fine Chemicals		
2.	Date or Expected Date of Commencement of Commercial Production.	Company is already engaged in manufacturing activities.		
3.	In case of New Companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus.	Not applicable.		
4.	Financial performance based on given indicators	**Particulars**	**2025-26 (Rs. in Lacs except EPS)**	**2024-25 (Rs. in Lacs except EPS)**
		Revenue from operations	10365.56	10097.35
		Profit before Tax	1730.16	1792.29
		Profit After Tax	1310.86	1335.79
		EPS	10.65	10.86
5.	Foreign Investments or Collaborators, if any.	At present, the Company does not have any foreign investments or collaborations.		

II. INFORMATION ABOUT THE APPOINTEE:

1. Background Details:

Falgun Vallabhbhai Savani has been the Director of our Company since inception and was subsequently designated as Chairman and Managing Director of the Company w.e.f. November 26, 2018. He holds Bachelor's degree in Pharmacy from B. K. Modi Government Pharmacy Collage, Rajkot affiliated with Saurashtra University. He has more than two decades of experience in API Industry. He is playing vital role in formulating business strategies and effective implementation of the same. He is responsible for expansion, growth and overall management of the business of our Company. His leadership abilities have been instrumental in leading the core team of our Company.

2. Past Remuneration:

Period	Remuneration paid (Rs. in Lakhs)
2023-24	Remuneration: 51.50 Sitting Fees: 0.60
2024-25	Remuneration: 51.50 Sitting Fees: 0.70
2025-26	Remuneration: 51.50 Sitting Fees: 0.50

3. Recognition or awards:

Mr. Falgun Vallabhbhai Savani is well recognized for his leadership, visionary, and entrepreneur skills in managing business activities and has been efficiently managing overall affairs of the Company.

4. **Job Profile and his suitability:**

   In the capacity of Managing Director of the Company Mr. Falgun Vallabhbhai Savani shall be responsible for defining and executing business strategy, strengthening governance practices and providing overall leadership to the Company's operations or such other roles and responsibilities as may be assigned to him by the Board from time to time.

5. **Remuneration proposed:**

   Salary including Perquisites and allowances at the rate of ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028.

6. **Comparative remuneration profile with respect to industry, size of the company, profile of the position and person.**

   Considering the specialised nature of the Company's business, which encompasses the manufacturing of Active Pharmaceutical Ingredients (APIs) and Fine Chemicals, the remuneration payable has been considered with reference to the size and scale of the Company's operations, the complexity and nature of its business, the responsibilities attached to the respective positions, the experience and qualifications of the individuals, and the level of involvement required in managing the Company's operations and affairs.

   Given the specialised nature of the Company's business, it is not considered appropriate or meaningful to directly compare the proposed remuneration with that of companies operating in similar industries, as there may be significant differences in the nature and scale of operations, the positions and responsibilities involved, and the qualifications, experience and profiles of the respective managerial personnel. Accordingly, such industry comparison may not be feasible and may not provide a meaningful benchmark or basis for determining comparable remuneration payable for any particular year.

   Mr. Falgun Vallabhbhai Savani, Chairman & Managing Director, is a founding member of the Company and possesses more than two decades of industry experience, with a degree in Pharmacy. He is responsible for providing overall leadership and strategic direction to the Company, including oversight of organisational management and governance.

   The remuneration proposed has been considered in the context of their respective roles, responsibilities, experience, contribution and the requirements of managing the Company's business. The Board is of the view that the proposed remuneration is appropriate having regard to the Company's size, operations and managerial requirements

7. **Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any.**

   Mr. Falgun Vallabhbhai Savani is holding 2645952 Equity Shares i.e. 21.50% of the equity share capital of the company. In addition to above, his relatives are also holding shares in the company. Accordingly, he may be deemed having pecuniary relation, directly and indirectly, with the company.

III. OTHER INFORMATION:

1. **Reasons of Loss or Inadequate Profits:**

   The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Fine Chemicals. The business operates in a competitive environment and is subject to pricing pressures, fluctuations in input costs, changing customer requirements, regulatory requirements and prevailing market conditions. These factors may impact operating margins and profitability from time to time.

2. **Steps taken or proposed to be taken for improvement:**

   The Company continues to focus on strengthening its sales and marketing initiatives, expanding customer relationships and improving market penetration with a view to increasing sales and improving operating performance. Simultaneously, continued emphasis is being placed on cost optimisation, operational efficiency, prudent working-capital management and effective utilisation of resources. These measures are expected to support sustainable improvement in margins and profitability.

3. **Expected increase in productivity and profits in measurable terms:**

   Given the nature of the Company's business and the various external factors influencing its operations, including competitive intensity, market conditions, input-cost fluctuations, customer requirements and regulatory developments, the precise impact of the above measures on productivity and profitability cannot be determined with certainty. Nevertheless, management expects that the continued focus on sales growth, operational efficiency, cost optimisation and prudent resource utilisation will contribute to improvement in productivity and profitability over the medium to long term.

IV. REASONS AND JUSTIFICATION FOR PAYMENT BEYOND LIMITS SPECIFIED IN SCHEDULE.

Falgun Vallabhbhai Savani has been the Director of our Company since inception and was subsequently designated as Chairman and Managing Director of the Company w.e.f. November 26, 2018. He holds Bachelor's degree in Pharmacy from B. K. Modi Government Pharmacy Collage, Rajkot affiliated with Saurashtra University. He has more than two decades of experience in API Industry. He is playing vital role in formulating business strategies and effective implementation of the same. He is responsible for expansion, growth and overall management of the business of our Company. His leadership abilities have been instrumental in leading the core team of our Company. Looking to his expertise and experience, it is proposed to approve remuneration beyond the Limits.

Pursuant to the provisions of Sections 197 and other applicable provisions read along with Schedule V of the Companies Act, 2013 and applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, increase in remuneration of Mr. Falgun Vallabhbhai Savani is required to be approved by the members of the company by Special Resolution.

The Board commends the Special Resolution set out at Item No. 6 of the Notice for approval by the members.

Mr. Falgun Vallabhbhai Savani is interested in the resolution set out at Item No. 6 of the Notice. The relative of Mr. Falgun Vallabhbhai Savani i.e. Mr. Jignesh Vallabhbhai Savani, CEO & Director is also deemed to be interested in the resolution set out at Item No. 6 of the Notice, to the extent of their shareholding interest, if any, in the Company.

Save and except the above, none of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in this Resolution except to the extent of their respective shareholding in the Company to the same extent as that of every other member of the Company.

ITEM NO. 7: To increase Remuneration payable to Mr. Jignesh Vallabhbhai Savani (DIN: 00198203) as a CEO of the company:

Mr. Jignesh Vallabhbhai Savani has been the Director of our Company since inception and was also appointed as CEO of the Company w.e.f. 26th Day of November, 2018. Mr. Jignesh Vallabhbhai Savani has completed Matriculation education from Gujarat Secondary Education Board. He has more than two decades of experience in the API Industry. He has been actively involved in the day-to-day operations of our Company and looks after the sales, administration and finance department of our Company. He has work experience in all departments of Company like logistics, HR, Manufacturing, Accounts etc.

Considering his contribution and progress made by the company under his leadership and guidance and as per the recommendations and approval of Nomination and Remuneration Committee and Audit Committee, the Board at its meeting held on 22nd August, 2026 approved to increase the remuneration payable to **Mr. Jignesh Vallabhbhai Savani (DIN: 00198203)** as a CEO of the company amounting to ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028 on terms and conditions mentioned hereinafter.

The aforesaid remuneration shall exclude all the fees payable to Mr. Jignesh Vallabhbhai Savani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, Committees, Shareholders and such other meetings as organized by the Company from time to time.

The remuneration may exceed the statutory limits prescribed under Section 197 of the Act but shall be subject to a maximum limit of ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum. Further, in case of loss or inadequacy of profits, the said amount would be paid as minimum remuneration in accordance with Schedule V of the Act, with requisite approvals.

The Company has not defaulted in payment of dues to any bank or public financial institution or any other secured creditors. The Company have not issued any debentures.

The main terms and conditions of remuneration of Mr. Jignesh Vallabhbhai Savani are furnished below:

1) Salary, perquisites and allowances:

Salary including Perquisites and allowances at the rate of ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028.

The aforesaid remuneration shall exclude all the fees payable to Mr. Jignesh Vallabhbhai Savani for attending the meetings of the Board and Committees of the Board and also exclude the expenses incurred/reimbursement of expenses for attending the meetings of the Board, Committees, Shareholders and such other meetings as organized by the Company from time to time.

Perquisites and allowances:

Perquisites and allowances shall include -

A. Car with driver: CEO will be provided a Car with driver for use on Company's business. All the expenses for maintenance and running of the same including salary of the driver to be borne by the company.

B. Medical reimbursement / allowance: As per the rules of the Company.

C. Personal accident insurance: As per the rules of the Company.

D. The Company shall reimburse actual entertainment and travelling expenses incurred by the Managing Director in connection with the Company's business.

Provided Salary, perquisites and allowances may be revised periodically by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee and Audit Committee within the limits as prescribed in Section 197 read Schedule V of the Companies Act, 2013, including any amendment, modification, variation or re-enactment thereof and subject to the condition that the value of any increment in the annual Salary, perquisites and allowances payable to CEO shall not exceed 3% of the Annual Net Profit of the company as per the latest audited financial statements of the company.

2) Sitting Fees:

Sitting fees at the rate of Rs. 5,000/- (Rupees Five Thousands Only) per meeting of Board of Directors and its committees attended which may be revised by the Board of director as per requirement.

3) Perquisites as per the Section IV of the Schedule V of the Act as provided below:

A. The Board has considered the relation of the CEO in terms of his involved in the management of the company through his substantial interest in the company and based on that, it is duly considered that there is no employer and employee relation between the company and CEO on his appointment but the same is an agency relationship. Hence, the remuneration as mentioned in point no. 1 above shall not be subject to the provisions of any Provident Fund or ESI under the respective Act(s) and/or Rules framed thereunder and no provisions under the aforesaid Act(s) shall be made over and above of the remuneration payable to the CEO.

B. Encashment of leave at the end of tenure as per rules of the company.

C. Gratuity computed as per the provisions of the Gratuity Act shall be payable on retirement of the director from the Company.

It is clarified that employees stock options as might be granted to Mr. Jignesh Vallabhbhai Savani, from time to time, shall not be considered as a part of perquisites mentioned above and that the perquisite value of stock options exercised shall be in addition to the remuneration under point no. 1 above.

Statement pursuant to Clause (iv) of Section II of Part-II of schedule V of the Companies Act, 2013:

I. GENERAL INFORMATION:

1.	**Nature of Industry.**	**Active Pharma Ingredients & Fine Chemicals**		
2.	Date or Expected Date of Commencement of Commercial Production.	Company is already engaged in manufacturing activities.		
3.	In case of New Companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus.	Not applicable.		
4.	Financial performance based on given indicators	**Particulars**	**2025-26 (Rs. in Lacs except EPS)**	**2024-25 (Rs. in Lacs except EPS)**
		Revenue from operations	10365.56	10097.35
		Profit before Tax	1730.16	1792.29
		Profit After Tax	1310.86	1335.79
		EPS	10.65	10.86
5.	Foreign Investments or Collaborators, if any.	At present, the Company does not have any foreign investments or collaborations.		

II. INFORMATION ABOUT THE APPOINTEE:

1. Background Details:

Mr. Jignesh Vallabhbhai Savani has been the Director of our Company since inception and was also appointed as CEO of the Company w.e.f. 26th Day of November, 2018. Mr. Jignesh Vallabhbhai Savani has completed Matriculation education from Gujarat Secondary Education Board. He has more than two decades of experience in the API Industry. He has been actively involved in the day-to-day operations of our Company and looks after the sales, administration and finance department of our Company. He has work experience in all departments of Company like logistics, HR, Manufacturing, Accounts etc.

2. **Past Remuneration:**

Period	Remuneration paid (Rs. in Lakhs)
2023-24	Remuneration: 51.50 Sitting Fees: 0.35
2024-25	Remuneration: 51.50 Sitting Fees: 0.40
2025-26	Remuneration: 51.50 Sitting Fees: 0.30

3. **Recognition or awards:**

   Mr. Jignesh Vallabhbhai Savani is well recognized for his leadership, visionary, and entrepreneur skills in managing business activities and has been efficiently managing overall affairs of the Company.

4. **Job Profile and his suitability:**

   In the capacity of CEO of the Company, Mr. Jignesh Vallabhbhai Savani shall be responsible for executing business strategy and providing overall leadership to the Company's operations or such other roles and responsibilities as may be assigned to him by the Board from time to time.

5. **Remuneration proposed:**

   Salary including Perquisites and allowances at the rate of ₹ 64,00,000/- (Rupees Sixty Four Lakhs Only) per annum for a period of Two (2) years commencing from 26th Day of November, 2026 to 25th Day of November, 2028.

6. **Comparative remuneration profile with respect to industry, size of the company, profile of the position and person.**

   Considering the specialised nature of the Company's business, which encompasses the manufacturing of Active Pharmaceutical Ingredients (APIs) and Fine Chemicals, the remuneration payable has been considered with reference to the size and scale of the Company's operations, the complexity and nature of its business, the responsibilities attached to the respective positions, the experience and qualifications of the individuals, and the level of involvement required in managing the Company's operations and affairs.

   Given the specialised nature of the Company's business, it is not considered appropriate or meaningful to directly compare the proposed remuneration with that of companies operating in similar industries, as there may be significant differences in the nature and scale of operations, the positions and responsibilities involved, and the qualifications, experience and profiles of the respective managerial personnel. Accordingly, such industry comparison may not be feasible and may not provide a meaningful benchmark or basis for determining comparable remuneration payable for any particular year.

   Mr. Jignesh Vallabhbhai Savani, Executive Director & CEO, is a founding team member with extensive industry experience and is responsible for sales, administration, finance and the day-to-day management of the Company's operations.

   The remuneration proposed has been considered in the context of their respective roles, responsibilities, experience, contribution and the requirements of managing the Company's business. The Board is of the view that the proposed remuneration is appropriate having regard to the Company's size, operations and managerial requirements.

7. **Pecuniary relationship directly or indirectly with the company, or relationship with the managerial personnel, if any.**

   Mr. Jignesh Vallabhbhai Savani is holding 2692440 Equity Shares i.e. 21.88% of the equity share capital of the company. In addition to above, his relatives are also holding shares in the company. Accordingly, he may be deemed having pecuniary relation, directly and indirectly, with the company.

III. OTHER INFORMATION:

1. **Reasons of Loss or Inadequate Profits:**

   The Company is primarily engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and Fine Chemicals. The business operates in a competitive environment and is subject to pricing pressures, fluctuations in input costs, changing customer requirements, regulatory requirements and prevailing market conditions. These factors may impact operating margins and profitability from time to time.

2. **Steps taken or proposed to be taken for improvement:**

   The Company continues to focus on strengthening its sales and marketing initiatives, expanding customer relationships and improving market penetration with a view to increasing sales and improving operating performance. Simultaneously, continued emphasis is being placed on cost optimisation, operational efficiency, prudent working-capital management and effective utilisation of resources. These measures are expected to support sustainable improvement in margins and profitability.

3. **Expected increase in productivity and profits in measurable terms:**

   Given the nature of the Company's business and the various external factors influencing its operations, including competitive intensity, market conditions, input-cost fluctuations, customer requirements and regulatory developments, the precise impact of the above measures on productivity and profitability cannot be determined with certainty. Nevertheless, management expects that the continued focus on sales growth, operational efficiency, cost optimisation and prudent resource utilisation will contribute to improvement in productivity and profitability over the medium to long term.

IV. REASONS AND JUSTIFICATION FOR PAYMENT BEYOND LIMITS SPECIFIED IN SCHEDULE.

Mr. Jignesh Vallabhbhai Savani has been the Director of our Company since inception and was also appointed as CEO of the Company w.e.f. 26th Day of November, 2018. Mr. Jignesh Vallabhbhai Savani has completed Matriculation education from Gujarat Secondary Education Board. He has more than two decades of experience in the API Industry. He has been actively involved in the day-to-day operations of our Company and looks after the sales, administration and finance department of our Company. He has work experience in all departments of Company like logistics, HR, Manufacturing, Accounts etc. Looking to his expertise and experience, it is proposed to approve remuneration beyond the Limits.

Pursuant to the provisions of Sections 197 and other applicable provisions read along with Schedule V of the Companies Act, 2013 and applicable regulations of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, increase in remuneration of Mr. Jignesh Vallabhbhai Savani is required to be approved by the members of the company by Special Resolution.

The Board commends the Special Resolution set out at Item No. 7 of the Notice for approval by the members.

Mr. Jignesh Vallabhbhai Savani is interested in the resolution set out at Item No. 7 of the Notice. The relative of Mr. Jignesh Vallabhbhai Savani i.e. Mr. Falgun Vallabhbhai Savani, Chairman & Managing Director is also deemed to be interested in the resolution set out at Item No. 7 of the Notice, to the extent of their shareholding interest, if any, in the Company.

Save and except the above, none of the Directors and Key Managerial Personnel of the Company or their respective relatives are concerned or interested, financially or otherwise, in this Resolution except to the extent of their respective shareholding in the Company to the same extent as that of every other member of the Company.

By Order of the Board of Directors
For Par Drugs and Chemicals Limited

Sd/-
Mr. Sanket B. Trivedi
Company Secretary & Compliance Officer
(Membership No: FCS: 13800)

Place: Bhavnagar
Date: August 22, 2026

Par Drugs And Chemicals Limited
CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph,
Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0278-2447013
Website: www.pardrugs.com Email: investors@pardrugs.com

ANNEXURE - A:

INFORMATION REQUIRED PURSUANT TO SECRETARIAL STANDARD ON GENERAL MEETINGS (SS-2) AND PURSUANT TO REGULATION 36 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015), IN RESPECT OF DIRECTORS SEEKING APPOINTMENT / RE-APPOINTMENT AT THE 27th ANNUAL GENERAL MEETING.

Directors retiring by rotation and eligible for re-appointment:

1. Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203)

Name of Director	**Mr. Jignesh Vallabhbhai Savani**
	
DIN No.	00198203
Designation	Director & CEO
Date of Birth	15/12/1977
Age	48 Years
Date of first appointment on the Board	Appointed as Director on 26/02/1999. Appointed as CEO on 26/11/2018
Qualification / Brief Resume / Expertise in specific functional area / experience	Mr. Jignesh Vallabhbhai Savani has been the Director of our Company since inception and was also appointed as CEO of the Company w.e.f. 26th Day of November, 2018. Mr. Jignesh Vallabhbhai Savani has completed Matriculation education from Gujarat Secondary Education Board. He has more than two decades of experience in the API Industry. He has been actively involved in the day-to-day operations of our Company and looks after the sales, administration and finance department of our Company. He has work experience in all departments of Company like logistics, HR, Manufacturing, Accounts etc.
Terms and conditions of appointment / re-appointment along with details of remuneration sought to be paid	Liable to retire by rotation Mr. Jignesh Vallabhbhai Savani will be eligible for remuneration subject to approval of shareholder as mentioned in the item no. 7 & it's explanatory statement in the capacity of CEO
No. of Shares held in the Company as on 31/03/2026	2692440 Equity Shares
Promoter / Non-Promoter	Promoter
Remuneration	Rs. 51.50 Lakh Remuneration and 0.30 lakh sitting fees F.Y. 2025-26
Relationship with other Directors and Key Managerial Personnel	Brother of Mr. Falgun Vallabhbhai Savani, Chairman & Managing Director of the company.
No of meetings of the Board attended during the year	5 (Five) out of 5 (Five)
Details of Directorship held in other Companies as on 31/03/2026	NIL

Name of Director	**Mr. Jignesh Vallabhbhai Savani**
Details of Chairmanship / Membership of Committees of other companies as on 31/03/2026	NIL
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years	NIL
Affirmation: (Information as required under NSE circular no. NSE/CML/2018/02, dated June 20, 2018.)	Director is not debarred from holding the office by virtue of any SEBI Order or any other authority.

Details required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 Issued on July 11, 2023 and last updated on January 30, 2026

1. Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203)

Name of Director	Mr. Jignesh Vallabhbhai Savani
DIN No.	00198203
Designation	Director & CEO
Reason for change viz. ~~appointment~~, re-appointment, ~~resignation, removal, death or otherwise;~~	Retiring by rotation and being eligible offers himself for re-appointment
Date of ~~appointment~~/ reappointment/ ~~cessation (as applicable)~~ & term of ~~appointment~~ /reappointment;	26th September, 2026 Retiring by rotation and being eligible offers himself for re-appointment
Brief profile	Mr. Jignesh Vallabhbhai Savani has been the Director of our Company since inception and was also appointed as CEO of the Company w.e.f. 26th Day of November, 2018. Mr. Jignesh Vallabhbhai Savani has completed Matriculation education from Gujarat Secondary Education Board. He has more than two decades of experience in the API Industry. He has been actively involved in the day-to-day operations of our Company and looks after the sales, administration and finance department of our Company. He has work experience in all departments of Company like logistics, HR, Manufacturing, Accounts etc.
Disclosure of relationships between directors (in case of appointment of a director);	Brother of Mr. Falgun Vallabhbhai Savani, Chairman & Managing Director of the company

2. M/s. Sarupria Somani & Associates, Chartered Accountants, Statutory Auditors of the company

Reason for change viz. ~~appointment~~, re-appointment, resignation, ~~removal, death or otherwise;~~	Term of M/s. Sarupria Somani & Associates, Chartered Accountants (Firm Registration No.: 010674C) as Statutory Auditors of the Company will end in ensuing 27th Annual General Meeting of the company. It is proposed to re-appoint them as Statutory Auditors of the Company from the conclusion of ensuing 27th Annual General Meeting till the conclusion of the next 28th Annual General Meeting of the Company to be held for the F.Y. 2026-27
Date of ~~appointment~~/ reappointment/ ~~cessation (as applicable)~~ & term of ~~appointment~~ /reappointment;	26th September, 2026
Brief profile	The firm has standing of more than 36 years and the firm is having sufficient work force and is capable of employing more staff as per the need of assignment. The firm has tie up across India for rendering services on PAN India basis. The firm has rich experience in the field of Bank Audits, Accounting, Auditing, Taxation, Company Law, Finance and Management Consultancy. Further, you can find the detailed profile from the outcome of the Company dated 22.08.2026
Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

Par Drugs And Chemicals Limited

CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph, Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0278-2447013
Website: www.pardrugs.com Email: investors@pardrugs.com

ATTENDANCE SLIP

(TO BE HANDED OVER AT THE ENTRANCE)

I/we hereby record my/our presence at the 27th Annual General Meeting of the Company held on Saturday, 26th Day of September, 2026 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India

PLEASE FILL ATTENDANCE SLIP AND HAND IT OVER AT THE ENTRANCE OF THE MEETING VENUE

Full name of the member attending: ____________________

Address: ____________________

Name of Proxy: ____________________

Regd. Folio No.: ____________________

DP Id: ____________________ **Client Id :** ____________________

Number of shares held: ____________________

____________________ ____________________

Full Name of Shareholder (In block letters) **Signature of Shareholder**

____________________ ____________________

Full Name of Proxy (In block letters) **Signature of Proxy**

Par Drugs And Chemicals Limited
CIN: L24117GJ1999PLC035512
Registered office: 815, Nilamber Triumph, Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021, 0278-2447013
Website: www.pardrugs.com Email: investors@pardrugs.com

FORM NO. MGT- 11

PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

Venue of Meeting: Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India

Day, date & time: 27th Annual General Meeting, Saturday, 26th Day of September, 2026 at 11:00 A.M.

Name of the member(s) ______________________________

Registered address : ______________________________

Email Id : ______________________________

Folio No./Client Id : ____________________ DP ID : ____________________

I/We, being the member(s) of .... equity shares of the above named company, hereby appoint

1. Name :..

   Address : ....

   E-mail ID: ....Signature..

or failing him/her

2. Name : ....

   Address : ....

   E-mail ID: ....Signature ....

or failing him/her

3. Name :..

   Address : ....

   E-mail ID: ....Signature ....

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 27th Annual General Meeting of the Company to be held on Saturday, 26th Day of September, 2026 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India and at any adjournment thereof in respect of such resolutions as are indicated below:

I/We direct my/our Proxy to vote on the Resolutions in the manner as indicated below:

Resolution No.	Particulars of Resolution(s)	Vote	
		For	Against
ORDIANARY BUSINESS			
1	To receive, consider and adopt the Audited Standalone Financial Statements of the company for the financial year ended on 31st March, 2026 together with the report of the Board of Directors and Auditors thereon.		
2	To appoint a Director in place of Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203), who retires by rotation and being eligible offer himself for re-appointment.		
3	To re-appoint statutory auditors of the Company and to fix their remuneration and in this regard to consider and if thought fit, to pass, with or without modification(s), the resolution as an Ordinary resolution		
SPECIAL BUSINESS			
4	To approve the remuneration payable to Mr. Pravin Manjibhai Bhayani (DIN: 08332851) as an Independent Director of the Company and in this regard to consider and if thought fit, to pass, with or without modification (s), the resolution as a Special resolution		
5	Ratification of Remuneration of Cost Auditors and in this regard to consider and if thought fit, to pass, with or without modification (s), the resolution as an Ordinary resolution		
6	To increase Remuneration payable to Mr. Falgun Vallabhbhai Savani (DIN: 00198236) as a Managing Director of the Company and to consider and if thought fit, to pass with or without modification(s) the Resolution as a Special Resolution		
7	To increase Remuneration payable to Mr. Jignesh Vallabhbhai Savani (DIN: 00198203) as a CEO of the Company and to consider and if thought fit, to pass with or without modification(s) the Resolution as a Special Resolution		

Please put a tick mark (√) in the appropriate column against the resolutions indicated in the box. If a Member leaves the "For" or "Against" column blank against any or all the Resolutions, the proxy will be entitled to vote in the manner he/she thinks appropriate. If a Member wishes to abstain from voting on a particular resolution, he/she should write "Abstain" across the boxes against the Resolution.

Signed this ....day of 2026

Signature of member (s) ....

Affix Revenue stamp Here

Signature of Proxy holder(s) ....

Note:

1. The Proxy to be effective should be deposited at the Registered office of the company not less than **FORTY EIGHT HOURS before the commencement of the Meeting.** A Proxy need not be a Member of the Company.
2. In the case of joint holders, the vote of the senior who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the vote of the other joint holders. Seniority shall be determined by the order in which the names stand in the Register of Members.
3. A member may vote either for or against each resolution.

Route Map of Venue of 27th Annual General Meeting of the Company to be held on Saturday, 26th Day of September, 2026 at 11:00 A.M. at Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India

Prominent Landmark: Yash Complex, Gotri Circle, Vadodara



Map Link: https://goo.gl/maps/7jQeoU8434ggfvAP6

DIRECTORS' REPORT

Dear Members,

Your Directors have immense pleasure in presenting the Twenty Seventh (27^{th}) Annual Report on the business and operations of the Company together with the Audited Financial Statements of your Company for the financial Year ended March 31^{st}, 2026.

The Director Report is prepared based on the standalone financial statements of the company and the Report on the performance and financial position of the Company.

1. FINANCIAL RESULTS:

(Amount in Lakhs except EPS)

Particulars	For the Year ended 31^{st} March,2026	For the Year ended 31^{st} March,2025
Revenue from Operations	10,365.56	10,097.35
Other Income	400.07	215.03
Total Income	**10,765.63**	**10,312.38**
Less: Total Expenses (excluding Depreciation)	8,665.15	8,155.43
Profit Before Depreciation &Tax	**2,100.48**	**2,156.95**
Less: Depreciation	370.33	364.66
Profit before extraordinary items and tax	**1,730.15**	**1,792.29**
Less: Extraordinary Items	0.00	0.00
Profit before tax	**1,730.15**	**1,792.29**
Less:(i) Current Tax	452.90	452.50
(ii)Deferred Tax	-33.60	4.00
Net Profit/(Loss) For The Year	**1,310.85**	**1,335.79**
EPS (Basic)	10.65	10.86
EPS (Diluted)	10. 65	10.86

2. PERFORMANCE REVIEW & STATE OF COMPANY'S AFFAIRS:

1. The Company is primarily engaged in the business of manufacturing Active Pharmaceutical Ingredients ("APIs") and Fine Chemicals. The Company's product portfolio comprises APIs and Fine Chemicals, which are marketed in domestic as well as international markets.

2. The highlights of the Company's performance during the financial year ended March 31, 2026 are as under:

   - Revenue from operations increased to Rs.10,365.56 Lakhs during FY 2025-26 as compared to Rs.10,097.35 Lakhs during FY 2024-25, representing an increase of Rs.268.21 Lakhs, or approximately 2.66%.

   - Profit after tax stood at Rs.1,310.85 Lakhs during FY 2025-26 as compared to Rs.1,335.79 Lakhs during FY 2024-25, representing a decrease of approximately 1.87%. The moderation in profitability was primarily attributable to pressure on operating margins arising from input-cost and pricing dynamics.

   - Other income increased to Rs.400.07 Lakhs during FY 2025-26 as compared to Rs.215.03 Lakhs during FY 2024-25.

   - Earnings per share ("EPS") decreased to Rs.10.65 during FY 2025-26 from Rs.10.86 during FY 2024-25, representing a decrease of approximately 1.93%.

   - The Company continued to maintain a strong financial position. As at March 31, 2026, the Company had no current or non-current borrowings and remained debt-free.

   - The Company had liquidity of approximately Rs.68.98 Crores, comprising cash and cash equivalents of Rs.41.84 Crores and non-current investments of Rs.27.14 Crores.

   - The Company generated approximately Rs.16.43 Crores of net cash from operating activities during FY 2025-26.

- As at March 31, 2026, the Company's equity share capital stood at Rs.12.30 Crores and other equity stood at Rs.99.68 Crores, resulting in total shareholders' equity of approximately Rs.111.98 Crores.

Product-wise Performance

During FY 2025-26, the Company continued to operate across its two principal product categories, namely APIs and Fine Chemicals. The revenue and volume contribution of the respective product categories were as follows:

Particulars	API	Fine Chemicals	Total
Revenue Share	65.42%	34.58%	100.00%
Volume Share	40.90%	59.10%	100.00%

The above product mix reflects the continued contribution of both APIs and Fine Chemicals to the Company's overall business operations.

Manufacturing Facilities

The Company has four manufacturing blocks at Bhavnagar, comprising facilities for different products, with an aggregate manufacturing capacity of approximately 9,700 MTPA. The manufacturing blocks are broadly utilised for APIs, Magnesium Hydroxide and Fine Chemicals, with certain blocks having capabilities for manufacturing APIs and/or Fine Chemicals.

Operational and Financial Performance

The Company's financial performance during FY 2025-26 remained resilient despite a competitive operating environment and continued pressure on operating margins. Revenue from operations registered modest growth during the year, while profitability moderated compared with the previous year.

The Company continued to focus on maintaining product quality, strengthening customer relationships, improving production efficiency and exercising prudent working-capital management. The improvement in debtor turnover and inventory turnover during the year reflects better management of receivables and inventory.

The Company's debtor turnover ratio improved from 6.04 times in FY 2024-25 to 8.62 times in FY 2025-26, while inventory turnover improved from 16.54 times to 19.29 times. The current ratio also improved from 3.31 times to 4.68 times, reflecting the Company's strong liquidity position.

At the same time, operating profit margin moderated from 19.31% to 16.53%, primarily due to an increase in the cost of materials and other operating costs. The Company continues to monitor input costs, pricing conditions and market developments with a view to maintaining sustainable operating margins.

Business Environment and Outlook

The Company operates in a competitive business environment and its performance is influenced by various factors, including fluctuations in input costs, product pricing, customer requirements, market conditions, regulatory requirements and competitive intensity.

The management continues to focus on strengthening sales and marketing initiatives, expanding and retaining customer relationships, improving market penetration, enhancing operational efficiency and optimising costs. The Company also continues to place emphasis on prudent working-capital management and effective utilisation of its resources.

Going forward, the Company intends to focus on sustainable growth by strengthening its core business, improving operational efficiencies, managing costs effectively and responding appropriately to changing market and customer requirements. The management will continue to evaluate business opportunities based on commercial viability, risk, return, liquidity, regulatory requirements and long-term stakeholder interests.

Capital Allocation and Financial Flexibility

The Company continues to maintain a strong and largely unleveraged financial position. The absence of borrowings, coupled with cash and cash equivalents and investments aggregating to approximately Rs.68.98 Crores, provides the Company with significant financial flexibility.

The management recognises the importance of disciplined capital allocation and will continue to evaluate opportunities available to the Company with due regard to risk, expected returns, liquidity requirements, regulatory considerations and long-term stakeholder interests. Any material capital allocation decision will be undertaken through the appropriate governance processes and in accordance with applicable laws and regulations.

Strategic Initiatives and Proposed Business Diversification

During the previous financial year, the Company had proposed certain strategic initiatives, including the proposed divestment of an existing undertaking and expansion into identified new business verticals. The proposed slump sale was approved by the members pursuant to the requisite resolutions and was subject to applicable regulatory requirements and proceedings.

However, the proposed slump sale remained pending during the year under review due to regulatory proceedings initiated by the Securities and Exchange Board of India ("SEBI"). Consequently, the proposed strategic restructuring and entry into new business segments have not been implemented as originally contemplated.

As on the date of this Report, the matter remains subject to the applicable regulatory process. The Company continues to comply with the applicable regulatory requirements and will take appropriate steps in accordance with the outcome of the proceedings and applicable law.

3. CHANGE IN THE BUSINESS OF THE COMPANY:

The Company is primarily engaged in the business of manufacturing Active Pharmaceutical Ingredients ("APIs") and Fine Chemicals, which are marketed in domestic as well as international markets.

There was no change in the nature of business or business activities of the Company during the financial year ended March 31, 2026.

The Company had proposed certain strategic initiatives, including the proposed divestment of an existing undertaking and entry into certain new business verticals. However, the proposed restructuring and diversification activities were not implemented during the year under review as stated above and, accordingly, there was no change in the nature of business of the Company during FY 2025-26.

4. DIVIDEND:

Your directors don't recommend any Interim and final dividend for the year under review.

5. TRANSFER TO RESERVE:

Pursuant to provisions of Section 134(1)(j) of the Companies Act, 2013, the company has not proposed to transfer any amount to general reserves account of the company during the year under review.

Further, there are no changes in Capital Reserve. During the year an amount of ₹ 1,310.85/- Lakhs transferred to the Surplus in the Statement of Profit & Loss whereas an amount of ₹ 9.88/- Lakhs utilized for income tax adjustment of earlier year.

6. MATERIAL CHANGES AND COMMITMENTS AFFECTING THE FINANCIAL POSITION OF THE COMPANY:

There have been no material changes or commitments affecting the financial position of the Company between the end of the financial year ended March 31, 2026 and the date of this Report.

The proposed strategic initiatives, including the proposed divestment of an existing undertaking and proposed entry into certain new business verticals, as referred to elsewhere in this Board's Report, have not been implemented during the year under review and have not resulted in any material change or commitment affecting the financial position of the Company as at the date of this Report.

The Company continues to operate its existing business of manufacturing Active Pharmaceutical Ingredients ("APIs") and Fine Chemicals, and there has been no material change in the nature of its business or financial position subsequent to the close of the financial year.

7. INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI').

These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

The management finds that the Verification of Financial Accounting & Documents, GST Compliances, Stores, Factory Gate, Statutory Payments, Statutory Returns, Pending Claims are satisfactory and nature and in Physical Verification of Inventories & Capital Assets need some improvement.

All the transactions are properly authorized, recorded and reported to the Management. The Company is following all the applicable Accounting Standards for properly maintaining the books of accounts and reporting financial statements. The Management of the Company and internal auditor checks and verifies the internal control and monitors them in accordance with.

8. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS, COURTS AND TRIBUNALS:

Except as stated below, no significant or material orders were passed by any regulator, court or tribunal during the financial year ended March 31, 2026 which may have an impact on the going concern status of the Company or its operations in the future.

In connection with the strategic initiatives, including the proposed divestment of an existing undertaking and entry into certain new business verticals, the Company received certain communications from the Securities and Exchange Board of India ("SEBI") and the National Stock Exchange of India Limited ("NSE") detailed as under:

1. Communication received from SEBI on Thursday, 12th June 2025 at 4:47 PM via e-mail advising its representatives to attend a meeting in this regard.

   Communication received from SEBI on Wednesday, 18th June 2025 at 12:37 PM via physical meeting.

2. The Securities and Exchange Board of India (SEBI), through an Ex-Parte Interim Order bearing Order No. TM/KV/CFID/CFID-SEC4/31660/2025- 26 dated September 15, 2025, has issued the directions to Par Drugs and Chemicals Limited ("PDCL" or "the Company") and the buyer, Phal-Jig Fine Chemicals Private Limited ("PJFCPL"), in relation to the proposed Business Transfer Agreement ("BTA") with respect to slump sale transaction.

   Key directions include restraint on execution of the BTA, appointment of an independent valuer by NSE, obtaining a fairness opinion from a merchant banker, prohibition on asset alienation, and submission of reports by NSE within prescribed timelines.

3. The NSE has appointed a registered valuer named BANSI S MEHTA VALUERS LLP (IBBI registration number: IBBI/RV- /06/2022/172) to independently carry-out the valuation of the business undertaking proposed to be transferred through the BTA following appropriate valuation methodology as per recognised valuation standards.

4. The NSE has appointed Kunvarji Finstock Private Limited, SEBI-registered merchant banker having SEBI Registration No. INM000012564, effective from December 12, 2025, to obtain a fairness opinion as directed by SEBI in accordance with the SEBI Interim Order dated September 15, 2025.

5. The Securities and Exchange Board of India (SEBI) through Confirmatory Nature and details the action(s) taken or order(s) passed. Order confirmed the directions issued vide Ex- Parte Interim Order bearing Order No. WTM/KV/CFID/CFID-SEC4/31660/2025-26 dated September 15, 2025.

   The Confirmatory Order directions are as under:

   I. Exercise of the powers conferred in terms of section 19 read with sub-sections (1) and (4) of Section 11, Section 118 and Section 11D of the SEBI Act, 1992, confirming the directions issued vide the Interim Order dated September 15, 2025.

   II. The observations made in the Confirmatory Order are tentative in nature, pending detailed investigation. The detailed investigation shall be carried out without being influenced by any of the directions passed or any observation made either in the Interim Order or in the Confirmatory Order.

   III. Based on the outcome of the detailed investigation, appropriate action shall be taken in accordance with law.

   IV. Confirmatory Order shall take effect immediately and shall be in force until further orders.

   V. A copy of Confirmatory Order shall be served upon Noticee, Exchanges, Depositories, RTAs and Banks to ensure necessary compliance.

   As at March 31, 2026 and up to the date of this Report, the aforesaid regulatory proceedings and orders have **not resulted in any identified monetary impact on the financial position or financial statements of the Company.** The Company continues to carry on its existing business operations.

9. DETAILS OF SUBSIDIARY, JOINT VENTURE OR ASSOCIATE COMPANIES:

The Company does not have any Subsidiary, Joint Venture or Associate Company.

10. DEPOSITS:

The Company has neither accepted nor renewed any deposits falling within the purview of Section 73 and 76 of the Companies Act, 2013 read with Companies (Acceptance of Deposits) Rules, 2014 as amended from time to time, during the year under review.

11. AUDITORS & AUDITORS' REPORT:

Statutory Auditors:

It is recommended to appoint M/s. Sarupria Somani & Associates, Chartered Accountants (Firm Registration No.: 010674C), having valid Peer Review certificate, as the Statutory Auditors of the company from the conclusion of the 27th Annual General Meeting till the conclusion of the 28th Annual General Meeting of the Company to be held for the F.Y. 2026-27 at an annual remuneration / fee of ₹ 2,25,000/- (Rupees Two Lakh Twenty-Five Thousand only) plus out of pocket expenses and taxes as applicable from time to time with the power to the Board/Audit Committee to alter and vary the terms and conditions of appointment, revision including upward revision in the remuneration during the remaining tenure. As required under the provisions of Section 139 of the Companies Act, 2013, company has obtained confirmation from M/s. Sarupria Somani & Associates, Chartered Accountants (Firm Registration No.: 010674C), that their appointment, if made, would be in conformity with the limits specified in the said Section.

Statutory Audit report:

Except as mentioned below, Audit report to the Shareholders does not contain any qualification, reservation or adverse remarks:

During the year, the proposed slump sale of the Company's principal business undertaking, approved in the previous year, remained pending due to regulatory proceedings initiated by the Securities and Exchange Board of India (SEBI). Consequently, the Company's proposed strategic restructuring and entry into new business segments have not been implemented as planned.

These circumstances required significant management judgement in assessing the Company's ability to continue as a going concern, considering the uncertainty surrounding completion of the proposed transaction, the Company's existing operations, liquidity position, and future funding plans. Accordingly, this matter was considered to be one of the most significant in our audit.

Based on the audit procedures performed and the evidence obtained, we found management's use of the going concern basis of accounting to be appropriate and the related disclosures in the financial statements to be adequate.

As at the reporting date, the investigation by SEBI is continuing. The observations contained in the Confirmatory Order are tentative in nature and no final determination of liability or wrongdoing has been made. The Company has represented that it is contesting the matters and is cooperating with the ongoing investigation. The ultimate outcome of the proceedings and its financial impact, if any, cannot presently be determined with reasonable certainty.

Board's comment on the Auditors' Report:

The Board has taken note of the observations and disclosures contained in the Statutory Auditors' Report. The Statutory Auditors have expressed an **unmodified opinion** on the standalone financial statements of the Company for the year under review and have not reported any qualification, reservation or adverse remark. The Auditors have, however, drawn attention to the matter relating to the ongoing regulatory proceedings initiated by the Securities and Exchange Board of India ("SEBI").

With regard to the matter relating to the regulatory proceedings initiated by the Securities and Exchange Board of India ("SEBI"), the details thereof have already been disclosed above in this Board's Report. The Board further states that the Company continues to carry on its existing business operations and has adequate financial resources and liquidity to meet its present obligations and operational requirements as a going concern.

Secretarial Auditor:

Pursuant to provisions of Section 204 of the Companies Act, 2013, Board of Directors had appointed M/s. DG Patel & Associates, Practicing Company Secretaries (C.P. No.: 13774) as Secretarial Auditor to conduct Secretarial Audit of the Company for Financial Year 2025-26.

Secretarial Auditor's Report:

Secretarial Audit report to the Shareholders contains following qualification, reservation or adverse remarks:

1. The Special Resolution for Alteration in object clause of the Memorandum of Association of the company passed by the company in the Extra-ordinary General Meeting held on 12th February, 2025 has not been yet filed with the Registrar of Companies in Form No. MGT-14 as required under provisions of Section 13 read with Section 117 of the Companies Act, 2013 and Rules made thereunder.

2. Company had obtained approval of members of the company vide special resolution in the Extra-ordinary General Meeting held on 12th February, 2025 for Slump Sale of the existing establishment (Land, Building, Plant & Machinery, Specific Current Assets & Current Liabilities) under Section 180(1)(A) of The Companies Act, 2013 and Regulation 37A of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 to Phal-Jig Fine Chemicals Private Limited, being a Related Party.

   However, in the matter of the said Slump Sale, several communications received from SEBI and NSE and SEBI has passed Interim & Confirmatory Orders. Consequently, the Company's slump sale and entry into new business segments have not been implemented as planned and as on the date of this report, the investigation by SEBI is continuing. The observations contained in the Confirmatory Order are tentative in nature and no final determination of liability or wrongdoing has been made.

   Directors' comments on above mentioned qualification:

   The Board has taken note of and acknowledgement of the observations made by the Secretarial Auditor in the Secretarial Audit Report for the financial year ended March 31, 2026.

The Company shall take appropriate steps to complete the requisite statutory filing with the Registrar of Companies and ensure compliance with the applicable provisions of the Companies Act, 2013 and the rules made thereunder, subject to the directions issued by the regulatory authorities. The Company shall also take such further actions as may be required in accordance with the outcome of the ongoing regulatory proceedings.

The Secretarial Audit Report for the financial year ended 31st March, 2026 is annexed herewith as **Annexure - I** to this report.

Internal Auditor:

As per Section 138 of Companies Act 2013, every Listed Company is required to appoint an Internal Auditor or a firm of Internal Auditors.

M/s Siddhpura & Co., Chartered Accountants was appointed as Internal Auditors to conduct internal audit for F.Y. 2025-26 as per agreed scope of works pursuant to the provision of section 138 of Companies Act, 2013 read with Companies (Accounts) Rules, 2014.

12. DETAILS OF FRAUD REPORTING BY AUDITOR:

Pursuant to provisions of Section 143(12) of the Companies Act, 2013, the Statutory Auditors have not reported any incident of fraud.

13. MAINTENANCE OF COST RECORDS AND COST AUDITORS AND COST AUDIT REPORT:

Maintenance of Cost Records:

Maintenance of cost records as specified by the Central Government under sub-section (1) of section 148 of the Companies Act, 2013 is required by the Company and accordingly such accounts and records are made and maintained.

Cost Auditors:

As per Section 148 of the Companies Act, 2013, the Company is required to have the audit of its cost records conducted by a Cost Accountant in practice for the F.Y. 2026-27. Accordingly, **M/s Maulin Shah & Associates, Cost Accountants** (Firm Registration Number-101527) were appointed by the Board of Directors of the Company in its meeting held on 22nd August, 2026 as Cost Auditors to conduct the audit of the cost accounting records of the Company as prescribed under the Companies (Cost Records and Audit) Rules, 2014 for the financial year ending on March 31, 2027.

Cost Audit Report:

Cost Audit Report of the cost records by the Cost Auditors **M/s Maulin Shah & Associates, Cost Accountants** (Firm Registration Number -101527) for the F.Y. 2025-26 does not contain any qualification, reservation or adverse remarks.

14. DIRECTORS AND KEY MANAGERIAL PERSONNEL (KMP):

14.1 Composition of Board of Directors:

The Board of Directors of Company is a balanced one with an optimum mix of Executive and Non-Executive Directors The Board of the Company is headed by an Executive Chairman.

As on 31st March, 2026 the Board of Company consists of following Directors:

Sr. No.	Name of Director & DIN	Category	Age in Years	No. of Directorship in other companies	No. of membership &Chairmanship of committees in other Public Limited Company
1.	Mr. Falgun Vallabhbhai Savani DIN: 00198236	Chairman and Managing Director (Promoter)	51	NIL	NIL
2.	Mr. Jignesh Vallabhbhai Savani DIN: 00198203	Executive Director & CEO (Promoter)	48	NIL	NIL
3.	Mr. Pravin Manjibhai Bhayani DIN: 08332851	Non- Executive Independent Director	54	NIL	NIL
4.	Mrs. Krishna Mitulbhai Shah DIN: 08317678	Non- Executive Independent Director	47	NIL	NIL
5.	Mrs. Kajal Chintanbhai Vaghani DIN: 08317641	Non- Executive Independent Director	46	NIL	NIL
6.	Mrs. Bintal Bhaveshkumar Shah DIN: 08893054	Non- Executive Independent Director	50	NIL	NIL

Notes:

(i) *Chairmanship/Membership of Committee only includes Audit Committee and Stakeholders' Relationships Committee in Indian Public Limited companies other than Par Drugs and Chemicals Limited. Members of the Board of the Company do not have membership of more than ten Board-level Committees or Chairperson of more than five such Committees.*

(ii) *None of the directors are related to each other except Mr. Falgun Vallabhbhai Savani and Mr. Jignesh Vallabhbhai Savani who are related to each other.*

(iii) *Details of Director(s) retiring or being re-appointed are given in notice to Annual General Meeting.*

(iv) *Brief profiles of each of the above Directors are given in the beginning of the report.*

14.2 Key Managerial Personnel (KMP):

As on 31st March, 2026, Mr. Falgun Vallabhbhai Savani, Chairman & Managing Director; Mr. Jignesh Vallabhbhai Savani, Chief Executive Officer; Mr. Chintan Pratapbhai Chauhan, Chief Financial Officer and Mr. Sanket Bhupendrabhai Trivedi, Company Secretary and Compliance Officer of the Company are the Key Managerial Personnel as per the provisions of the Companies Act, 2013. There is no change in Key Managerial Personnel during the year under review.

14.3 Directors retiring by rotation and seeking appointment/re-appointment:

In terms of section 152 of the Companies Act, 2013, **Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203),** who retires by rotation and being eligible offers himself for re-appointment. Based on the performance evaluation and recommendation of the nomination and remuneration committee, the Board recommends his reappointment.

Term of **Mrs. Bintal Bhaveshkumar Shah (DIN: 08893054)** as an Independent Director of the Company ended on 27th September, 2025. She was to re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 28th Day of September, 2025 to 27th September, 2030 in the 26th Annual General Meeting of the company held on 27th September, 2025.

Term of **Mr. Falgun Vallabhbhai Savani (DIN: 00198236)** as Chairman & Managing Director ended on 25th Day of November, 2023. He was re-appointed as Chairman & Managing Director for further period of 5 years from 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting of the company held on 16th September, 2023.

Term of **Mr. Jignesh Vallabhbhai Savani (DIN: 00198203)** as CEO ended on 25th Day of November, 2023. He was re-appointed as CEO for further period of 5 years from 26th Day of November, 2023 to 25th Day of November, 2028 in the 24th Annual General Meeting of the company held on 16th September, 2023.

Term of **Mr. Pravin Manjibhai Bhayani (DIN: 08332851)** as an Independent Director of the Company ended on 16th Day of January, 2024. He was re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029 in the 24th Annual General Meeting of the company held on 16th September, 2023.

Term of **Mrs. Krishna Mitulbhai Shah (DIN: 08317678)** as an Independent Director of the Company ended on 16th Day of January, 2024. She was re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029 in the 24th Annual General Meeting of the company held on 16th September, 2023.

Term of **Mrs. Kajal Chintanbhai Vaghani (DIN: 08317641)** as an Independent Director of the Company ended on 16th Day of January, 2024. She was re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029 in the 24th Annual General Meeting of the company held on 16th September, 2023.

15. MEETINGS OF BOARD OF DIRECTORS:

Details of the Board Meetings held during the Financial Year ended 31st March, 2026 are as under**.** The intervening gap between the Meetings was within the period prescribed under Companies Act, 2013.

Meeting No.	Date of Board Meeting	Total no. of Directors	No. of Directors present
1/2025-26	08-05-2025	6	6
2/2025-26	07-08-2025	6	6
3/2025-26	29-08-2025	6	6
4/2025-26	13-11-2025	6	6
5/2025-26	10-02-2026	6	6

The names of members of the Board and their attendance at the Board Meetings are as under:

Name of the Directors	Number of Meetings which Director was entitled to attend	Number of Board Meetings attended during the F.Y. 2025-26
Mr. Falgun Vallabhbhai Savani	5	5
Mr. Jignesh Vallabhbhai Savani	5	5
Mrs. Krishna Mitulbhai Shah	5	5
Mrs. Kajal Chintanbhai Vaghani	5	5
Mr. Pravin Manjibhai Bhayani	5	5
Mrs. Bintal Bhaveshkumar Shah	5	5

15.1 Board Committees and their Meetings:

1. Audit Committee:

The Audit Committee comprises of four members with three Independent Directors and one Executive Director as on 31st March, 2026.

The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	5/5
Mrs. Kajal Chintanbhai Vaghani	Non-Executive & Independent Director	Member	5/5
Mr. Falgun Vallabhbhai Savani	Chairman & Managing Director	Member	5/5
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	5/5

Meeting No.	Date of Audit Committee Meeting	Total no. of Member	No. of Member present
1/AC/2025-26	08-05-2025	4	4
2/AC/2025-26	07-08-2025	4	4
3/AC/2025-26	29-08-2025	4	4
4/AC/2025-26	13-11-2025	4	4
5/AC/2025-26	10-02-2026	4	4

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

2. Nomination and Remuneration Committee:

The Nomination and Remuneration Committee comprises of three members with two Independent Directors and one Non-executive Director as on 31st March, 2026.

The Committee met two times during the year August 29, 2025 and February 10, 2026. The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	2/2
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	2/2
Mrs. Bintal Bhaveshkumar Shah	Non-Executive & Independent Director	Member	2/2

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

3. Stakeholder's Relationship Committee:

Company has constituted a Stakeholders Relationship Committee to redress complaints of the shareholders The Stakeholder's Relationship Committee comprises of three members with two Independent Directors and one Executive Director as on 31st March, 2026.

The Committee met once on August 29, 2025. The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	1/1
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	1/1
Mr. Jignesh V. Savani	Executive Director & CEO	Member	1/1

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

4. CSR Committee:

The board of directors have formulated the CSR Committee on January 23, 2020 in order to take corporate initiative to assess and take responsibility for the company's effects on the environment and impact on social welfare.

The CSR Committee comprises of three members with all Independent Directors as on March 31, 2026.The Committee met once during the year i.e. on March 26, 2026.

The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	1/1
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	1/1
Mrs. Bintal Bhaveshkumar Shah	Non-Executive & Independent Director	Member	1/1

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

5. Independent Director Meeting:

One Meeting of Independent Directors held on March 26, 2026 during the year under review and attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	1/1
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	1/1
Mrs. Kajal Chintanbhai Vaghani	Non-Executive & Independent Director	Member	1/1
Mrs. Bintal Bhaveshkumar Shah	Non-Executive & Independent Director	Member	1/1

16. DETAILS OF REMUNERATION PAID TO DIRECTORS/KMPS:

Name of Director/KMP	Designation	Remuneration / Sitting Fees* p.a.(in Lakhs)
Mr. Falgun Vallabhbhai Savani	Chairman & Managing Director	51.50 0.50*
Mr. Jignesh Vallabhbhai Savani	CEO and Executive Director	51.50 0.30*
Mrs. Krishna Mitulbhai Shah	Non- Executive Independent Director	0.75*
Mrs. Kajal Chintanbhai Vaghani	Non- Executive Independent Director	0.55*
Mr. Pravin Manjibhai Bhayani	Non- Executive Independent Director	24.00# 0.75*
Mrs. Bintal Bhaveshkumar Shah	Non- Executive Independent Director	0.45*
Mr. Sanket Bhupendrabhai Trivedi	Company Secretary & Compliance Officer	8.23
Mr. Chintan Pratapbhai Chauhan	Chief Financial Officer (CFO)	7.65

** Sitting Fees*

 # the remuneration paid to Independent Director as approved by passing special resolution by the members in the previous annual general meeting of the Company held on September 21, 2024 & September 27, 2025

17. POLICY ON APPOINTMENT AND REMUNERATION TO DIRECTORS, KMP & SENIOR MANAGEMENT PERSONNEL:

The Board has, on the recommendation of the Nomination and Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration. Company's policy on Directors' appointment and remuneration and other matters provided in Section 178(3) of the Companies Act, 2013 is available on the website of the company at http://pardrugs.com/pdf/policies/Nomination%20and%20Remuneration%20Policy%20-%20PAR.pdf

18. CODE OF CONDUCT:

The Board has laid down a Code of Conduct for all Board Members and Senior Management of the Company which is posted on the website of the Company at http://pardrugs.com/pdf/policies/Code%20of%20Director%20&%20Senior%20Management%20Personnel%20-%20PAR.pdf

19. INSIDER TRADING:

As per SEBI (Prohibition of Insider Trading) Regulations, 2015, the Company has devised the Code of Conduct to regulate, monitor and report trading in Company's securities by persons having access to unpublished price sensitive information of the Company. The Company Secretary is the Compliance Officer for the purpose of this code.

20. FAMILIARIZATION PROGRAMME FOR INDEPENDENT DIRECTOR:

The Independent Directors are very enthusiastic to get involved in the activity of the Company and on continuous basis they are in constant touch with the executive directors of the Company and also they have taken part in the activity like to visit Company's plants, where plant heads appraise them of the operational and sustainability aspects of the plants to enable them to have full understanding on the activities of the Company and initiatives taken on safety, quality, CSR, Sustainability etc. Further detailed programme is available on the website of the company at http://pardrugs.com/familiraisation-programme.php

21. BOARD EVALUATION:

Pursuant to the provisions of the Companies Act, 2013 and Regulation 17(10) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, the Board has carried out an annual performance evaluation of its own performance, the directors individually as well as the evaluation of the working of its all committees.

22. DECLARATION BY INDEPENDENT DIRECTORS:

The Company has received declarations from all the Independent Directors confirming that they meet criteria of independence as prescribed under Section 149(6) of the Companies Act, 2013 and under Regulation 16(1)(b) of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. Pursuant to Ministry of Corporate Affairs Notification, dated October 22, 2019 all the Independent Directors of the Company have already registered themselves on IICA and also they have successfully qualified online proficiency for Independent Director's Data bank from Indian Institute of Corporate Affairs as on date this report.

23. PARTICULARS OF LOANS, GUARANTEES AND INVESTMENT U/S 186 OF THE COMPANIES ACT, 2013:

During the reporting period, your Company has not granted any loans, guarantees or made investments or provided securities in violation of Section 186 of the Companies Act, 2013 and rules thereof.

The details of loans, guarantees, securities and investments, wherever applicable, requiring disclosure under Section 186 of the Companies Act, 2013 are provided in the relevant Notes to the Financial Statements forming part of this Annual Report.

24. WEB LINK OF ANNUAL RETURN:

Pursuant to Section 92(3) and Section 134(3)(a) of the Companies Act, 2013, the Company has placed a copy of the Annual Return as of March 31, 2025, on its website at http://www.pardrugs.com/annual-reports.php The Company will also place annual return in Form No MGT-7 for FY 2025-26 on completion of ensuing annual general meeting of shareholders of the Company in due course.

25. SHARE CAPITAL:

Authorized Share Capital:

The authorized share capital of the Company is ₹ 12,50,00,000/- divided into 1,25,00,000 Equity Shares

Paid up Share Capital:

At present, paid-up equity share capital is ₹ 12,30,46,360/- consisting of 12304636 equity shares of ₹ 10/- each.

Buy Back of Securities:

The Company has not bought back any of its securities during the year under review.

Sweat Equity:

The Company has not issued any Sweat Equity Shares during the year under review.

Bonus Shares:

The Company has not issued any Bonus Shares during the year under review.

Employees Stock Option Plan:

The Company has not provided any Stock Option Scheme to the employees during the year under review.

26. DEMATERIALISATION OF SHARES:

100% of the company's paid-up Equity Share Capital is in dematerialized form as on 31st March, 2026.

27. CONTRACTS AND ARRANGEMENTS WITH RELATED PARTIES:

During the year under review, company has not entered into contracts or arrangements under Section 188 of the Companies Act, 2013 with related parties. Therefore, details in Form AOC-2 is not applicable. Further, the disclosure of transactions with related party for the year, as per Accounting Standard-18 Related Party Disclosures is given in Note no. 30 to the Balance Sheet as on 31st March, 2026.

The Board of Directors of the Company has, on the recommendation of the Audit Committee, adopted a policy to regulate transactions between the Company and its related parties, in compliance with the applicable provisions of the Companies Act 2013, the rules made thereunder and the SEBI (Listing Obligation and Disclosure Requirement) Regulation, 2015. This policy was considered and approved by the Board and has been uploaded on the website of the Company at http://pardrugs.com/pdf/policies/Revised_Policy_on_Related_Party_Tranactions.pdf

28. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE EARNINGS & OUTGO:

A. Conservation of Energy & Technology Absorption:

The particulars as required under the provisions of Section 134(3) (m) of the Companies Act, 2013 in respect of conservation of energy and technology absorption have been furnished considering the nature of activities undertaken by the company during the year under review is annexed hereto as **Annexure-II** and forms part of this report.

B. Foreign Exchange earnings and Outgo:

Foreign Earnings: ₹ Rs 2,804.93 Lacs (FOB value of Export)

Foreign Outgo:

1. ₹ 7.28 Lacs (Value of imported raw materials consumed)
2. ₹ 312.00 Lacs (Commission Expenses)
3. ₹ 0.07 Lacs (Bank Charges)

29. PARTICULARS OF EMPLOYEES:

During the year under review, none of the employees of the Company were in receipt of remuneration exceeding ₹ 1,02,00,000/- p.a., if employed throughout the year or ₹ 8,50,000/- p.m. if employed for part of the year. Further, statement containing particulars of employees under Section 197(12) of the Companies Act, 2013 read with Rule 5(1) and 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is as under:

INFORMATION AS PER RULE 5(1) OF THE COMPANIES (APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL) RULES, 2014

1. Ratio of the remuneration of each director to the median remuneration of the employees and percentage increase in remuneration of each Director, CEO, CFO and CS of the Company for the financial year 2025-26:

Name	Designation	% increase/ (decrease) in remuneration in the FY 2025-26	Ratio of the remuneration of each director to the median remuneration of the employees of the company for the financial year
Mr. FALGUN VALLABHBHAI SAVANI	Chairman & Managing Director	0.00	17.26:1
Mr. JIGNESH VALLABHBHAI SAVANI	Executive Director & Chief Executive Officer	0.00	17.26:1
Mr. PRAVIN MANJIBHAI BHAYANI	Independent Director**	0.00	8.04:1
Mr. PRAVIN MANJIBHAI BHAYANI	Independent Director*	-25.00	0.25:1
Mrs. KRISHNA MITULBHAI SHAH	Independent Director*	-25.00	0.25:1
Mrs. KAJAL CHINTANBHAI VAGHANI	Independent Director*	-15.38	0.18:1
Mrs. BINTAL BHAVESHKUMAR SHAH	Independent Director*	0.00	0.15:1
Mr. SANKET BHUPENDRABHAI TRIVEDI	Company Secretary and Compliance Officer	12.89	-
Mr. CHINTAN PRATAPBHAI CHAUHAN	Chief Financial Officer	13.00	-

*Note: * Remuneration of the Directors consists only of sitting fees drawn by them.*

*** Remuneration of the Independent Director which is approved in the previous AGM by members*

****The percentage increase in remuneration is calculated basis the remuneration as per Section 17 of the Income Tax Act, 1961.*

2. Median remuneration of employee during the year of the company is ₹ 2.98 Lakh
3. Percentage increase in the median remuneration of employees in the financial year (Median 2025-26/Median 2024-25): 29.85%
4. The number of permanent employees on the rolls of company: 118
5. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration:-
   a. Average percentage increase in salary of employees other than managerial personnel is 11.83%
   b. Average percentage increase in salary of managerial personnel is 0.68%
6. The Company hereby affirm that the remuneration is as per remuneration policy of the Company

   Information pursuant to Rule 5(2) & 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 also forms part of this report pursuant to proviso to Section 136(1) of the Act. Any shareholder interested in obtaining a copy of the same may write to the Company Secretary at the registered office address of the Company

30. RISK MANAGEMENT POLICY:

At Par Drugs and Chemicals Limited, risks are measured, estimated and controlled with the objective to mitigate adverse impact. Your company's fundamental approach to risk management includes to ensure sustainable business growth with stability and to promote a pro-active approach in reporting, evaluating and resolving risks associated with the business. The Company has adopted an approach towards risk assessment, risk management and risk monitoring, which is periodically reviewed by the Board.

31. CORPORATE SOCIAL RESPONSIBILITY:

The brief outline of the corporate social responsibility (CSR) policy of the Company and the initiatives undertaken by the Company on CSR activities during the year are set out in **Annexure-III** of this report in the format prescribed in the Companies (Corporate Social Responsibility Policy) Rules, 2014. For other details regarding the CSR Committee, please refer to the said Report, which is a part of this report. CSR Policy is available on the Company's website at http://pardrugs.com/pdf/policies/Final_CSR_POLICY.pdf

32. VIGIL MECHANISM:

In pursuant to the provisions of section 177(9) & (10) of the Companies Act, 2013, a Vigil Mechanism for directors and employees to report genuine concerns has been established. The Vigil Mechanism Policy has been uploaded on the website of the Company at https://www.pardrugs.com/pdf/policies/Vigil%20Mechanism%20Policy%20-%20PAR.pdf

33. HUMAN RESOURCES:

During the period under review, the personal and industrial relations with the employees remained cordial in all respects. The management has always carried out systematic appraisal of performance and imparted training at periodic intervals.

34. CORPORATE GOVERNANCE:

Your company is committed to good Corporate Governance and has taken adequate steps to ensure that the requirements of Corporate Governance SEBI (LODR) Regulations, 2015 are complied with. The Corporate Governance Report with the Auditors' Certificate thereon, and Management Discussion and Analysis Report are attached, and Corporate Governance Report is attached as an **Annexure-IV.** Further Company regularly filed Corporate Governance Report as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 which are available on the website of the Company at http://pardrugs.com/corporate-governance-report.php

35. MANAGEMENT DISCUSSION AND ANALYSIS REPORT:

As required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Management Discussion and Analysis Report is enclosed as a part of this report.

36. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE:

The Company has zero tolerance towards sexual harassment at the workplace and has adopted a policy on prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. Internal Complaint Committee is set up to redress complaints received regularly. There were no complaints received and reported under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. Following are the data with respect to complaints received and reported under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

Particulars	Instances
Number of complaints of sexual harassment received in the year	0
Number of complaints disposed off during the year	0
Number of cases pending for more than ninety days	0

37. DISCLOSURE WITH RESPECT TO COMPLIANCE OF THE PROVISIONS RELATING TO THE MATERNITY BENEFIT ACT 1961:

The Company affirms that it has duly complied with all provisions of the Maternity Benefit Act, 1961, and has extended all statutory benefits to eligible women employees during the year under review.

38. DIRECTOR'S RESPONSIBILITY STATEMENT:

Pursuant to Section 134 (5) of the Companies Act, 2013 the Board of Directors of the Company confirms that-

a) In the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;

b) The Directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit and loss of the Company for that period;

c) The Directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;

d) The Directors had prepared the annual accounts on a 'going concern' basis;

e) the directors had laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and were operating effectively and

f) The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.

39. COMPLIANCE WITH SECRETARIAL STANDARDS:

The company has complied with the applicable Secretarial Standards issued time to time by the Institute of Company Secretaries of India.

40. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONGWITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR:

Not applicable as no application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016.

41. THE DETAILS OF DIFFERENCE BETWEEN AMOUNT OF THE VALUATION DONE AT THE TIME OF ONE TIME SETTLEMENT AND THE VALUATION DONE WHILE TAKING LOAN FROM THE BANKS OR FINANCIAL INSTITUTIONS ALONG WITH THE REASONS THEREOF.

Not applicable.

42. ACKNOWLEDGMENT:

Your Directors would like to express their sincere appreciation for the assistance and cooperation received from the banks, Government authorities, customers, vendors and members during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed services by the Company's executives, staff and workers.

For & On Behalf of Board of Directors
PAR DRUGS AND CHEMICALS LIMITED

Date: August 22, 2026	**Sd/-** **(Mr. Falgun V. Savani)** Chairman & Managing Director (DIN: 00198236)	**Sd/-** **(Mr. Jignesh V. Savani)** Director & CEO (DIN: 00198203)
Place: Bhavnagar		

Annexure - I

Form No. MR-3

SECRETARIAL AUDIT REPORT

For the financial year ended 31ST MARCH, 2026

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
PAR DRUGS AND CHEMICALS LIMITED
815, Nilamber Triumph, Gotri Vasna Road,
Vadodara- 390007 Gujarat, India.

We have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Par Drugs And Chemicals Limited (hereinafter called "the Company"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company, the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, the explanations and clarifications given to us and the representations made by the Management, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on **March 31, 2026** generally complied with the statutory provisions listed hereunder and also that the Company has proper Board processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records made available to us and maintained by the Company for the financial year ended on **March 31, 2026** according to the provisions of:

(i) The Companies Act, 2013 ('the Act') and the Rules made thereunder;

We hereby report that the Special Resolution for Alteration in object clause of the Memorandum of Association of the company passed by the company in the Extra-ordinary General Meeting held on 12th February, 2025 has not been yet filed with the Registrar of Companies in Form No. MGT-14 as required under provisions of Section 13 read with Section 117 of the Companies Act, 2013 and Rules made thereunder.

(ii) The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;

(iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;

(iv) Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;

(v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):

a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;

b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 and amendments from time to time;

d. The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2021 - **Not applicable to the company during Audit period;**

e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008 **- Not applicable to the company during Audit period;**

f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 and amendments from time to time regarding the Companies Act and dealing with client**;**

g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 **- Not applicable to the company during Audit period;**

h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 - **Not applicable to the company during Audit period;**

(vi) Other laws applicable to the Company as per the representations made by the Company, its officers and authorized representatives during the conduct of audit namely:

a. Environment (Protection) Act, 1986 and Rules made thereunder;

b. Hazardous Waste (Management and Handling) Rules, 1989;

c. Hazardous and Other Wastes (Management and Transboundary Movement) Rules, 2016;

d. Air (Prevention and Control of Pollution) Act, 1981;

e. Water (Prevention and Control of Pollution) Act, 1974;

f. The Drugs and Cosmetics Act, 1940 as amended from time to time;

g. The Drugs and Cosmetic Rules, 1945 as amended from time to time;

h. Labour, Employee, Industrial and other Laws to the extent applicable to the Company.

The examination and reporting on abovementioned laws and rules are limited to whether there are adequate systems and process in place to monitor and ensure compliance with those laws.

We have also examined compliance with the applicable clauses of the following:

(i) Secretarial Standards issued by The Institute of Company Secretaries of India with respect to board and general meetings;

(ii) SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and the Listing Agreements entered into by the Company with Stock exchange.

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above except as mentioned below:

1. The Special Resolution for Alteration in object clause of the Memorandum of Association of the company passed by the company in the Extra-ordinary General Meeting held on 12th February, 2025 has not been yet filed with the Registrar of Companies in Form No. MGT-14 as required under provisions of Section 13 read with Section 117 of the Companies Act, 2013 and Rules made thereunder.

2. Company had obtained approval of members of the company vide special resolution in the Extra-ordinary General Meeting held on 12th February, 2025 for Slump Sale of the existing establishment (Land, Building, Plant & Machinery, Specific Current Assets & Current Liabilities) under Section 180(1)(A) of The Companies Act, 2013 and Regulation 37A of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 to Phal-Jig Fine Chemicals Private Limited, being a Related Party.

However, in the matter of the said Slump Sale, several communications received from SEBI and NSE and SEBI has passed Interim & Confirmatory Orders. Consequently, the Company's slump sale and entry into new business segments have not been implemented as planned and as on the date of this report, the investigation by SEBI is continuing. The observations contained in the Confirmatory Order are tentative in nature and no final determination of liability or wrongdoing has been made.

We further report that during the audit period, The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance other than those held at shorter notice, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

We further report that the systems and processes in the company are commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

We further report that during the Audit period following events/actions have been occurred, which have a major bearing on company's affairs in pursuance of the above referred Laws, Rules, regulations, guidelines, Standards etc.:

1. Company had obtained approval of members of the company vide special resolution in the Extra-ordinary General Meeting held on 12th February, 2025 for Slump Sale of the existing establishment (Land, Building, Plant & Machinery, Specific Current Assets & Current Liabilities) under Section 180(1)(A) of The Companies Act, 2013 and Regulation 37A of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 to Phal-Jig Fine Chemicals Private Limited, being a Related Party.

   However, in the matter of the said Slump Sale, several communications received from SEBI and NSE and SEBI has passed Interim & Confirmatory Orders. Consequently, the Company's slump sale and entry into new business segments have not been implemented as planned and as on the date of this report, the investigation by SEBI is continuing. The observations contained in the Confirmatory Order are tentative in nature and no final determination of liability or wrongdoing has been made.

FOR DG PATEL & ASSOCIATES
Company Secretaries

Place: Bhavnagar
Date: 22/08/2026
UDIN: F010533H001186081

Sd/-
Dip G. Patel
(Proprietor)
FCS: 10533
C.P. No.: 13774
PR: 1839/2022

Note: This Report is to be read with our letter of even date which is annexed as 'Annexure A' and forms an integral part of this report.

'Annexure A'

To,
The Members
PAR DRUGS AND CHEMICALS LIMITED
815, Nilamber Triumph, Gotri Vasna Road,
Vadodara- 390007 Gujarat, India.

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. We believe that the process and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, we have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

FOR DG PATEL & ASSOCIATES
Company Secretaries

Place: Bhavnagar
Date: 22/08/2026
UDIN: F010533H001186081

Sd/-
Dip G. Patel
(Proprietor)
FCS: 10533
C.P. No.: 13774
PR: 1839/2022

Annexure – II

PARTICULARS REGARDING CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION:

(A) Conservation of energy-

(i) the steps taken or impact on conservation of energy:

The Company is engaged in the manufacturing business of Active Pharmaceutical Ingredients ("APIs"), antacid molecules and other chemical and pharmaceutical products. The Company's product portfolio presently comprises APIs and fine chemicals, which are marketed domestically as well as exported internationally. Energy consumption is substantial in the Company's manufacturing processes. Accordingly, the Company has undertaken various measures to minimise energy consumption, optimise productivity and promote efficient utilisation of resources. Considerable efforts have been made across the Company's manufacturing facilities towards conservation of power and improvement in energy efficiency. As part of its initiatives towards energy conservation and sustainable operations, the Company has also installed solar panels for generation of electricity from renewable energy sources. The generation and utilisation of solar power has contributed towards reducing dependence on conventional sources of electricity, thereby supporting energy conservation, reducing energy costs and promoting environmentally sustainable operations. The Company continues to explore and implement appropriate measures for efficient utilisation of energy and optimisation of energy resources.

Details of energy consumption for the Financial Year 2025-26 are as under:

Electricity		Coal		Diesel		GAS	
UNIT (In KWH)	Total Cost (Rs. In Lakh)	UNIT (In MT)	Total Cost (Rs. In Lakh)	UNIT (In LITER)	Total Cost (Rs. In Lakh)	Unit (SCM)	Total Cost (Rs. In Lakh)
4091755	329.99	11095	1,163	2000	1.84	39524.57	25.09









(ii) the steps taken by the company for utilizing alternate sources of energy –

During FY 2025-26, the solar panels generated 126551 kWh of electricity for captive consumption, resulting in an estimated reduction of approximately 103.77 tonnes of CO_2 emissions

(iii) the capital investment on energy conservation equipments – Installation of new solar panel units on administration building of 150 kva cost of Rs.71.70 Lakh.

(B) Technology absorption-

(i) The efforts made towards technology absorption – Nil

(ii) the benefits derived like product improvement, cost reduction, product development or import substitution – None

(iii) imported technology (imported during the last three years reckoned from the beginning of the financial year)- Nil

(iv) the expenditure incurred on research & development: Nil

For & On Behalf of Board of Directors
PAR DRUGS AND CHEMICALS LIMITED

Sd/-	Sd/-
(Mr. Falgun V. Savani)	**(Mr. Jignesh V. Savani)**
Chairman & Managing Director	Director & CEO
(DIN: 00198236)	(DIN: 00198203)

Date: August 22, 2026
Place: Bhavnagar

Annexure – III

ANNUAL REPORT ON CSR ACTIVITIES

1. **Corporate Social Responsibility Policy:**

Philosophy:

Company vision is to empower communities by connecting people by recognizing economic organs of society and draw on societal resources, it is Company's belief that its performance must be measured by its Triple Bottom Line contribution to building economic, social and environmental capital towards enhancing societal sustainability. Company believes that in the strategic context of business, enterprises possess beyond mere financial resources, the transformational capacity to create game-changing development models by unleashing their power of entrepreneurial vitality, innovation and creativity. In line with this belief, company will continue crafting unique models to generate livelihoods and environmental capital. Such Corporate Social Responsibility ("CSR") projects are far more replicable, scalable and sustainable, with a significant multiplier impact on sustainable livelihood creation and environmental replenishment. These initiatives are independent of the normal conduct of Company's business. Programmes, projects and activities (collectively "CSR Programmes") carried out in this regard are the subject matter of this Policy.

CSR Policy:

The key purpose of this Policy is to:

- Define governance structure for CSR management within the Company.
- Serve as a guiding document aiding in identification, execution and monitoring the CSR projects.
- Describe the treatment of surpluses from CSR activities
- Outline the development areas in which the Company shall get involved in

Scope of the Policy : This Policy applies to all CSR projects that will be undertaken by the Company and shall fulfill all the requirements of Section 135 of the Companies Act, 2013. The Company shall ensure all these activities are over and above the normal course of business and are in line with Schedule VII of the Companies Act, 2013. This Policy will be periodically reviewed and updated in line with the relevant codes of legislation and best practices that can be adopted by the Company.

Policy: It is Company's policy to direct Company's CSR Programmes, inter alia, towards achieving one or more of the following:

1. To promote education –
   a. By way of promoting digital literacy in the rural villages around Bhavnagar, Gujarat or within the state of Gujarat especially in the primary schools, government Institutes etc. by Contributing towards innovative learning, technical assistance with latest equipments like computers, projectors, Interactive flat panel, building or development of digital class etc. and help students to learn in facilitative environment;
   b. Offering scholarships to the students of colleges/universities for supplying study materials, instruments for practical experiments, arranging Industry visit at our Company etc. as we endeavor to support education initiatives and give wings to students' dreams especially to the students of Masters.
   c. Offering scholarship to the PHD students for helping them viz their research and producing a thesis of their specialization.
   d. Any other educational activities for the promotion & development of education sector as deemed fit which will fall within the CSR activities as per Companies Act, 2013.
2. To promote health care including preventive health care and sanitation in the local areas nearer to the factory site of the company and such other areas as may be determined by the CSR committee.
3. To promote health care by way of contributions to PM CARES Fund, State Disaster Management Authority to combat COVID-19 or any other fund set up by the government and spending CSR funds for COVID-19 related activities etc.
4. To undertake any of the CSR activities as prescribed under Schedule VII of the Companies Act, 2013.

Implementation:

To implement the Company's CSR Programmes through Company personnel or through external implementing agencies or through Trusts, Society and Section 8 companies that may be established by the Company from time to time. In such cases, the Company will specify the CSR Programmes which may be undertaken by those Trusts in accordance with their Objects and administrative and accounting processes laid down in the respective Trust Deeds/ Memorandum and Articles of Association.

Governance:

Every year, the CSR Committee will place for the Board's approval, a CSR Plan delineating the CSR Programmes to be carried out during the financial year and the specified budgets thereof. The Board will consider and approve the CSR Plan with any modification that may be deemed necessary. The CSR Committee will assign the task of implementation of the CSR Plan within specified budgets and timeframes to such persons or bodies as it may deem fit. The persons/bodies to which the implementation is assigned will carry out such CSR Programmes as determined by the CSR Committee within the specified budgets and timeframes and report back to the CSR Committee on the progress thereon at such frequency as the CSR Committee may direct. The CSR Committee shall review the implementation of the CSR Programmes once in every six months and issue necessary directions from time to time to ensure orderly and efficient execution of the CSR Programmes in accordance with this Policy. At the end of every financial year, the CSR Committee will submit its report to the Board.

CSR Expenditure:

CSR expenditure will include all expenditure, direct and indirect, incurred by the Company on CSR Programmes undertaken in accordance with the approved CSR Plan. Moreover, any surplus arising from any CSR Programmes shall be used for CSR. Accordingly, any income arising from CSR Programmes will be netted off from the CSR expenditure and such net amount will be reported as CSR expenditure.

The above CSR Policy is available at our website link at http://pardrugs.com/pdf/policies/Final_CSR_POLICY.pdf

2. Composition of the CSR committee:

Sr. No.	Name of Director	Designation / Nature of Directorship	Number of meetings of CSR Committee held during the year	Number of meetings of CSR Committee attended during the year
1	Mr. Pravin Manjibhai Bhayani	Chairman, Independent, Non-Executive Director	1	1
2	Mrs. Krishna Mitulbhai Shah	Member, Independent, Non-Executive Director	1	1
3	Mrs. Bintal Bhaveshkumar Shah	Member, Independent, Non-Executive Director	1	1

The Committee met once during the year i.e. on March 26, 2026.

3. Provide the web-link where Composition of CSR committee, CSR Policy and CSR projects approved by the board are disclosed on the website of the Company

Composition of the CSR committee shared above and is available on the Company's website on http://pardrugs.com/corporate-governance-committee.php

CSR policy - http://pardrugs.com/pdf/policies/Final_CSR_POLICY.pdf

CSR projects - http://pardrugs.com/csr-par-drugs-and-chemicals.php

4. Provide the details of Impact assessment of CSR projects carried out in pursuance of sub-rule (3) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, if applicable (attach the report).

As per Rule (3) (a) of rule 8 of the Companies (Corporate Social Responsibility Policy) Rules, 2014, Every company having average CSR obligation of ten crore rupees or more in pursuance of subsection (5) of section 135 of the Act, in the three immediately preceding financial years, shall undertake impact assessment, through an independent agency, of their CSR projects having outlays of one crore rupees or more, and which have been completed not less than one year before undertaking the impact study. Hence, Company is out of purview of this rule due to the less CSR obligation i.e. less than ten crore rupees for the F.Y. 2025-26

5.

a. **Average net profit of the Company as per Section 135(5):** Rs. 17,50,62,355 /-

b. **Two percent of average net profit of the Company as per section 135(5) :** Rs. 35,01,247 /-

c. **Surplus arising out of the CSR projects or programmes or activities of the previous financial years :** Nil /-

d. **Amount required to be set off for the financial year, if any :** Nil

e. **Total CSR obligation for the financial year (b+c-d) :** Rs. 35,01,247 /-

6. **(a) Amount spent on CSR Projects (both Ongoing Project and other than Ongoing Project): Rs. 35,06,500/-**

Details of CSR amount spent against ongoing projects for the financial year: Not Applicable

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	(9)	(10)	(11)	
Sr. No.	Name of the Project	Item from the list of activities in Schedule VII to the Act	Local area (Yes/No)	Location of the project		Project duration	Amount allocated for the project (In ₹)	Amount spent in the current financial Year (In ₹)	Amount transferred to Unspent CSR Account for the project as per Section 135(6)	Mode of Implementation - Direct (Yes/No)	Mode of Implementation Through Implementing Agency	
				State	District						Name	CSR Registration number
-	-	-	-	-	-	-	-	-	-	-	-	-

Details of CSR amount spent against other than ongoing projects for the financial year:

(1)	(2)	(3)	(4)	(5)		(6)	(7)	(8)	
Sr. No.	Name of the Project	Item from the list of activities in schedule VII to the Act	Local area (Yes/No)	Location of the project		Amount spent for the project	Mode of implementation - Direct (Yes/No)	Mode of implementation – Through implementing agency	
				State	District			Name	CSR registration number
1	**Project:- "GAU SNEH"***	(iv)	Yes	Gujarat	Bhavnagar	6,51,000	No	Shree Sarveshwar Gau Dham Trust Kobadi	CSR 00071472
2	**Project:- "PRAGATI PATH"****	(ii)	Yes	Gujarat	Bhavnagar	20,00,000	No	Gohilwad Leauva Patidar Kelavani Mandal	CSR 00029769
3	**Project:- "SWARGA SPARSH"*****	(iv)	Yes	Gujarat	Bhavnagar	8,55,500/-	No	Society For Research And Initiatives For Sustainable Tech And Institutions, (SRISTI)	CSR 00009748
	Total	-	-	-	-	**35,06,500/-**	-	-	-

*** GAU SNEH -** Animal Welfare Activities for Cow Feeds and Medical Care of Cows at Shree Nilkanth Mahadev Ashram, Kobadi, Talaja Road, District Bhavnagar-364050,Gujarat, India. The adequate nutrition will significantly enhance the health and quality of life of the cows. Elderly and disabled cows will be benefited from a tailored diet that addresses their unique need.

**** PRAGATI PATH** – The initiative is aligned with the Company's broader Corporate Social Responsibility objectives of promoting education, supporting the development of young talent, and creating durable community assets. By providing improved hostel infrastructure, the Company aims to facilitate a conducive environment for students to pursue their education and contribute to their overall well-being and future development. The Company has utilized CSR for construction of three hostel rooms along with supporting structure at Madhav Sankul, Late Ramajibhai Monabhai Monpara, Kumar Chhatralay, Survey no. 279/4 paiki 1 Near Samaras Hostel, University area, Bhavnagar-364001, Gujarat, India, which will create safe, functional, and sustainable accommodation facilities for students.

***** "SWARGA SPARSH" -** Implementation of the "SWARGAROHAN" Climate-Friendly Cremation System to provide dignified, environmentally sustainable cremation infrastructure at Chitra Smashan, GIDC, Chitra, Bhavnagar-364001, Gujarat. Environment Protection, Community Development and Public Health, project focuses on environmental protection, reduction of air pollution, conservation of forests, and provision of dignified cremation infrastructure for communities, especially benefiting economically weaker sections of society

(b) Amount spent in Administrative Overheads: 0

(c) Amount spent on Impact Assessment, if applicable: 0

(d) Total amount spent for the Financial Year [(a)+(b)+(c)].: Rs. 35,06,500/-

(e) CSR amount spent or unspent for the Financial Year:

Total Amount Spent for the Financial Year. (In Rs.)	Amount Unspent				
	Total Amount transferred to Unspent CSR Account as per Section 135(6)		Amount transferred to any fund specified under Schedule VII as per second proviso to Section 135(5)		
	Amount	Date of transfer	Name of the Fund	Amount	Date of transfer
35,06,500/-	NIL	-	-	NIL	-

(f) Excess amount for set-off, if any:

Sr. No.	Particular	Amount (In Rs.)
(i)	Two percent of average net profit of the Company as per Section 135(5)	35,01,247
(ii)	Total amount spent for the Financial Year	35,06,500
(iii)	Excess amount spent for the financial year [(ii)-(i)]	5,253
(iv)	Surplus arising out of the CSR projects or programmes or activities of the previous financial years, if any	NIL
(v)	Amount available for set off in succeeding financial years [(iii)-(iv)]	5,253

7. Details of Unspent Corporate Social Responsibility amount for the preceding three Financial Years: Not Applicable

Sr. No.	Preceding Financial Year	Amount transferred to Unspent CSR Account under Section 135 (6)	Balance Amount in Unspent CSR Account under sub-section (6) of section 135 (in Rs.)	Amount spent in the reporting Financial Year	Amount transferred to any fund specified under Schedule VII as per Section 135(6), if any			Amount remaining to be spent in succeeding financial years	Deficiency, if any
					Name of the Fund	Amount	Date of transfer		
-	-	NIL	NIL	-	-	NIL	-	-	-

8. **Whether any capital assets have been created or acquired through Corporate Social Responsibility amount spent in the Financial Year:**

YES

Number of Capital assets created/acquired: 3 (Three)

The details relating to such asset(s) so created or acquired through Corporate Social Responsibility amount spent in the Financial Year:

Sr. No.	Short particulars of the property or asset(s) [including complete address and location of the property]	Pincode of the property or asset (s)	Date of creation	Amount of CSR amount spent	Details of entity/Authority/beneficiary of the registered owner		
(1)	(2)	(3)	(4)	(5)	(6)		
					CSR Registration Number, if applicable	Name	Registered Address
1.	Kumar Chhatralay, Survey no. 279/4 paiki 1 Near Samaras Hostel, University area, Bhavnagar-364001, Gujarat, India. Construction of 3 hostel room of Rs. 15.5 Lacs and other structure for room Rs. 4.5 Lacs only.	364002	26/03/2026	20,00,000/-	CSR 00029769	GOHILWAD LEAUVA PATIDAR KELAVANI MANDAL	C/O G. M. Vanani Niru Patel Boarding, Plot no.1992, Near Shamaldas College Gate, Waghawadi Road, Bhavnagar, 364002

9. **Specify the reason(s), if the company has failed to spend two per cent of the average net profit as per subsection (5) of section 135:**

Not Applicable

Date: August 22, 2026
Place: Bhavnagar

Sd/- **(Mrs. Bintal Bhaveshkumar Shah)** Independent Director, Member of CSR Committee (DIN: 08893054)	Sd/- **(Mr. Pravin M. Bhayani)** Independent Director, Chairman of CSR Committee (DIN: 08332851)	Sd/- **(Mrs. Krishna Mitulbhai Shah)** Independent Director Member of CSR Committee (DIN: 08317678)

REPORT ON CORPORATE GOVERNANCE

1. Company's Philosophy on Corporate Governance:

Your Company's Corporate Governance philosophy is based on transparency, accountability, values and ethics, which forms an integral part of the Management's initiative in its ongoing pursuit towards achieving excellence, growth and value creation. Your Company has a strong legacy of fair, transparent and ethical governance practices and its efforts in these regard. The commitment to uphold highest standards of corporate governance still continues post listing of the Company in May 16, 2019 and September 16, 2021 Listing of equity shares of Par Drugs And Chemicals Limited on Capital Market Segment (Main Board) pursuant to Migration from SME Emerge platform, the Company is in compliance with all the norms & disclosure requirements as prescribed under Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). The Company has adopted a Code of Conduct for Board Members and Senior Management including Independent Directors which suitably incorporates the duties of Independent Directors as laid down in the Companies Act, 2013 ('the Act') as well. The Company has taken all necessary steps to ensure the Rights of Shareholders and seek approval of the shareholders as and when required as per the provisions of the Companies Act, 2013 or other applicable legislations. The Company ensures timely and complete dissemination of information on all matters which are required to be made public. The website of the Company and the Annual Report of the Company contain exhaustive information regarding every aspect of the functioning, financial health, ownership and governance practices of the Company. Democratization of information increases scrutiny of corporate actions and raises the standards of governance. All disclosures by Company are made in line with the formats prescribed by the concerned regulatory authority in respect of accounting, financial and non-financial matters. The Company fully complies with the corporate governance requirements stipulated under Regulations 17 to 27 read with Schedule V and clauses (b) to (i) and (t) of sub-regulation (2) of Regulation 46 and para C of Schedule V of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), as applicable.

2. Board of Directors

A. Composition of Directors

The Board of Directors along with its Committees provide leadership and guidance to the Management and directs and supervises the performance of the Company, thereby enhancing stakeholder value. The Board has a fiduciary relationship in ensuring that the rights of all stakeholders are protected. The Board of Company comprises of Executive and Non-Executive Directors (which include Independent Directors, including further an Independent Woman Directors). Independent Directors are eminent persons with skills in diverse areas like business, accounting, marketing, finance, administration, etc. The composition of Board of Directors represents optimal mix of professionalism, qualification, knowledge, skill sets, track record, integrity, expertise and diversity. The Board of Directors, as on March 31, 2026, comprised of 6 Directors, out of which 2 was Executive Director ("ED") who are the promoters of the Company and out of which 1 was Chairman & Managing Director and 1 was Director & CEO; 4 were Non-Executive Directors ("NEDs"), which all are Independent Directors ("IDs") out of which 3 women Independent Directors. The Chairman of the Board is an executive and half of the total number of Directors comprises of Non-Executive & Independent Directors. Detailed profile of our Directors are available on our website at http://pardrugs.com/board-of-directors.php The terms and conditions of appointment of Independent Directors are hosted on the website of the Company at http://pardrugs.com/policies-par-drugs-and-chemicals.php In India, the Securities and Exchange Board of India (SEBI) regulates corporate governance for listed companies through SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'). Listing Regulations mandate the following:

For a company does not have a regular non-executive chairperson, at least half of the board of directors shall comprise of independent directors: **Complied**

The Board of directors of the top 1000 listed entities shall have at least one independent woman director: **Complied, though we are not within the top 1000 listed entity**

The Board of directors of the top 2000 listed entities shall comprise of not less than six directors: **Complied, though we are not within the top 2000 listed entity**

The composition of the Board of Directors of the Company is in conformity with Regulation 17 of the Listing Regulations and Section 149 of the Act.



None of the Directors on the Board:

a. holds directorships in more than ten public companies;

b. serves as Director or as Independent Directors (ID) in more than seven listed entities; and

c. who are the Executive Directors serves as IDs in more than three listed entities.

The Chairman of the Board is an Executive Director. In the judgment of the Board of Directors of the Company, all the Independent Directors as mentioned below fulfill the conditions specified in Listing regulations and are independent of the management:

- Mr. Pravin Manjibhai Bhayani, Independent & Non-executive Director
- Mrs. Krishna Mitulbhai Shah, Independent & Non-executive Director
- Mrs. Kajal Chintanbhai Vaghani, Independent & Non-executive Director
- Mrs. Bintal Bhaveshkumar Shah, Independent & Non-executive Director

None of the Directors on the Board holds positions in any Committees in other public companies as on March 31, 2026. None of the Directors is related to each other except as mentioned below:

Name of the Director	Name of the Other Director	Relation
Falgun Vallabhbhai Savani	Jignesh Vallabhbhai Savani	Brother
Jignesh Vallabhbhai Savani	Falgun Vallabhbhai Savani	Brother

Independent Directors are non-executive directors as defined under Regulation 16(1)(b) of the SEBI Listing Regulations and Section 149(6) of the Companies Act, 2013 along with rules framed thereunder. In terms of Regulation 25(8) of SEBI Listing Regulations, they have confirmed that they are not aware of any circumstance or situation, which exist or may be reasonably anticipated, that could impair or impact their ability to discharge their duties with an objective independent judgment and without any external influence. Based on the declarations received from the Independent Directors, the Board of Directors has confirmed that they meet the criteria of independence as mentioned under Regulation 16(1)(b) of the SEBI Listing Regulations and that they are independent of the management. Further, the Independent Directors have included their names in the data bank of Independent Directors maintained with the Indian Institute of Corporate Affairs in terms of Section 150 of the Act read with Rule 6 of the Companies (Appointment & Qualification of Directors) Rules, 2014. Further, in compliance with Rule 6 of the Companies (Appointment and Qualification of Directors) Rules, 2014, all the Independent Directors of the Company have passed the Online Proficiency Self-Assessment through the Independent Director's Databank platform.

B. Board Meetings, attendance and other directorships

The Board / Committee Meetings are held as per the annual calendar set out well in advance with concurrence of all the Directors, to ensure 100% participation in the meetings. Meetings which were held through video conferencing are as per the prescribed, guidelines, after giving adequate notice to that effect to the Board Members. All the meetings are conducted as per well designed, and structured agenda and in accordance with the requirements under the Companies Act, 2013,("Act"), Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and Secretarial Standards prescribed by Institute of Company Secretaries of India ("ICSI"). Agenda with detailed explanatory notes for the Board / Committee Meetings are set out by the Company Secretary in consultation with the Chairman and Managing Director ("MD"). The Board has complete access to any information within the Company. Agenda papers with minutes of previous meeting, committee meetings & also other information/proposals with detailed notes/ background information with applicable regulatory provisions and requisite disclosures, are circulated prior /during the meetings, thereby enabling the Board to take decisions on an informed basis. Apart from the Board members, the Company Secretary attend all the Board Meetings. Detailed presentation is made by the Management in each meetings to apprise the Board of important developments in the industry, business segments, operations, capex, sales & marketing, products, HR initiatives, important developments, regulatory changes etc.

Five Board Meetings were held during the year under review and the gap between two meetings did not exceed one hundred and twenty days. The said meetings were held on 08-05-2025, 07-08-2025, 29-08-2025, 13-11-2025, 10-02-2026.

The necessary quorum was present for all the meetings.

The names and categories of the Directors on the Board, their attendance at Board Meetings held during the year under review and at the last Annual General Meeting ("AGM"), details regarding name of other listed entities in which the Director is a director and the number of Directorships and Committee Chairmanships / Memberships held by them in other public limited companies as on March 31, 2026 are given herein below.

Attendance of each Director at Board Meeting and the last Annual General Meeting (AGM) and the number of Companies and Committees where he/she is Director/Member are as under:

Name of Director & Designation & DIN	Category	No. of Board Meeting attended during FY 2025-26	Attendance at the last AGM held on September 27, 2025	No. of Directorship in other Public Companies		No. of Committees Positions held in other Public Companies (Other than Par Drugs And Chemicals Limited)		Directorship in other listed entity (Category of Directorship)
				Chairman	Member	Chairman	Member	
Mr. Falgun Vallabhbhai Savani Chairman & Managing Director (DIN: 00198236)	Non-Independent, Executive Director, Promoter	5	YES	-	-	-	-	
Mr. Jignesh Vallabhbhai Savani Executive Director & CEO (DIN: 00198203)	Non-Independent, Executive Director, Promoter	5	YES	-	-	-	-	
Mrs. Krishna Mitulbhai Shah, Independent Director (DIN: 08317678)	Independent, Non-Executive	5	YES	-	-	-	-	
Mrs. Kajal Chintanbhai Vaghani, Independent Director (DIN: 08317641)	Independent, Non-Executive	5	YES	-	-	-	-	
Mr. Pravin Manjibhai Bhayani, Independent Director (DIN: 08332851)	Independent, Non-Executive	5	YES	-	-	-	-	
Mrs. Bintal Bhaveshkumar Shah (DIN: 08893054)	Independent, Non-Executive	5	YES	-	-	-	-	

None of them is a member of more than ten committees or chairman of more than five committees across all the public companies in which he / she is a Director. For the purpose of determination of limit of the Board Committees, chairpersonship and membership of the Audit Committee and Stakeholders' Relationship Committee has been considered as per Regulation 26(1)(b) of SEBI Listing Regulations.

During FY 2025-2026, information as mentioned in Part A of Schedule II of the Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015, has been placed before the Board for its consideration.

C. Directors retiring by rotation:

Mr. Jignesh Vallabhbhai Savani , Director & CEO (DIN: 00198203) who retires by rotation and being eligible offer himself for re-appointment. As per Regulation 36 of the Listing Regulations, brief profile of Director seeking re-appointment at the forthcoming AGM, is annexed to the Notice convening the AGM and forming part of this Annual Report.

D. Independent Directors meeting & familiarisation programme

All the Independent Directors ("IDs") fulfill the independence criteria laid down under the Listing Regulations and as per opinion of the Board, they are independent of the management.

During FY 2025-26 under review, one meeting of IDs was held on March 26, 2026 and was chaired by lead Independent Director, Mr. Pravin M. Bhayani and attended by all IDs. The IDs reviewed all the matters as per Schedule IV of the Companies Act, 2013. The meeting was informal, enabling the IDs to discuss matters pertaining to the Company's affairs and put forth their combined views to the Board of Directors. The IDs expressed satisfaction at the robustness of the evaluation process, overall functioning of the Board, openness and transparency of the Board deliberations on business issues and the agenda items as also the information and disclosures made to IDs. They noted that the suggestions made by them were implemented satisfactorily.

Familiarisation program for IDs enables them to understand the Company, its business, regulatory framework in which it operates, update them about newer challenges, risks and opportunities in the business, helps them in lending perspective to strategic direction of the company and equips them to discharge their role & contribute effectively as a Director of the Company. The Company has an on-going familiarization process for IDs. Departmental Heads and executives from different functions give presentation to the IDs to familiarise them with their areas of operations.

IDs are updated through presentations and discussions on overall economic trends, pharma industry developments, legal and regulatory amendments, operations, marketing, finance, HR, etc. and various initiatives taken/proposed to be taken to bring about an overall growth in the performance of the Company. Familiarisation programs conducted for IDs, have been put on the website of the company. The link can be accessed at: http://pardrugs.com/familiraisation-programme.php

E. Performance evaluation of Board, Committees and Directors

Pursuant to the provisions of the Act and the Listing Regulations and as suggested by the Nomination and Remuneration Committee ("NRC"), the Board carried out annual performance evaluation of its own, various Committees and of all the Directors individually. Performance evaluation of the Non-Independent Directors, Chairman and the Board as a whole was also carried out by the IDs at a separate meeting. Performance evaluation of Executive Directors, IDs, Chairman, Board as a whole and of the Board Committees was done based on the following parameters:

Chairman: Knowledge & skill competence, leadership effectiveness, managing relationship, strategy formulation, strategy execution, providing guidance & counselling, ensuring effectiveness of Corporate Governance practices, promoting continual training & development of Directors etc.

Board committees: Composition & terms of reference, cohesive relationship with management, adequate independency, periodicity of meetings, bringing objectivity, ensuring adherence to company policies, ensuring efficiency of external auditors etc. Evaluation sheets containing parameters were circulated to the Board members who responded the same and results were collated. Performance evaluation done by the Board and IDs revealed an "Outstanding" rating for the Board as a whole

Board as a whole: Composition, Qualities & Attributes, Board Meetings and Procedures, Board and Management Relations, Stakeholder value and responsibility, establishment of vision & mission, creating value for stakeholders, timeliness and appropriateness of ongoing development programmes to enhance skills, strategic perception and business acumen in critical matters, succession planning, corporate governance, stakeholder value and responsibility, providing leadership & directions, etc.

Executive Directors: Anticipating business trends, strategy formulation and execution, team-building, skillset & knowledge, statutory compliances, ethical standards, risk mitigation, sustainability, financial planning & performance, succession planning, interface with industry forums etc.

Independent Directors: Effective participation, Managing Relationship, integrity and probity, objectivity, bringing independent judgement, time devotion, protecting interest of shareholders, domain knowledge contribution, personal attributes etc.

F. Skills / expertise / competencies of Directors

The Board comprises of competent members who possess repertoire of skills, expertise and competencies that permits them to make effective contributions to the Board and its Committees. The Board has identified the following skills / expertise / competencies fundamental for its effective functioning and below table demonstrates skill & competencies possessed by Directors:

SKILLS / EXPERTISE / COMPETENCIES	FALGUN SAVANI	JIGNESH SAVANI	PRAVIN BHAYANI	KRISHNA SHAH	KAJAL VAGHANI	BINTAL SHAH
Strategy and Planning	✓	✓	✓		✓	
Corporate Governance and Compliance	✓	✓	✓	✓	✓	✓
Leadership & Management	✓	✓	✓			
Management & administration	✓	✓	✓	✓	✓	✓
Accounting & Finance	✓	✓	✓	✓	✓	
Sustainability	✓	✓	✓	✓	✓	✓
Relationship & CSR	✓	✓	✓	✓	✓	✓

G. Legal Compliance

The Board has periodically reviewed legal compliance and monitor and ensure compliance with all applicable laws and regulatory requirements applicable to the Company. The Company has done best at its possible to be a Compliance driven Company covers all important functions.

H. Equity shares of the Company held by the Directors as on March 31, 2026 are given below:

Name	Category	No. of equity shares held
Mr. Falgun Vallabhbhai Savani	Non- Independent, Executive Director, Promoter	2645952
Mr. Jignesh Vallabhbhai Savani	Non- Independent, Executive Director, Promoter	2692440
Mrs. Krishna Mitulbhai Shah	Independent, Non-Executive	0
Mrs. Kajal Chintanbhai Vaghani	Independent, Non-Executive	0
Mr. Pravin Manjibhai Bhayani	Independent, Non-Executive	0
Mrs. Bintal Bhaveshkumar Shah	Independent, Non-Executive	0

The Company has not issued any convertible instruments.

I. Code of Conduct

Board of Directors have laid down Code of Conduct setting forth legal and ethical standards to be followed by Directors and Senior Management ("the Code"). The Code lays emphasis amongst other things, on the integrity at workplace and in business practices, honest and ethical personal conduct, diversity, fairness and respect etc which is expected to be followed by the Directors and Senior management. The Code has been posted on the website of the Company at Policy section of under the tab of Investors at https://www.pardrugs.com/policies-par-drugs-and-chemicals.php The Directors & Senior Management have made disclosures to the Board confirming that there are no material financial and commercial transactions between them and the Company which could have potential conflict of interest with the Company.

J. Prevention of Insider Trading

Pursuant to the Securities And Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 ("PIT") as amended, the Company has formulated, Code of Conduct to Regulate, monitor and Report Trading by Insiders. These Codes are framed in keeping with the standards set out in the Regulations to monitor and facilitate reporting of trading by employees.

Company has identified Designated Persons who can be privy to the Unpublished Price Sensitive Information (UPSI), based on their grade, department and other factors. It includes obligations and responsibilities of Designated Persons, maintenance of digital database, mechanism for preventing insider trading & handling of UPSI, disclosure of UPSI for legitimate purposes, prohibited and permitted transactions, consequence for violation etc.

The Company has been disseminated through the Company's periodic mailers. Further, the Company has put in place adequate and effective system of internal controls as to monitor trading in securities by the Insiders in order to ensure compliance with the PIT. Structured digital database is being maintained by the Company as prescribed under the PIT. Company Secretary has been appointed as the Compliance Officer for ensuring implementation of Code.

K. Information about Directors seeking appointment and re-appointment:

Details of Directors seeking appointment and reappointment at the forthcoming Annual General Meeting (Pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

Director retiring by rotation and eligible for reappointment

1. Mr. Jignesh Vallabhbhai Savani, Director & CEO (DIN: 00198203)

Name of Director	**Mr. Jignesh Vallabhbhai Savani**
	
DIN No.	00198203
Designation	Director & CEO
Date of Birth	15/12/1977
Age	48 Years
Date of first appointment on the Board	Appointed as Director on 26/02/1999. Appointed as CEO on 26/11/2018
Qualification / Brief Resume / Expertise in specific functional area / experience	Mr. Jignesh Vallabhbhai Savani has been the Director of our Company since inception and was also appointed as CEO of the Company w.e.f. 26th Day of November, 2018. Mr. Jignesh Vallabhbhai Savani has completed Matriculation education from Gujarat Secondary Education Board. He has more than two decades of experience in the API Industry. He has been actively involved in the day-to-day operations of our Company and looks after the sales, administration and finance department of our Company. He has work experience in all departments of Company like logistics, HR, Manufacturing, Accounts etc.
Terms and conditions of appointment / re-appointment along with details of remuneration sought to be paid	Liable to retire by rotation Mr. Jignesh Vallabhbhai Savani will be eligible for remuneration subject to approval of shareholder as mentioned in the item no. 7 & it's explanatory statement in the capacity of CEO
No. of Shares held in the Company as on 31/03/2026	2692440 Equity Shares
Promoter / Non-Promoter	Promoter
Remuneration	Rs. 51.50 Lakh Remuneration and 0.30 lakh sitting fees F.Y. 2025-26
Relationship with other Directors and Key Managerial Personnel	Brother of Mr. Falgun Vallabhbhai Savani, Chairman & Managing Director of the company.
No of meetings of the Board attended during the year	5 (Five) out of 5 (Five)
Details of Directorship held in other Companies as on 31/03/2026	NIL

Name of Director	Mr. Jignesh Vallabhbhai Savani
Details of Chairmanship / Membership of Committees of other companies as on 31/03/2026	NIL
Names of listed entities in which the person also holds the directorship and the membership of Committees of the board along with listed entities from which the person has resigned in the past three years	NIL
Affirmation: (Information as required under NSE circular no. NSE/CML/2018/02, dated June 20, 2018.)	Director is not debarred from holding the office by virtue of any SEBI Order or any other authority.

3. Committees of the Board:

(i) Audit Committee:

The Audit Committee comprises of four members with three Independent Directors and one Executive Director as on 31st March, 2026.

The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	5/5
Mrs. Kajal Chintanbhai Vaghani	Non-Executive & Independent Director	Member	5/5
Mr. Falgun Vallabhbhai Savani	Chairman & Managing Director	Member	5/5
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	5/5

Meeting No.	Date of Audit Committee Meeting	Total no. of Member	No. of Member present
1/AC/2025-26	08-05-2025	4	4
2/AC/2025-26	07-08-2025	4	4
3/AC/2025-26	29-08-2025	4	4
4/AC/2025-26	13-11-2025	4	4
5/AC/2025-26	10-02-2026	4	4

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

The Company Secretary and Compliance Officer of the Company would act as the Secretary to the Audit Committee.

Terms of Reference:

The Audit Committee shall have following powers/ responsibilities:

a. To investigate any activity within its terms of reference.

b. To seek information from any employee.

c. To obtain outside legal or other professional advice, and

d. To secure attendance of outsiders with relevant expertise if it considers necessary

e. Others as mentioned in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended time to time.

The Audit Committee shall mandatorily review the following information:

a. Management discussion and analysis of financial condition and results of operations Statement of significant related party transactions (as defined by the audit committee), submitted by management;

b. Management letters / letters of internal control weaknesses issued by the statutory auditors;

c. Internal Audit reports relating to internal control weaknesses;

d. The appointment, removal and terms of remuneration of the Chief Internal Auditor; and

e. statement of deviations: Not Applicable during the year under review

   - quarterly statement of deviation(s) including report of monitoring agency, if applicable, submitted to stock exchange(s) in terms of Regulation 32(1).
   - annual statement of funds utilized for purposes other than those stated in the offer document/prospectus/notice in terms of Regulation 32(7).

(ii) Nomination and Remuneration Committee:

The Nomination and Remuneration Committee comprises of three members with all Independent Directors as on March 31, 2026.

The Committee met two times during the year on August 29, 2025 and February 10, 2026. The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	2/2
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	2/2
Mrs. Bintal Bhaveshkumar Shah	Non-Executive & Independent Director	Member	2/2

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

The Company Secretary and Compliance Officer of the Company would act as the Secretary to Nomination and Remuneration Committee.

Terms of Reference:

1. Formulation of the criteria for determining qualifications, positive attributes and independence of a director and recommend to the Board a policy relating to the level and composition of remuneration of the directors, key managerial personnel and other employees;

   1.1. For every appointment of an independent director, the Nomination and Remuneration Committee shall evaluate the balance of skills, knowledge and experience on the Board and on the basis of such evaluation, prepare a description of the role and capabilities required of an independent director. The person recommended to the Board for appointment as an independent director shall have the capabilities identified in such description. For the purpose of identifying suitable candidates, the Committee may:

   1.1.1. use the services of an external agencies, if required;

   1.1.2. consider candidates from a wide range of backgrounds, having due regard to diversity; and

   1.1.3. consider the time commitments of the candidates.

2. Formulation of criteria for evaluation of independent directors and the Board;

3. To ensure that the relationship of remuneration to performance is clear and meets appropriate performance benchmarks;

4. Devising a policy on Board diversity;

5. Identifying persons who are qualified to become directors and who may be appointed in senior management in accordance with the criteria laid down, and recommend to the Board their appointment and removal;

6. Whether to extend or continue the term of appointment of the independent director, on the basis of the report of performance evaluation of independent directors;

7. Recommend to the board, all remuneration, in whatever form, payable to senior management;

8. Others as mentioned in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended time to time.

(iii) Stakeholder's Relationship Committee:

Company has constituted a Stakeholders Relationship Committee to redress complaints of the shareholders. The Stakeholder's Relationship Committee comprises of three members with two Independent Directors and one executive Director as on March 31, 2026.

The Committee met on August 29, 2025. The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	1/1
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	1/1
Mr. Jignesh V. Savani	Executive Director & CEO	Member	1/1

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

The Company Secretary of our Company shall act as a Secretary to the Stakeholder's Relationship Committee.

Terms of Reference:

Redressal of shareholders' and investors' complaints, including and in respect of:

1) Resolving the grievances of the security holders of the Company including complaints related to transfer/ transmission of shares, non-receipt of annual report, non-receipt of declared dividends, issue of new/ duplicate certificates, general meetings etc.
2) Review of measures taken for effective exercise of voting rights by shareholders.
3) Review of adherence to the service standards adopted by the Company in respect of various services being rendered by the Registrar & Share Transfer Agent.
4) Review of the various measures and initiatives taken by the Company for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company
5) Efficient transfer of shares; including review of cases for refusal of transfer / transmission of shares and debentures;
6) Redressal of security holder's/investor's complaints Efficient transfer of shares; including review of cases for refusal of transfer / transmission of shares and debentures;
7) Reviewing on a periodic basis the approval/refusal of transfer or transmission of shares, debentures or any other securities;
8) Issue of duplicate certificates and new certificates on split/consolidation/renewal;
9) Allotment and listing of shares;
10) Reference to statutory and regulatory authorities regarding investor grievances; and
11) To otherwise ensure proper and timely attendance and redressal of investor queries and grievances;
12) Others as mentioned in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended time to time.
13) Any other power specifically assigned by the Board of Directors of the Company.

Name, designation and contact of Compliance Officer:

Mr. Sanket B. Trivedi, Company Secretary & Compliance Officer

Contact: +91 - 278 – 244 7013

E-mail: investors@pardrugs.com

Details of shareholders' complaints received and redressed during FY 2025-26 are as follows:

Opening	Received during the year	Resolved during the year	Not solved to the satisfaction of shareholders	Pending
NIL	7	7	N.A.	NIL

(iv) CSR Committee:

The CSR Committee comprises of three members with all are Independent Directors as on March 31, 2026.

The Committee met on March 26, 2026. The Composition of the Committee as on March 31, 2026 and its attendance for meetings held during the year is set out below:

Name of Member	Category	Status	No. of meeting attended/ held
Mr. Pravin Manjibhai Bhayani	Non-Executive & Independent Director	Chairman	1/1
Mrs. Krishna Mitulbhai Shah	Non-Executive & Independent Director	Member	1/1
Mrs. Bintal Bhaveshkumar Shah	Non-Executive & Independent Director	Member	1/1

The Chairman of the Committee has attended the last Annual General Meeting of the Company held on September 27, 2025.

Terms of Reference of Corporate Social Responsibility Committee:

1. To formulate and recommend to the Board, a CSR policy which shall indicate the activities to be undertaken by the Company as per the Companies Act, 2013;
2. To review and recommend the amount of expenditure to be incurred on the activities to be undertaken by the company;
3. To monitor the CSR policy of the Company from time to time;
4. Any other matter as the CSR Committee may deem appropriate after approval of the Board of Directors or as may be directed by the Board of Directors from time to time.

(v) Risk Management Committee: Not applicable, because we are not in the top 1000 listed entities criteria.

(vi) Senior management:

A. Particulars of senior management are as follows:-

Details of Senior Management Personnel (SMP) as on March 31, 2026 is as follows:

Sr. No.	Name	Designation
1.	Mr. Ghanshyam Bhagvanbhai Savani	Production Head
2.	Mr. Harshadbhai Jayantilal Rajyaguru	QC & QA Head
3.	Mr. Jayeshbhai Jayantibhai Rajyaguru	Export, Sales & Marketing Head
4.	Mr. Chintan Pratapbhai Chauhan	Chief Financial Officer
5.	Mr. Sanket Bhupendrabhai Trivedi	Company Secretary & Compliance Officer

B. Changes in the senior management since the close of the previous financial year:- No changes during the F.Y. 2025-26 in the senior management

4. Remuneration Policy:

The Board has, on the recommendation of the Nomination and Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration. Company's policy on Directors' appointment and remuneration and other matters provided in Section 178(3) of the Companies Act, 2013 is available on the website of the company at https://www.pardrugs.com/policies-par-drugs-and-chemicals.php

The Company paid Sitting Fees of Rs. 5000/- per meeting of Board of Directors and Committees Meetings to all directors of the Company including its Non-Executive Directors (NEDs) for attending the Meeting of the Board of Directors and its Committees. The details of the remuneration paid to the Directors/KMPs for the year 2025-26 are as follows:

A. To Executive Directors/KMPs: (Rs. In Lakh)

Name of Director/KMP	Designation	Remuneration	Benefits, Perquisites and Allowances	Sitting Fees	Total
Mr. Falgun Vallabhbhai Savani	Chairman & Managing Director	51.50	-	0 .50	52.00
Mr. Jignesh Vallabhbhai Savani	CEO and Executive Director	51.50	-	0 .30	51.80
Mr. Sanket Bhupendrabhai Trivedi	Company Secretary & Compliance Officer	8.23	-	-	8.23
Mr. Chintan Pratapbhai Chauhan	CFO	7.65	-	-	7.65
Total		**118.88**	-	**0.80**	**119.68**

B. To Non-Executive Directors: (Rs.in Lakh)

Name of Director/KMP	Designation	Remuneration	Sitting Fees	Total
Mrs. Krishna Mitulbhai Shah	Non- Executive Independent Director	-	0.75	0.75
Mrs. Kajal Chintanbhai Vaghani	Non- Executive Independent Director	-	0.55	0.55
Mr. Pravin Manjibhai Bhayani	Non- Executive Independent Director	24.00*	0.75	24.75
Mrs. Bintal Bhaveshkumar Shah	Non- Executive Independent Director	-	0.45	0.45
Total		**24.00**	**2.50**	**26.50**

* The remuneration of Independent Director approved by passing special resolution by the members in the previous annual general meeting of the Company held on September 21, 2024 & September 27, 2025.

5. General Body Meetings:

(A) Annual General Meeting:

Date and time of the Annual General Meeting held during the preceding 3 years and the Special Resolution(s) passed thereat are as follows:

For Financial Year	Location	Date & Time	Special Resolution Passed
2024-25	Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India	27th Day of September, 2025 at 11:00 A.M.	1. To fix remuneration payable to Mr. Pravin Manjibhai Bhayani (DIN: 08332851) as an Independent Director of the Company 2. To re-appoint Mrs. Bintal Bhaveshkumar Shah (Din: 08893054) as an independent director of the company
2023-24	Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India	21st Day of September, 2024 at 11:00 A.M	1. To fix remuneration payable to Mr. Pravin Manjibhai Bhayani (DIN: 08332851) as an Independent Director of the Company

For Financial Year	Location	Date & Time	Special Resolution Passed
2022-23	Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India	16th Day of September, 2023 at 11:00 A.M.	1. To re-appoint Mr. Pravin Manjibhai Bhayani (DIN: 08332851) as an Independent Director of the Company and to fix remuneration payable to him 2. To re-appoint Mrs. Krishna Mitulbhai Shah (DIN: 08317678) as an Independent Director of the Company 3. To re-appoint Mrs. Kajal Chintanbhai Vaghani (DIN: 08317641) as an Independent Director of the Company 4. To re-appoint Mr. Falgun Vallabhbhai Savani (DIN: 00198236) as Chairman & Managing Director of the company and fix Remuneration payable to him 5. To re-appoint Mr. Ghanshayambhai Bhagvanbhai Savani (DIN: 03055941) as a Wholetime Director and to fix Remuneration payable to him 6. To re-appoint Mr. Jignesh Vallabhbhai Savani (DIN: 00198203) as a CEO of the company and to fix Remuneration payable to him

(B) Extra Ordinary General Meeting:

Date and time of the Extra Ordinary General Meeting ("EGM") held during the year and preceding 3 years, the Special Resolution(s) proposed/passed thereat are as follows:

Year	Location	Date & Time	Special Resolution Passed/Remarks
2025-26	-	-	No EGM of the members was held during the financial year 2025-26.
2024-25	Video Conferencing ("VC") / Other Audio Visual Means ("OAVM")	31st Day of December, 2024 at 3:00 P.M	***Special Resolutions** 1. Approval for slump sale of the existing establishment (Land, Building, Plant & Machinery, Specific Current Assets & Current Liabilities) under Section 180(1)(A) of the Companies Act, 2013 and regulation 37A of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015: 2. To make venture in to the business of real-estate and construction directly or indirectly, capital market and directly or indirectly enter into the business of the clean and renewable energy by alteration of main object of the Company

Year	Location	Date & Time	Special Resolution Passed/Remarks
2024-25	Video Conferencing ("VC") / Other Audio Visual Means ("OAVM")	12th Day of February, 2025 at 3:00 P.M	**Special Resolutions** 1. Approval for Slump Sale of the existing establishment (Land, Building, Plant & Machinery, Specific Current Assets & Current Liabilities) with revised terms under Section 180(1)(A) of The Companies Act, 2013 and Regulation 37A of Securities And Exchange Board of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 2. To make venture in to the business of real-estate and construction directly or Indirectly, capital market directly or indirectly and enter into the business of the clean and renewable energy by alteration of main object clause of the Company
2023-24	-	-	No EGM of the members was held during the financial year 2023-24.
2022-23	-	-	No EGM of the members was held during the financial year 2022-23.
2021-22	Video Conferencing ("VC")/ Other Audio Visual Means ("OAVM")	15/04/2021 4.00 P.M	**Ordinary Resolutions** 1. Increase authorized share capital of the company to enable issue of bonus shares 2. To alter clause v of memorandum of association to reflect the increase in the authorized share capital proposed under item no. 1 3. To approve issue of bonus equity shares.
2020-21	-	-	No EGM of the members was held during the financial year 2020-21.
2019-20	-	-	No EGM of the members was held during the financial year 2019-20.

* All Special Resolutions as set out in the Notice of EGM held on 31st Day of December, 2024 at 3:00 P.M have not been approved by the Shareholders and were not carried out with requisite majority.

(C) Details of special resolution passed through postal ballot, the persons who conducted the postal ballot exercise, details of the voting pattern and procedure of postal ballot during the F.Y. 2025-26:

The Company did not pass any resolution by Postal Ballot during the financial year 2025-26. Further, there is no immediate proposal for passing any resolution through postal ballot. Hence, no need to disclose person who conducted the postal ballot exercise and procedure for postal ballot as per requirement of SEBI (LODR) Regulations, 2015.

6. M/s. Sarupria Somani & Associates, Chartered Accountants (Firm Registration No.: 010674C) has been appointed as the Statutory Auditors of the Company. The particulars of payment of Statutory Auditors' fees, for FY 2025-26 is given below:

2,25,000/- (Rupees Two Lakh Twenty Five Thousand only)

7. Means of Communication:

a. Financial Results:

Quarterly and Half Yearly and year to date Results were taken on record by the Board of Directors and submitted to stock exchanges in terms of the requirements Regulation 33 of the listing agreement. The results are also displayed on the Company's website at http://pardrugs.com/quarterly-result.php The said Results are normally published in English Edition of Economic Times & in Gujarati Edition of Navgujarat Samay.

b. Website:

The Company's website www.pardrugs.com contains a separate dedicated section 'Investors' on the home page, wherein information appropriate for shareholders is available. It displays vital information relating to the

Company and its performance, announcement submitted to NSE, Financials, Corporate Governance Report, Shareholding Pattern, presentation to analysts, policies & codes, CSR and other material information relevant to shareholders. The Company's Annual Reports are also available in downloadable form.

c. Annual Report:

The Annual Report containing, inter-alia, Audited Standalone Financial Statements, Directors' Report, Auditors' Report and other important information is circulated to members and others as entitled. The Management Discussion and Analysis (MDA) Report forms part of the Annual Report. As a part of the green initiative, the Annual Reports are sent by e-mail to the Shareholders whose e-mail IDs are registered with the Depositories / Registrar & Transfer Agent ("RTA"). If any member wishes to get a duly printed copy of the Annual Report, the Company sends the same, free of cost, upon receipt of request from the member. The Company's Annual Reports are also available in downloadable form by https://www.pardrugs.com/annual-reports.php

d. Reminders to Shareholders for unclaimed shares / dividend:

The Company sends reminders to all those shareholders whose unclaimed dividend / shares are liable to be transferred to the Investor Education and Protection Fund ("IEPF") account. The details of statement of unclaimed and unpaid Dividend available at https://www.pardrugs.com/dividend.php

e. Filing with the Stock Exchanges:

All other submission to be made to the Stock Exchanges viz., shareholding pattern, corporate governance report, statement of investor complaints, etc are filed electronically with National Stock Exchange of India Limited.

Material developments related to the Company that are potentially price sensitive in nature in accordance with Regulation 30 of the Listing Regulations, are also disclosed to the Stock Exchanges as per the Policy for Disclosure of Material Information. They are also made available on Company's website.

f. Investors:

To serve the investors better and as required under Regulation 46(2)(j) of the Listing Regulations, the Company's Grievance Redressal Division has a designated email address for investor complaints vide investors@pardrugs.com. The Company's Compliance Officer monitors this email regularly. A copy of Investor presentations are also made available by the Company on its website at www.pardrugs.com

8. General shareholder information:

(1) Annual General Meeting for FY 2025-26:

Date: Saturday, 26th Day of September, 2026

Time: 11:00 A.M. IST

Venue: Hotel Tara Suns, B/h Yash Complex, B/s Sonal Park, G.E.R.I. Road, Gotri, Vadodara -390021, Gujarat, India

For more details, please refer to the Notice of this AGM. As required under Regulation 36(3) of the SEBI Listing Regulations and Secretarial Standard 2 on General Meetings, particulars of Directors seeking appointment/re-appointment at this AGM are given in the Annexure to the Notice of this AGM.

(2) Financial Year:

April to March

Reporting calendar: Within 45 / 60 days from the end of the quarter / financial year respectively, as stipulated under the Listing Regulations

(3) Dividend Payment:

Interim Dividend - Not Applicable as the Board has not declared any interim dividend during the FY 2025-26.

Final dividend - Not Applicable as the Board has not declared any final dividend for the FY 2025-26.

(4) Date of Book Closure /Cut-off date: As mentioned in AGM Notice.

(5) Listing on Stock Exchanges:

Equity shares of the company are listed on Capital Market Segment of NSE Limited

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G, Bandra Kurla Complex Bandra (East), Mumbai 400 051

(6) Stock Codes / Symbol:

NSE SYMBOL: PAR

ISIN: INE04LG01015

Listing Fees as applicable have been paid.

(7) Corporate Identity Number (CIN) of the Company: L24117GJ1999PLC035512

(8) Market Price Data:

Equity shares of the Company traded during each month during F.Y. 2025-26 on NSE*:

Month	SERIES**	Average of Open	Month's High Price	Month's Low Price	Average of Previous Close	Month's total No. of Trades	Month's Total Volume
April-2025	BE	97.82	109.72	81.01	97.85	4373	335641
May-2025	BE	102.61	108.36	97.59	102.34	3685	192938
June-2025	BE	98.50	102.88	93.00	97.99	3711	185249
July-2025	BE	101.52	117.90	92.70	101.17	2974	204095
August-2025	BE	99.18	105.04	90.81	99.20	1062	71813
September-2025	BE	109.41	122.43	95.00	107.14	3787	265327
October-2025	BE	103.01	109.50	98.70	103.07	1400	71672
October-2025	EQ	102.20	104.00	100.11	101.80	638	25549
November-2025	EQ	95.78	104.99	89.10	95.37	3609	150963
December-2025	EQ	98.23	114.00	84.00	98.10	19282	919152
January-2026	EQ	94.66	104.00	82.80	94.35	6329	147174
February-2026	EQ	95.76	105.05	88.10	95.36	5145	211998
March-2026	EQ	89.40	95.48	78.05	88.96	4222	629729
Yearly		98.99	122.43	78.05	98.56	60217	3411300

*Source: Historical data of Company available on www.nseindia.com

**EQ - This series allows trading in Intra-day transactions for equity permissible, normal trading is done in this category. BE - This series does not allow trading in Intra-day transactions Shares falling in the Trade for Trade

(9) Registrars and Transfer Agents

MUFG INTIME INDIA PRIVATE LIMITED

(Erstwhile known as LINK INTIME INDIA PRIVATE LIMITED)

5th Floor, 506 TO 508, Amarnath Business Centre – 1 (ABC-1),

Beside Gala Business Centre, Nr. St. Xavier's College Corner,

Off C G Road, Ellisbridge, Ahmedabad - 380006.

Tel : 079 - 2646 5179

Email : ahmedabad@in.mpms.mufg.com

SEBI registration no: INR000004058

(10) Places for acceptance of documents:

Documents will be accepted at the above address between 10:00 AM - 5:00 (Monday to Friday except list of holidays as mentioned on the website at https://web.in.mpms.mufg.com/office-network.html.

(11) Share Transfer System:

In terms of Regulation 40(1) of the SEBI Listing Regulations, as amended from time to time, transfer, transmission and transposition of securities shall be effected only in dematerialized form. Pursuant to SEBI Circular dated January 25, 2022, the listed companies shall issue the securities in dematerialized form only, for processing any service requests from shareholders viz., issue of duplicate share certificates, endorsement, transmission, transposition, etc. After processing the service request, a letter of confirmation will be issued which shall be valid for a period of 120 days, within which the shareholder shall make a request to the Depository Participant for dematerializing those shares. In case of failure to make such request, those shares shall be credited in the Suspense Escrow Demat account held by the Company, for which shareholders can submit necessary documents to claim.

The Directors and certain Company officials (Company Secretary) are authorized by the Board severally to approve transactions, which are noted at subsequent Board Meetings.

(12)Shareholding as on March 31, 2026:

a. Distribution of equity shareholding as on March 31, 2026:

SERIAL #	SHARES RANGE			NUMBER OF SHAREHOLDERS	% OF TOTAL SHAREHOLDERS	TOTAL SHARES FOR THE RANGE	% OF ISSUED CAPITAL
1	1	to	500	12562	93.5717	936522	7.6111
2	501	to	1000	437	3.2551	334449	2.7181
3	1001	to	2000	224	1.6685	339523	2.7593
4	2001	to	3000	62	0.4618	158679	1.2896
5	3001	to	4000	44	0.3277	163405	1.3280
6	4001	to	5000	22	0.1639	99704	0.8103
7	5001	to	10000	37	0.2756	265581	2.1584
8	10001	to	**********	37	0.2756	10006773	81.3252
Total				**13425**	**100.0000**	**12304636**	**100.0000**

b. Categories of equity shareholding as on March 31, 2026:

Category	Demat Securities	Demat Holders	Physical Securities	Physical Holders	Total Securities	Total Holders	% of Issued Capital
Clearing Members	580	3	0	0	580	3	0.0047
Other Bodies Corporate	405321	26	0	0	405321	26	3.2941
Hindu Undivided Family	152766	172	0	0	152766	172	1.2415
Non Resident Indians	29402	63	0	0	29402	63	0.2390
Non Resident (Non Repatriable)	105534	70	0	0	105534	70	0.8577
Public	2456782	13079	0	0	2456782	13079	19.9663
Promoters	9032750	7	0	0	9032750	7	73.4093
Body Corporate - Ltd Liability Partnership	121501	5	0	0	121501	5	0.9874
TOTAL :	**12304636**	**13425**	**0**	**0**	**12304636**	**13425**	**100**

c. Top ten equity shareholders of the Company as on March 31, 2026:

SERIAL NO.	CATEGORY	NAME OF SHAREHOLDER	SHARES	% OF HOLDING
1	Promoter	JIGNESH VALLABHBHAI SAVANI	2692440	21.88
2	Promoter	FALGUN VALLABHBHAI SAVANI	2645952	21.50
3	Promoter Group	SARITABEN VALLABHBHAI SAVANI	2525318	20.52
4	Promoter Group	GHANSHAYAMBHAI B SAVANI	802284	6.52
5	CBO	ECONO TRADING AND INVESTMENT PRIVATE LIMITED	221872	1.80
6	Promoter Group	SAVANI NAYNA JIGNESH	189384	1.54
7	Promoter Group	SHILPABEN FALGUN SAVANI	177372	1.44
8	Body Corporate - Limited Liability Partnership	ADEQUATE REAL TRADE LLP	108000	0.88
9	Other Bodies Corporate	TRADEDEAL ENTERPRISES PRIVATE LIMITED	87400	0.71
10	HUF	MILAN NATVARLAL BHAYANI	56722	0.46

d. **Top ten Public equity shareholders of the Company as on March 31, 2026:**

SERIAL NO.	CATEGORY	NAME OF SHAREHOLDER	SHARES	% OF HOLDING
1	Clearing Members	ECONO TRADING AND INVESTMENT PRIVATE LIMITED	221872	1.80
2	Body Corporate - Limited Liability Partnership	ADEQUATE REAL TRADE LLP	108000	0.88
3	Other Bodies Corporate	TRADEDEAL ENTERPRISES PRIVATE LIMITED	87400	0.71
4	HUF	MILAN NATVARLAL BHAYANI	56722	0.46
5	Non Resident (Non-Repatriable)	SACHIN BHUTADA	56326	0.46
6	Public	KIRITBHAI MAKANBHAI RAVAL	48000	0.39
7	Public	PRAVEEN KUMAR GUPTA	48000	0.39
8	Other Bodies Corporate	PRAFUL METAL WORKS PRIVATE LIMITED	34388	0.28
9	Public	ANNAPURNA THUNUGUNTLA	25991	0.21
10	Public	AVANI HARDIKBHAI MANDALIYA	20588	0.17

(13) Dematerialization of shares and liquidity:

The Company's shares are compulsorily traded in dematerialized form on NSE Capital Market platform. Equity shares of the Company representing 100 % of the Company's equity share capital are dematerialized as on March 31, 2026. Under the Depository System, the International Securities Identification Number (ISIN) allotted to the Company's shares is INE04LG01015.

(14) Outstanding GDRs / ADRs / Warrants or any convertible instruments, conversion date and likely impact on equity:

The Company has not issued any GDRs / ADRs / Warrants or any convertible instruments in the past and hence, as on March 31, 2026, the Company does not have any outstanding GDRs / ADRs / Warrants or any convertible instruments.

(15) Commodity price risk or foreign exchange risk and hedging activities:

For a detailed discussion on foreign exchange risk and no any hedging activities, please refer to Management Discussion and Analysis Report.

(16) Reconciliation of Share Capital Audit:

As stipulated by SEBI, a Practicing Company Secretary carries out the Share Capital Audit to reconcile the total admitted capital with NSDL and CDSL and the total issued, listed and paid up capital. This audit is carried out every quarter and the report thereon is submitted to the Stock Exchanges and is also placed before the Board of Directors. No discrepancies were noticed during these audits.

(17) Equity shares in the suspense account:

None of the equity shares are in the suspense account.

(18) Transfer of unclaimed / unpaid amounts to the Investor Education and Protection Fund:

Pursuant to Sections 124 and 125 of the Act read with the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules"), dividend, if not claimed for a period of seven years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF").

Further, all the shares in respect of which dividend has remained unclaimed for seven consecutive years or more from the date of transfer to unpaid dividend account shall also be transferred to IEPF Authority. The said requirement does not apply to shares in respect of which there is a specific order of Court, Tribunal or Statutory Authority, restraining any transfer of the shares. Company was not required to transfer unclaimed dividend or shares to IEPF during the year under review as there is no unclaimed dividend for seven years. The details of statement of unclaimed and unpaid Dividend available at https://www.pardrugs.com/dividend.php

(19) Plant location:

There are four Manufacturing Blocks at Plot No. 333/1, 333/2, 334, 335, 336/A, 336/B, 337, 338, 339/3 GIDC, Estate, Phase-II, Chitra, Bhavnagar-364004, Gujarat, India, which are for different products having a capacity of approx 9,700 MTPA. Block 1 – APIs, Block 2 - Magnesium Hydroxide, Block 3 - Fine Chemicals and Block 4 – APIs/ Fine Chemicals.

(20) Address for correspondence:

a. Registered Office

815, Nilamber Triumph, Gotri Vasna Road,

Vadodara-390007, Gujarat, India

Phone no.: 0265-2991021/1022, 0278-2447013

Email: investors@pardrugs.com

Website: www.pardrugs.com

b. Contact Details for Investor Correspondence

Mr. Sanket B. Trivedi

Company Secretary, Compliance Officer & Deputy Nodal Officer

Contact: +91 - 278 – 2447013

E-mail: investors@pardrugs.com

Website: www.pardrugs.com

(21) SEBI Complaints Redressal System (SCORES) & SMART ODR Portal:

SEBI has initiated SCORES for processing the investor complaints in a centralized web based redress system and online redressed of all the shareholders complaints. The company is in compliance with the SCORES and redressed the shareholders complaints well within the stipulated time. The Company has already registered it self at new SMART ODR Portal (Securities Market Approach for Resolution Through ODR Portal) during the year, pursuant to the SEBI Circular SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023. This platform is designed to enhance investor grievance redressal by enabling investors to access Online Dispute Resolution Institutions for the resolution of their complaints. The Investor may get details from Company's website at http://pardrugs.com/investor-contact.php

(22) List of all credit ratings obtained by the entity along with any revisions thereto during the relevant financial year, for all debt instruments or any fixed deposit programme or any scheme or proposal of the listed entity involving mobilization of funds, whether in India or abroad: Not Applicable because no any debt instrument or fixed deposit programme or any scheme or proposal of the Company involving mobilization of funds, whether in India or abroad during the year 2025-26

(23) Disclosure of certain types of agreements binding listed entities: No any agreement executed during the year which required disclosure under clause 5A of paragraph A of Part A of Schedule III of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

9. Other Disclosure:

Particulars	Statutes/Regulation	Details	Website link
Related party transactions	Regulation 23 of SEBI Listing Regulations and as defined under the Act.	There are no material related party transactions during the year under review that have conflict with the interest of the Company. The Board has approved policy for related party transactions and it is uploaded on the website of the Company	http://pardrugs.com/pdf/notices/Integrated_Financial_ended_on_30.09.2025.html http://pardrugs.com/pdf/notices/Integtated_FS_31.03.2026.html http://pardrugs.com/pdf/policies/Revised_Policy_on_Related_Party_Tranactions.pdf
Details of non-compliance by the Company, penalty, strictures imposed on the Company by the stock exchange, or Securities and Exchange Board of India ('SEBI') or any statutory authority on any matter related to capital markets during the last three financial years.	Schedule V (C) 10(b) to the SEBI Listing Regulations	Nil	http://pardrugs.com/pdf/secretarial/SignedASCRPAR31032026.pdf http://pardrugs.com/secretarial-compliance-certificate.php

Particulars	Statutes/Regulation	Details	Website link
Vigil Mechanism	Regulation 22 of SEBI Listing Regulations	A Vigil Mechanism for directors and employees to report genuine concerns has been established. The Vigil Mechanism Policy has been uploaded on the website of the Company	https://www.pardrugs.com/pdf/policies/Vigil%20Mechanism%20Policy%20-%20PAR.pdf https://www.pardrugs.com/policies-par-drugs-and-chemicals.php
Subsidiary Companies	Regulation 24 of SEBI Listing Regulations	The Company does not have any Subsidiary, Joint Venture or Associate Company.	http://pardrugs.com/pdf/policies/Policy%20for%20Determination%20of%20Material%20Subsidiary_PAR.pdf
Policy on Determination of Materiality for Disclosures	Regulation 30 of SEBI Listing Regulations	The Company has adopted this policy.	http://pardrugs.com/pdf/policies/Policy%20for%20Determination%20of%20Materiality%20of%20Events%20-%20PAR.pdf https://www.pardrugs.com/policies-par-drugs-and-chemicals.php
Policy on Archival and Preservation of Documents	Regulation 9 of SEBI Listing Regulations	The Company has adopted this policy.	https://www.pardrugs.com/pdf/policies/Policy%20for%20Preservation%20of%20Documents%20-%20PAR.pdf
Reconciliation of Share Capital Audit Report	Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 and SEBI Circulars	A qualified practicing Company Secretary carried out a share capital audit to reconcile the total admitted equity share capital with the National Securities Depository Limited ("NSDL") and the Central Depository Services (India) Limited ("CDSL") and the total issued and listed equity share capital. The audit report confirms that the total issued / paid-up capital is in agreement with the total number of shares in physical form and the total number of dematerialized shares held with NSDL and CDSL.	http://pardrugs.com/pdf/notices/SignedReco30062025.pdf http://pardrugs.com/pdf/notices/Q2_25-26.pdf http://pardrugs.com/pdf/notices/Q3_25-26.pdf http://pardrugs.com/pdf/notices/Q4_25-26.pdf

Particulars	Statutes/Regulation	Details	Website link
Code of Conduct	Regulation 17 of SEBI Listing Regulations	The members of the Board and Senior Management Personnel have affirmed compliance with the Code of Conduct applicable to them during the year ended March 31, 2026. The Annual Report of the Company contains a certificate by the Chief Executive Officer and Managing Director, on the compliance declarations received from the members of the Board and Senior Management.	http://pardrugs.com/pdf/policies/Code%20of%20Director%20&%20Senior%20Management%20Personnel%20-%20PAR.pdf
Dividend Distribution Policy	Regulation 43A of the SEBI Listing Regulations	Not Applicable	-
Terms of Appointment of Independent Directors	Regulation 46 of SEBI Listing Regulations and Section 149 read with Schedule IV of the Act	Terms and conditions of appointment/re-appointment of Independent Directors are available on the Company's website.	https://www.pardrugs.com/pdf/policies/Terms%20and%20Conditon%20of%20Independent%20Directors%20-%20PAR.pdf
Familiarization Program	Regulations 25(7) and 46 of SEBI Listing Regulations	Details of familiarization program imparted to Independent Directors are available on the Company's website.	https://www.pardrugs.com/familiraisation-programme.php
Disclosure under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013	Section 134 of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014	a. Number of complaints filed during the financial year: **Nil** b. Number of complaints disposed of during the financial year: **Not Applicable** c. Number of complaints pending as on end of the financial year.: **Nil** The details have been disclosed in the Directors Report forming part of the Annual Report.	-
Loans and advances in the nature of loans to firms/companies in which directors are interested by name and amount	Para C of schedule V: Annual Report See Regulation 34(3) of Listing Regulation	The Company has not given any loans and advances to firms/Companies in which directors are interested. Hence, it is not applicable	-

Particulars	Statutes/Regulation	Details	Website link
Disclosure of commodity price risk or foreign exchange risk and hedging activities;	Para C of schedule V: Annual Report See Regulation 34(3) of Listing Regulation	The Company does not deal in commodities and hence the disclosure pursuant to SEBI Master Circular dated November 11, 2024 is not applicable	-
Details of utilization of funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A).	Para C of schedule V: Annual Report See Regulation 34(3) of Listing Regulation	Not Applicable because no funds raised through preferential allotment or qualified institutions placement as specified under Regulation 32 (7A) during the year	-

Date: August 22, 2026
Place: Bhavnagar

For & On Behalf of Board of Directors
PAR DRUGS AND CHEMICALS LIMITED

Sd/-
(Mr. Falgun V. Savani)
Chairman & Managing Director
(DIN: 00198236)

Sd/-
(Mr. Jignesh V. Savani)
Director & CEO
(DIN: 00198203)

AFFIRMATION REGARDING COMPLIANCE BY BOARD MEMBERS AND SENIOR MANAGEMENT PERSONNEL WITH THE COMPANY'S CODE OF CONDUCT

This is to confirm that the Company has adopted a Code of Conduct for its employees including the Managing Director and Executive Directors. In addition, the Company has adopted a Code of Conduct for its Non-Executive Directors and Independent Directors. These Codes are available on the Company's website.

We, confirm that the Company has in respect of the year ended March 31, 2026, received from the members of board of directors and senior management personnel of the Company a declaration of compliance with the Code of Conduct as applicable to board of directors and senior management.

Further, Pursuant to Regulation 26(3) read with Schedule V of SEBI (LODR) Regulations, 2015, we hereby declare that the members of board of directors and senior management personnel have affirmed compliance with the code of conduct of board of directors and senior management as applicable to them for the year ended 31st March 2026.

For & on Behalf of Board of Directors
Par Drugs And Chemicals Limited

Sd/-
(Mr. Jignesh V. Savani)
Director & CEO
(DIN: 00198203)

For & on Behalf of Board of Directors
Par Drugs And Chemicals Limited

Sd/-
(Mr. Falgun V. Savani)
Chairman & Managing Director
(DIN: 00198236)

Date: 22/08/2026
Place: Bhavnagar

Certificate of Non-disqualification of Directors

[pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To ,
The Members,
PAR DRUGS AND CHEMICALS LIMITED

We have examined the relevant registers, records, forms, returns and disclosures received from the Directors of **PAR DRUGS AND CHEMICALS LIMITED** having CIN L24117GJ1999PLC035512 and having registered office at 815, Nilamber Triumph, Gotri Vasna Road, Vadodara- 390007 Gujarat (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In our opinion and to the best of our information and according to the verifications (including Directors Identification Number (DIN) status at the portal www.mca.gov.in) as considered necessary and explanations furnished to us by the Company & its officers, We hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on **March 31, 2026** have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, or any such other Statutory Authority.

Sr. No.	Name of Director & DIN	Designation & Category	Date of Appointment/ Re-appointment*
1.	Mr. Falgun Vallabhbhai Savani DIN: 00198236	Chairman and Managing Director (Promoter)	26/02/1999 (as a Director) 26/11/2018 (as a Chairman & Managing Director)
2.	Mr. Jignesh Vallabhbhai Savani DIN: 00198203	CEO and Executive Director (Promoter)	26/02/1999 (as a Director) 26/11/2018 (as a CEO)
3.	Mr. Pravin Manjibhai Bhayani DIN: 08332851	Non- Executive Independent Director	17/01/2019
4.	Mrs. Krishna Mitulbhai Shah DIN: 08317678	Non- Executive Independent Director	17/01/2019
5.	Mrs. Kajal Chintanbhai Vaghani DIN: 08317641	Non- Executive Independent Director	17/01/2019
6.	Mrs. Bintal Bhaveshkumar Shah DIN: 08893054	Non- Executive Independent Director	28/09/2020

***Notes for Date of re-appointment**

1. Term of **Mr. Falgun Vallabhbhai Savani** as Chairman & Managing Director ended on 25th Day of November, 2023. He was re-appointed as Chairman & Managing Director for further period of 5 years from 26th Day of November, 2023 to 25th Day of November, 2028.
2. Term of **Mr. Jignesh Vallabhbhai Savani** as CEO ended on 25th Day of November, 2023. He was re-appointed as CEO for further period of 5 years from 26th Day of November, 2023 to 25th Day of November, 2028.
3. Term of **Mr. Pravin Manjibhai Bhayani** as an Independent Director of the Company ended on 16th Day of January, 2024. He was re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 17th January, 2024 to 16th January.
4. Term of **Mrs. Krishna Mitulbhai Shah** as an Independent Director of the Company ended on 16th Day of January, 2024. She was re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029.
5. Term of **Mrs. Kajal Chintanbhai Vaghani** as an Independent Director of the Company ended on 16th Day of January, 2024. She was re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 17th January, 2024 to 16th January, 2029.

6. Term of **Mrs. Bintal Bhaveshkumar Shah** as an Independent Director of the Company ended on 27th September, 2025. She was to re-appointed as an Independent Director for a second term of Five consecutive years w.e.f. 28th Day of September, 2025 to 27th September, 2030.

   Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

FOR DG PATEL & ASSOCIATES
Company Secretaries

Sd/-
Dip G. Patel
(Proprietor)
FCS: 10533
C.P. No.: 13774
PR: 1839/2022

Place: Bhavnagar
Date: 26/08/2026
UDIN: F010533H001227298

Corporate Governance Compliance Certificate

[Pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015]

To ,
The Members,
PAR DRUGS AND CHEMICALS LIMITED

We have examined the compliance of conditions of Corporate Governance by **Par Drugs And Chemicals Limited** ('the Company') for the year ended on **31st March, 2026**, as stipulated under Regulations 17 to 27, Clauses (b) to (i) of sub-regulation (2) of Regulation 46 and Para C, D and E of Schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to a review of procedures and implementation thereof, adopted by the Company for ensuring compliance with the conditions of Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanations given to us and the representations made by the Directors and the Management, we certify that the Company has compiled with the conditions of Corporate Governance as stipulated in the provisions as specified in Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the year ended on **31st March, 2026**.

We further state that this certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

FOR DG PATEL & ASSOCIATES
Company Secretaries

Sd/-
Dip G. Patel
(Proprietor)
FCS: 10533
C.P. No.: 13774
PR: 1839/2022

Place: Bhavnagar
Date: 26/08/2026
UDIN: F010533H001227419

COMPLIANCE CERTIFICATE

(Pursuant to Regulation 17(8) read with Part B of Schedule II of SEBI (LODR) Regulations, 2015)

To,
The Board of Directors
Par Drugs And Chemicals Limited

We, the undersigned, in our respective capacities as Chief Executive Officer and Chief Financial Officer of Par Drugs And Chemicals Limited ("the Company"), to the best of our knowledge and belief certify that:

A. We have reviewed the financial statements and the cash flow statement for the year ended on 31st March, 2026 and based on our knowledge and belief, we state that:

   1. These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

   2. These statements together present a true and fair view of the Company's affairs and are in compliance with existing accounting standards, applicable laws and regulations.

B. We further state that to the best of our knowledge and belief, there are no transactions entered into by the Company during the year which are fraudulent, illegal or violative of the Company's Code of Conduct.

C. We accept responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or propose to take to rectify these deficiencies.

D. We have indicated, based on our most recent evaluation, wherever applicable, to the Auditors and the Audit committee:

   1. significant changes, if any, in internal control over financial reporting during the year;

   2. significant changes, if any, in accounting policies during the year and that the same have been disclosed in the notes to the financial statements; and

   3. instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or any employee having significant role in the Company's internal control system over financial reporting.

For Par Drugs And Chemicals Limited

Sd/-
(Mr. Jignesh V. Savani)
Chief Executive Officer

Date: 14/05/2026
Place: Bhavnagar

For Par Drugs And Chemicals Limited

Sd/-
(Mr. Chintan P. Chauhan)
Chief Financial Officer

Independent Auditor's Report

To,
The Members of,
PAR DRUGS AND CHEMICALS LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the accompanying standalone financial statements of PAR DRUGS AND CHEMICALS LIMITED ("the Company"), which comprise the balance sheet as at 31st March 2026, and the statement of Profit and Loss (including other comprehensive income), the statement of changes in equity and the statement of cash flows for the year ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended ("Ind AS") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2026, and its profit, total comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined the matters described below to be the key audit matters to be communicated in our report.

Assessment of Going Concern Assumption due to Delay in Strategic Business Restructuring

Why this matter was considered to be one of the most significant in the audit

During the year, the proposed slump sale of the Company's principal business undertaking, approved in the previous year, remained pending due to regulatory proceedings initiated by the Securities and Exchange Board of India (SEBI). Consequently, the Company's proposed strategic restructuring and entry into new business segments have not been implemented as planned.

These circumstances required significant management judgement in assessing the Company's ability to continue as a going concern, considering the uncertainty surrounding completion of the proposed transaction, the Company's existing operations, liquidity position, and future funding plans. Accordingly, this matter was considered to be one of the most significant in our audit.

How the matter was addressed in the audit

Our audit procedures included, among others:

- Obtaining an understanding of the status of the SEBI proceedings and management's assessment of their impact on the proposed transaction;
- Reviewing correspondence with regulators and legal advisors, where available;
- Evaluating management's revised cash flow forecasts and business plans;
- Assessing the Company's liquidity position and availability of financial resources to continue operations;
- Evaluating the assumptions underlying management's going concern assessment;
- Assessing the adequacy of disclosures relating to the pending regulatory proceedings, proposed restructuring, and going concern assessment.

Based on the audit procedures performed and the evidence obtained, we found management's use of the going concern basis of accounting to be appropriate and the related disclosures in the financial statements to be adequate.

Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Corporate Governance and Shareholder's Information, but does not include the standalone financial statements and our auditor's report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, including other comprehensive income, changes in equity and cash flows of the Company in accordance with the Ind AS and other accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Standards on Auditing ("SAs") will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Standards on Auditing ("SAs"), we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements:

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the "Annexure - A", a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, based on our audit we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

(b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

(c) The Balance Sheet, the Statement of Profit and Loss including other comprehensive income, the statement of changes in equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.

(d) In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

(e) On the basis of the written representations received from the directors as on 31st March, 2026 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2026 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure - B".

(g) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

In our opinion and to the best of our information and according to the explanation given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provision of section 197 of the Act.

(h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

i. The Company does not have any pending litigations which would impact its financial position except mentioned in assessment of going concern assumption due to delay in strategic business restructuring para. As at the reporting date, the investigation by SEBI is continuing. The observations contained in the Confirmatory Order are tentative in nature and no final determination of liability or wrongdoing has been made. The Company has represented that it is contesting the matters and is cooperating with the ongoing investigation. The ultimate outcome of the proceedings and its financial impact, if any, cannot presently be determined with reasonable certainty.

ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

iv. The Management has represented that, to the best of it's knowledge and belief, as disclosed in the note 29.4 to the accounts, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

v. The Management has represented, that, to the best of it's knowledge and belief, as disclosed in the note 29.5 to the accounts, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

vi. Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e) contain any material mis-statement.

vii. During the year company has not declare or paid any dividend, hence reporting under Rule 11(f) of Companies (Audit and Auditors) Rules, 2014 is not applicable for the financial year ended March 31, 2026.

viii. Proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 for maintaining books of account using accounting software which has a feature of recording audit trail (edit log) facility is applicable to the Company with effect from April 1, 2023, and accordingly, reporting under Rule 11(g) of Companies (Audit and Auditors) Rules, 2014 is applicable for the financial year ended March 31, 2026 and company has maintained books of accounts using accounting software which has a feature of reporting audit trail.

SARUPRIA SOMANI & ASSOCIATES
(Firm Registration No – 010674C)
CHARTERED ACCOUNTANTS

Sd/-
MIRAL MEHTA (Partner)
M.No.145361
UDIN: 26145361KMFAHE4611

Bhavnagar, 14th May, 2026

Annexure - A to the Auditors' Report

The Annexure referred to in our report to the members of PAR DRUGS AND CHEMICALS LIMITED, for the year ended 31st March, 2026.

On the basis of the information and explanation given to us during the course of our audit, we report that:

1. (a) The company has maintained proper records showing full particulars including quantitative details and situation of its property, plant and equipment. The accounting aspects of property, plant and equipment are dealt with Ind AS 16. The company has also maintained proper records showing full particulars of intangible assets, if any.

   (b) These fixed assets have been physically verified by the management at reasonable intervals and there were no Material discrepancies were noticed on such verification.

   (c) All immovable assets of company and the title deeds of immovable properties are held in the name of the company.

   No any property, plant and equipment (including right to use assets) or intangible asset have been revalued during the year.

   (d) No any proceedings have been initiated or are pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 and rules made thereunder.

2. (a) Physical verification of inventory has been conducted at reasonable intervals by the management and there are no material discrepancies were noticed. The coverage and procedure of such verification by the management is appropriate.

   (b) During any point of time of the year, the company has not been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets.

3. (a) The company has not provided any loans or advances in the nature of loans, or stood guarantee, or provided security to any other entity other than companies whose principal business is to give loans.

   (b) No any investment made, guarantees provided, security given and none of the term and conditions of the grant of all loans and advances are prejudicial to the company's interest. No any amount is overdue for more than ninety days. No any loan or advance in the nature of loan granted which has fallen due during the year, has been renewed or extended or fresh loans granted to settle the overdue of existing loans given to the same parties.

   (c) The company has not granted any loans or advances in the nature of loans either repayable on demand or without specifying any terms or period of repayment

4. In respect of loans, investments, guarantees and security all mandatory provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.

5. The company has not accepted any deposits.

6. We have broadly reviewed the books of accounts maintained by the company pursuant to the rules made by the Central Government for maintenance of cost records u/s. 148 of the Companies Act, 2013 and are of opinion that prima-facie prescribed accounts have been made and maintained. We have not however, made a detailed examination of the records with a view to determine whether they are accurate or complete.

7. (a) The company is regular in depositing undisputed statutory dues including Goods and Service Tax, Provident fund, Employee's state insurance, income-tax, sales-tax, service tax, duty of customs, duty of excise, value added tax, cess and any other statutory dues to the appropriate authorities.

   (b) Dues of income tax or goods and service tax or sales tax or service tax or duty of customs or duty of excise or value added tax have been deposited on time and there is no dispute is pending on the part of company.

8. No any transactions which are not recorded in the books of account, have been surrender or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961.

9. (a) The company has not made any default in repayment of loans or borrowing to a financial institution, bank, Government or dues to debenture holders.

   (b) No any bank or financial institution or other lender has declared the company as a defaulter.

   (c) During the year, no any term loan is outstanding.

   (d) During the year, no any short term funds has been raised.

   (e) The company doesn't have any subsidiaries, associates or joint ventures.

(f) Since company doesn't have any subsidiaries, associates or joint ventures, no question of raising fund on the pledge of securities held in its subsidiaries, joint ventures or associate companies.

10. (a) The company doesn't raise any money by way of initial public offer or further public offer (including debt instruments).

    (b) The company has not made any preferential allotment or private placement of shares of convertible debentures during the year.

11. Neither company has done any fraud nor by its officers or employees so nothing to be disclosed separately. Hence, no any separate disclosure required under sub-section (12) of section 143 of the companies act in prescribed form of ADT-4. No any whistle-blower complaints have been filed.

12. Company is not a Nidhi Company, therefore, nothing to be disclosed for any provisions applicable on Nidhi Company.

13. All transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc. as required by the applicable accounting standards;

14. The company has the proper internal audit system commensurate with the size and nature of its business. We have broadly reviewed the reports of the internal auditors for the period under audit.

15. The company hasn't entered into any non-cash transactions as described in section 192 of the Companies Act with directors or persons connected with him.

16. (a) The company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934.

    (b) The company has not conducted any Non-Banking Financial or Housing Finance activities without a valid Certificate of Registration from RBI.

    (c) The company is not a Core Investment Company (CIC) as defined in the regulations made by the RBI.

17. The company has not incurred any cash losses in the financial year or in the immediately preceding financial year.

18. During the year, there has been no any resignation of the statutory auditor.

19. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, we are of the opinion that no material uncertainty exists as on the date of the audit report. The company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

20. There is no any unspent amount to Fund specified in Schedule VII or shortfall which to be spent by the company in respect to CSR activities in compliance with section 135 of the companies act, 2013.

21. There have not been any qualifications or adverse remarks in the Companies (Auditor's Report) Order (CARO) reports of the companies.

SARUPRIA SOMANI & ASSOCIATES
(Firm Registration No – 010674C)
CHARTERED ACCOUNTANTS

Sd/-
MIRAL MEHTA (Partner)
M.No.145361
UDIN: 26145361KMFAHE4611
Bhavnagar, 14th May, 2026

Annexure - B to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of PAR DRUGS AND CHEMICALS LIMITED ("the Company") as of 31 March 2026 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March 2026, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

SARUPRIA SOMANI & ASSOCIATES
(Firm Registration No – 010674C)
CHARTERED ACCOUNTANTS

Sd/-
MIRAL MEHTA (Partner)
M.No.145361
UDIN: 26145361KMFAHE4611
Bhavnagar, 14th May, 2026

Balance Sheet

As At 31st March, 2026

Particulars	Note No.	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	2	3,643.86	3,891.49
(b) Capital Work-in-Progress	3	71.70	-
(c) Investment in Property		-	-
(d) Goodwill		-	-
(e) Other Intengible Assets		-	-
(f) Intengible Assets Under Development		-	-
(g) Biological Assets Other Than Bearer Plant		-	-
(h) Financial Assets			
(i) Investments	4	2,713.64	2,507.00
(ii) Trade receivables		-	-
(iii) Loans		-	-
(i) Deferred Tax Assets (net)		-	-
(j) Other non-current assets	5	59.44	54.41
Total Non-Current Assets		**6,488.64**	**6,452.91**
(2) Current Assets			
(a) Inventories	6	537.28	610.59
(b) Financial Assets			
(i) Investments		-	-
(ii) Trade receivables	7	1,202.77	1,671.41
(iii) Cash and cash equivalents	8	4,184.29	2,757.72
(iv) Bank balances other than (iii) above		-	-
(v) Loans	9	11.12	9.90
(vi) Other Financial Assets		-	-
(c) Current Tax Assets (Net)	10	474.76	424.36
(d) Other Current Assets	11	22.37	12.12
Total Current Assets		**6,432.59**	**5,486.10**
TOTAL ASSETS		**12,921.24**	**11,939.01**
EQUITY AND LIABILITIES			
Equity			
(a) Equity Share Capital	12	1,230.46	1,230.46
(b) Other Equity	13	9,968.00	8,667.03
Total Equity		**11,198.47**	**9,897.49**
Liabilities			
(1) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		-	-
(ia) Lease Liabilities		-	-
(ii) Trade Payables:-			
(A) Total outstanding dues of micro and small enterprises; and		-	-
(B) Total outstanding dues of creditors other than micro and small enterprises		-	-
(iii) Other financial libilities		-	-
(b) Provisions	14	24.01	26.66
(c) Deferred Tax Libilities (Net)	15	324.40	358.00
(d) Other Non-Current Liabilities		-	-
Total Non-Current Liabilities		**348.41**	**384.66**
(2) Current Liabilities			
(a) Financial Liabilities			
(i) Borrowings		-	-
(ia) Lease Liabilities		-	-
(ii) Trade Payables:-	16		
(A) Total outstanding dues of micro and small enterprises; and		80.06	34.49
(B) Total outstanding dues of creditors other than micro and small enterprises		739.33	1,054.65
(iii) Other financial libilities		-	-
(b) Other Current Liabilities	17	95.90	109.75
(c) Provisions	18	459.07	457.97
(d) Current Tax Libilities (Net)		-	-
Total Current Liabilities		**1,374.36**	**1,656.85**
TOTAL EQUITY AND LIBILITIES		**12,921.24**	**11,939.01**
Significant Accounting Policies	1		
Notes forming part of the financial statements	2-33		

As per our report of even dated.

For, Sarupria Somani & Associates
Firm Regn. No.010674C
Chartered Accountants

Sd/-
Miral Mehta (Partner)
M.No.145361
UDIN: 26145361KMFAHE4611

Bhavnagar, 14th May, 2026

For and on behalf of Board of Directors of
Par Drugs and Chemicals Limited

Sd/-
Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)

Sd/-
Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)

Sd/-
Chintan P Chauhan
(CFO)

Sd/-
Sanket B Trivedi (CS)
(M.No.- F13800)

Bhavnagar, 14th May, 2026

Statement of Profit & Loss

For The Year Ended 31st March, 2026

	Particulars	Note No.	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
I.	Revenue from operations	19	10,365.56	10,097.35
II.	Other income	20	400.07	215.03
III.	**Total Income (I + II)**		**10,765.63**	**10,312.38**
IV.	**Expenses:**			
	Cost of materials consumed	21	4,267.05	3,940.86
	Purchases of Stock-in-Trade		-	-
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	22	69.09	-127.83
	Employee benefits expense	23	612.01	585.18
	Finance costs	24	12.73	8.21
	Depreciation and amortization expense	25	370.33	364.66
	Other expenses	26	3,704.26	3,749.01
	Total expenses (IV)		**9,035.48**	**8,520.09**
V.	**Profit / (loss) before exceptional items and tax (III-IV)**		**1,730.15**	**1,792.29**
VI.	Exceptional items		-	-
VII.	**Profit / (loss) before tax (V - VI)**		**1,730.15**	**1,792.29**
VIII.	Tax expense:			
	(1) Current tax		452.90	452.50
	(2) Deferred tax		-33.60	4.00
IX	**Profit / (Loss) for the period from continuing operations (VII-VIII)**		**1,310.85**	**1,335.79**
X	Profit / (loss) from discontinued operations		-	-
XI	Tax expense of discontinued operations		-	-
XII	**Profit / (loss) from Discontinued operations (after tax) (X-XI)**		**-**	**-**
XIII	**Profit / (Loss) for the period (IX + XII)**		**1,310.85**	**1,335.79**
XIV	**Other Comprehensive Income**			
	A (i) items that will not be reclassified to profit or loss		-	-
	(ii) income tax relating to items that will not be reclassified to profit or loss		-	-
	B (i) items that will be reclassified to profit or loss		-	-
	(ii) income tax relating to items that will be reclassified to profit or loss		-	-
XV	**Total Comprehensive Income for the period (comprising profit / (loss) and other comprehencive income for the period) (XIII + XIV)**		**1,310.85**	**1,335.79**
XVI	Earnings per equity share (for discontinued operation)	27		
	(1) Basic		-	-
	(2) Diluted		-	-
XVII	Earnings per equity share (for discontinued & continuing operation)	27		
	(1) Basic		10.65	10.86
	(2) Diluted		10.65	10.86
	Significant Accounting Policies	1		
	Notes forming part of the financial statements	2-33		

As per our report of even dated.

For, Sarupria Somani & Associates
Firm Regn. No.010674C
Chartered Accountants

Sd/-
Miral Mehta (Partner)
M.No.145361
UDIN: 26145361KMFAHE4611

Bhavnagar, 14th May, 2026

For and on behalf of Board of Directors of
Par Drugs and Chemicals Limited

Sd/-
Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)

Sd/-
Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)

Sd/-
Chintan P Chauhan
(CFO)

Sd/-
Sanket B Trivedi (CS)
(M.No.- F13800)

Bhavnagar, 14th May, 2026

Cash Flow Statement Annexed To The Balance Sheet For The Year Ended 31st March, 2026

PARTICULARS	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
A: CASH FLOW FROM OPERATING ACTIVITIES:		
Net profit before tax	1,730.15	1,792.29
Adjusted for:		
Depreciation	370.33	364.66
Income-tax/Prior Year Adjustment	-9.88	-1.50
Interest Expense	-	-
Rent, Interest & Dividend Income	-183.83	-104.77
Profit/Loss on sale of assets	-0.56	-
	176.06	258.39
Operating Profit / (loss) before working capital changes	1,906.21	2,050.68
Adjustments for changes in working capital		
Adjustments for (increase)/decrease in operating assets		
Loans & Other Non-Current Assets	-5.03	9.66
Inventories	73.31	-192.89
Trade Receivables	468.64	-299.99
Loans (Current Assets)	-1.22	-0.42
Other Current Assets	-10.25	16.00
Adjustments for increase/(decrease) in operating liabilities		
Provisions (Non-Current Liabilities)	-2.65	26.66
Provisions (Current Liabilities)	0.70	-11.41
Other Current Liabilities	-13.85	-84.12
Trade Payables	-269.75	553.52
	239.90	17.02
Cash Generated from / (used in) Operating activities	**2,146.11**	**2,067.70**
Less: Income-Tax paid	-502.90	-451.68
Net Cash genereated from / (used in) Operating Activities:	**1,643.21**	**1,616.02**
B: CASH FLOW FROM INVESTING ACTIVITIES:		
Purchase of Fixed Assets	-196.17	-122.66
Sales of Fixed Assets	2.34	-
Purchase of Investment	-206.64	-2,505.81
Rent, Interest & Dividend Income	183.83	104.77
	-216.64	-2,523.70
Net Cash generated from / (used in) Investing Activities:	**-216.64**	**-2,523.70**
C: CASH FLOW FROM FINANCING ACTIVITIES:		
Proceeds from Issue of Shares	-	-
Proceeds from Long Term Borrowings	-	-
Repayment of Long Term Borrowings	-	-
Repayment of Short Term Borrowings	-	-
Dividend Paid	-	-
Interest paid	-	-
	-	-
Net Cash generated from / (used in) Financing Activities:	**-**	**-**
Net Increase/(Decrease) in Cash and Cash Equivalents	**1,426.57**	**-907.67**
Opening Balance of Cash and Cash Equivalents	2,757.72	3,665.39
Closing Balance of Cash and Cash Equivalents	4,184.29	2,757.72
Total:	**1,426.57**	**-907.67**

1. Purchase of fixed assets are stated inclusive of movement of Capital Work in Progress and advance for capital goods between the commencement and end of the year and are considered as part of investing activity.
2. The cash flow statement has been prepared under the "indirect method" as set out in Accounting Standard - 3 on Cash Flow Statement issued by the Institute of Chartered Accountants of India.

Notes forming part of the financial statements 2-33

As per our report of even dated.

For, Sarupria Somani & Associates
Firm Regn. No.010674C
Chartered Accountants

Sd/-
Miral Mehta (Partner)
M.No.145361
UDIN: 26145361KMFAHE4611

Bhavnagar, 14th May, 2026

For and on behalf of Board of Directors of
Par Drugs and Chemicals Limited

Sd/-
Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)

Sd/-
Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)

Sd/-
Chintan P Chauhan
(CFO)

Sd/-
Sanket B Trivedi (CS)
(M.No.- F13800)

Bhavnagar, 14th May, 2026

Notes to Financial Statement for the year ended on 31st March, 2026

NOTES NO.01 : SIGNIFICANT ACCOUNTING POLICIES

(A) Corporate Information

Company was originally incorporated on February 26, 1999 as Par Drugs and Chemicals Private Limited under the provisions of the Companies Act, 1956 with the Registrar of Companies, Ahmedabad, Gujarat. Company was converted in to Public Limited Company and consequently name of company was changed from Par Drugs and Chemicals Private Limited to Par Drugs and Chemicals Limited vide special resolution passed by the Shareholders at the Extraordinary General Meeting held on October 24, 2018 and a fresh certificate of incorporation dated November 5, 2018 issued by the Registrar of Companies, Ahmedabad.

The Company is primarily engaged in manufacturing of Active Pharma Ingredients and fine chemicals (API) for domestic market as well as for exports to international markets. APIs, also known as "bulk drugs" or "bulk actives" are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.

(B) Significant Accounting Policies

1) Basis of Preparation of Financial Statement

These financial statements are prepared in accordance with the Indian Accounting Standards prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 as amended ("Ind AS") and other accounting principles generally accepted in India under the historical cost convention on the accrual basis except for certain financial instruments which are measured at fair values. GAAP comprises mandatory accounting standards as prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014. Accounting policies have been consistently applied except where a newly issued accounting standard is initially adopted or a revision to an existing accounting standard requires a change in the accounting policy hitherto in use.

2) Use of Estimates:

The preparation of the financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported balances of assets and liabilities and disclosures relating to contingent liabilities as at the date of the financial statements and reported amounts of income and expenses during the period. Examples of such estimates include computation of percentage of completion which requires the Company to estimate the efforts or costs expended to date as a proportion of the total efforts or costs to be expended, provisions for doubtful debts, future obligations under employee retirement benefit plans, income taxes, post-sales customer support and the use-full lives of fixed tangible assets and intangible assets. Accounting estimates could change from period to period. Actual results could differ from those estimates. Appropriate changes in estimates are made as the Management becomes aware of changes in circumstances surrounding the estimates. Changes in estimates are reflected in the financial statements in the period in which changes are made and, if material, their effects are disclosed in the notes to the financial statements.

3) Property, Plant and Equipment and Intangible assets & Depreciation:

Tangible Assets:

All items of fixed assets are stated at historical cost less accumulated depreciation. Historical cost includes expenditure that is directly attributable to the acquisition of the items. Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance expenses are charged to profit or loss during the reporting period in which they are incurred

Depreciation on fixed assets is provided on pro rata basis as per WDV method based on the estimated useful life of various assets, as specified in Schedule II of the Companies Act, 2013.

Intangible Assets:

An intangible asset is recognized when it is probable that the future economic benefits attributable to the asset will flow to the enterprise and where its cost can be reliably measured. Intangible assets are stated at cost of acquisition less accumulated amortization and impairment losses, if any. Cost comprises the purchase price and any cost attributable to bringing the assets to its working condition for its intended use which includes taxes and allocated incidental expenditure during development / acquisition and exclusive of Input tax credit (IGST/CGST and SGST) or other tax credit available to the Company.

Subsequent expenditure relating to intangible assets is capitalized only if such expenditure results in an increase in the future benefits from such asset beyond its previously assessed standard of performance.

Assets Acquired as Lease:

Leases under which the Entity assumes substantially all the risks and rewards of ownership are classified as finance leases. Such assets are capitalized at fair value of the asset or present value of the minimum lease payments at the inception of the lease, whichever is lower. Lease payments under operating leases are recognized as an expense in the Proft and Loss Account on a straight-line basis over the lease term.

The cost of leasehold land is amortized over the period of the lease. Leasehold improvements and assets acquired on finance lease are amortized over the lease term or useful life, whichever is lower.

Advances paid towards the acquisition of Property, Plant and Equipment

Advances paid towards the acquisition of Property, Plant and Equipment, outstanding at each balance sheet date are shown under capital advances. The cost of the Property, Plant and Equipment not ready for its intended use on such date, is disclosed under capital work-in-progress.

4) Impairment of Assets:

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. Impairment loss is charged to the Statement of Profit and Loss in the year in which an asset is identified as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

5) Investments:

Investments are classified and measured in accordance with Ind AS 109 – *Financial Instruments*.

- **Equity investments** are measured at **fair value through profit or loss (FVTPL)** unless irrevocably designated at **fair value through other comprehensive income (FVOCI)** at initial recognition.
- **Debt instruments** are classified based on the Company's business model and contractual cash flow characteristics and are measured at **amortised cost**, **FVOCI**, or **FVTPL** accordingly.
- All investments are initially recognized at **fair value**.
- Changes in fair value of investments measured at FVTPL are recognized in the **Statement of Profit and Loss**.
- Investments classified at FVOCI are measured at fair value, and changes therein are recognized in **Other Comprehensive Income (OCI)**.
- The Company assesses expected credit losses (ECL) for debt investments where applicable.

6) Inventories : The inventories are valued on the following basis :

a) Raw Materials : Valued at Cost Price.

b) Finished goods : Valued at lower of Cost or Net Realizable Value.

c) Stock in Process : Valued at Cost Price.

7) Employee Benefits:

All short term employee benefits are accounted on undiscounted basis during the accounting period based on services rendered by employees.

The Company's contribution to Provident Fund and Employees State Insurance Scheme is determined based on a fixed percentage of the eligible employees' salary and charged to the Statement of Profit and Loss on accrual basis.

The Company's liability towards gratuity and compensated absences, being defined benefit plans are accounted for on the basis of an independent actuarial valuation and actuarial gains/losses are charged to the Statement of Profit and Loss.

8) Revenue Recognition:

(A) Revenue/income and Cost / Expenditure are generally accounted on accrual basis as they are earned or incurred, except those with significant uncertainties.

(B) Sales are recognized at the point of dispatch of goods to the customers. Sales are net of discounts, GST and returns.

(C) Interest income is recognized on time proportion basis.

(D) Dividend on Investments is accounted when approved by the shareholders' in the annual general meeting.

(E) Insurance claim receivable is recognized in the year of the loss to the extent ascertainable.

(F) The CENVAT / GST Credit available on purchase of raw materials / capital items and other eligible inputs are adjusted against GST payable on clearance of finished goods.

9) Foreign Currency Transaction:

Monetary assets and liabilities related to foreign currency transactions remaining unsettled at the end of the year are translated at year end rates.

The difference in translation of monetary assets and liabilities and realized gains and losses on foreign transactions are recognized in the Statement of Profit and Loss.

The premium or discount on forward exchange contracts is recognized in the statement of profit and loss over the period of the contract.

10) Accounting for Government Grants/Refunds:

Government grants/subsidies and refunds due from Government Authorities are accounted when there is reasonable certainty of their realization.

11) Taxation

Tax expenses comprise current tax (amount of tax for the period determined in accordance with the Income Tax Regulations in India) and deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period).

The deferred tax charge or credit and the corresponding deferred tax liabilities or assets are recognised using the tax rates that have been enacted or substantively enacted by the Balance Sheet date, Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realized in future; however, when there is unabsorbed depreciation or carry forward losses under taxation laws, deferred tax assets are recognised only if there is a virtual certainty of realization of such assets. Deferred tax assets are reviewed at each Balance Sheet date and written down or written up to reflect the amount that is reasonably / virtually certain, as the case may be, to be realized

Tax credit is recognised in respect of Minimum Alternate Tax (MAT) as per the provisions of Section 115JAA of the Income Tax Act, 1961 based on convincing evidence that the Company will pay normal income tax within the statutory time frame and is reviewed at each Balance Sheet date.

Company has policy of not considering MAT tax credit available to them under the Income Tax Act.

12) Borrowing Cost:

Borrowing Costs relating to the acquisition/ construction of qualifying assets are capitalized until the time all substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use. All other borrowing costs are charge to revenue.

13) Earning Per Share:

Basic earning per share is calculated by dividing the net profit or loss after tax for the year attributable to Equity Shareholders of the Company by the weighted average number of Equity Shares outstanding during the year.

Diluted earning per Share is calculated by dividing net profit or loss attributable to equity Shareholders by the weighted average number of equity shares outstanding during the year with adjustment of all dilutive potential equity shares.

14) Provisions, Contingent Liabilities & Contingent Assets:

The company recognizes as provisions, the liability being present obligations arising from past events, the settlement of which is expected to result in outflow of resources and which can be measured only by using a substantial degree of estimation. Contingent liabilities are disclosed by way of a note to the financial statement after careful evaluation by the management of the facts and legal aspect of the matters involved. Contingent assets are being neither recognized nor disclosed.

15) Curent Assets, Loans And Avances

The balance under items of Sundry Debtors, Loans and Advances and current liabilities are subject to confirmation and reconciliation and consequential adjustments, wherever applicable. However, in the opinion of the Management, the realisable value of the current assets, loans and advances in the ordinary course of business will not be less than the value at which they are stated in the Balance Sheet.

16) Cash Flow

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. Cash flows from operating, investing and financing activities of the Company are segregated, accordingly.

17) Segment Reporting

As the company is dealing in only one segment i.e. manufacturing industry, API, hence segment reporting is not applicable. Company does not have distinguishable component of an enterprise that is engaged in providing an individual product or service or group of related product or services and that is subject to risks and returns that are different from those of other business segment.

NOTES No.2. PROPERTY, PLANT AND EQUIPMENT :(NON-CURRENT ASSETS)

Rs in Lakhs

Particulars	Land	Buildings	Plant & Machineries	Furniture & Fixtures	Vehicles	Others	Total
Gross carrying amount							
As on 01-04-2025	314.84	2,028.09	4,164.30	179.55	287.66	534.94	7,509.37
Additions	-	23.00	50.54	4.15	27.90	18.89	124.48
Disposals	-	-	-	-	-35.55	-	-35.55
Effect of foreign exchange movements	-	-	-	-	-	-	-
Other movements	-	-	-	-	-	-	-
As on 31.03.2026	**314.84**	**2,051.09**	**4,214.84**	**183.70**	**280.00**	**553.83**	**7,598.30**
Depreciation and impairments							
As on 01-04-2025	-	587.39	2,402.55	70.53	249.67	307.74	3,617.88
Depreciation	-	65.06	234.30	17.80	12.38	40.79	370.33
Impairments	-	-	-	-	-33.77	-	-33.77
Effect of foreign exchange movements	-	-	-	-	-	-	-
Other movements	-	-	-	-	-	-	-
As on 31.03.2026	**-**	**652.45**	**2,636.85**	**88.33**	**228.28**	**348.53**	**3,954.44**
Net book value 31.03.2026	**314.84**	**1,398.64**	**1,577.99**	**95.38**	**51.72**	**205.30**	**3,643.86**
Net book value 31.3.2025	314.84	1,440.70	1,761.75	109.02	37.99	227.20	3,891.49

NOTES No.3. CAPITAL WORK-IN-PROGRESS : (NON-CURRENT ASSETS)

Rs in Lakhs

Particulars	Buildings	Plant & Machineries	Furniture & Fixtures	Total
Gross carrying amount				
As on 01-04-2025	-	-	-	-
Additions	-	71.70	-	71.70
Disposals	-	-	-	-
Effect of foreign exchange movements	-	-	-	-
Other movements	-	-	-	-
As on 31.03.2026	**-**	**71.70**	**-**	**71.70**
Depreciation and impairments				
Depreciation	-	-	-	-
Impairments	-	-	-	-
Effect of foreign exchange movements	-	-	-	-
Other movements				
As on 31.03.2026	**-**	**-**	**-**	**-**
Net book value 31.03.2026	**-**	**71.70**	**-**	**71.70**
Net book value 31.3.2025	**-**	**-**	**-**	**-**

CAPITAL WORK-IN-PROGRESS AGING SCHEDULE **Rs in Lakhs**

Capital Work-In-Progress	Amount in Capital WIP for a period of				
	Less than 1 Year	1-2 year	2-3 year	More than 3 year	Total
Project in progress- Factory Building	-	-	-	-	-
Projects temporarily suspended	-	-	-	-	-

NOTES No.4. INVESTMENTS (NON-CURRENT - FINANCIAL ASSETS) :

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1 Investments in Mutual Fund (Quoted);		
- ABCL Low Duration Fund	1.36	1.28
- Nuvama Asset Management Limited	3.00	1.57
- Nuvama Absolute Return Strategy-Collection A/C	2,282.94	2,102.37
- Mirae Asset Arbitrage Fund-Regular Plan Growth	53.16	50.21
- Nippon India Arbitrage Fund-Growth Plan	106.41	100.43
- Sbi Arbitrage Opportunities-Reg P G	106.73	100.45
- Uti Arbitrage Fund-Regular Plan Growth	160.04	150.70
TOTAL: INVESTMENTS	**2,713.64**	**2,507.00**

NOTES No.5. OTHER NON-CURRENT ASSETS (NON-CURRENT-ASSETS) :

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1 **Security Deposits;**		
a Unsecured, considered good;	59.44	54.41
	59.44	**54.41**
2 **Other loans and advances:** Unsecured, considered good;		
a Income Tax Refund Receivable	-	-
b Mat Tax Credit	-	-
	-	-
TOTAL: LOANS	**59.44**	**54.41**

NOTES No.6. INVENTORIES :(CURRENT ASSETS)

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
- Raw Materials.	102.81	62.99
- Finished goods.	366.39	432.90
- Semi-finished goods.	21.19	23.77
- Packing Material.	30.14	30.61
- Fuel, Fire wood & lignite	16.75	60.31
TOTAL: INVENTORIES	**537.28**	**610.59**

- Raw material, Packing materials, fuel & Consumable are valued at cost on FIFO method. Cost includes purchase value, freight and duties & taxes.
- Finished goods and Semi finished goods are valued at lower of cost or net realisable value on FIFO method. Cost includes purchase value, freight, proportionate manufacturing expense, wages & salary to employees and duties & taxes.
- The quantity and value of the stock as taken & certifed by the directors of the company.

NOTES No.7. TRADE RECEIVABLES :(CURRENT ASSETS-FINANCIAL ASSETS)

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1 Trade Receivables Aging Schedule		
Particulars		
Outstanding for Less than 6 months		
Undisputed Trade receivables – considered good	1,190.99	1,643.65
Undisputed Trade Receivables – considered doubtful	-	-
Disputed Trade Receivables considered good	-	-
Disputed Trade Receivables considered doubtful	-	-
Outstanding for 6 months - 1 years		-
Undisputed Trade receivables – considered good	0.76	-
Undisputed Trade Receivables – considered doubtful	-	16.75
Disputed Trade Receivables considered good	-	-
Disputed Trade Receivables considered doubtful	-	-
Outstanding for 1 years - 2 years		-
Undisputed Trade receivables – considered good	-	-
Undisputed Trade Receivables – considered doubtful	-	-
Disputed Trade Receivables considered good	-	-
Disputed Trade Receivables considered doubtful	-	-
Outstanding for 2 years - 3 years		-
Undisputed Trade receivables – considered good	-	7.38
Undisputed Trade Receivables – considered doubtful	-	1.63
Disputed Trade Receivables considered good	-	-
Disputed Trade Receivables considered doubtful	-	-
Outstanding for More than 3 years		-
Undisputed Trade receivables – considered good	7.38	-
Undisputed Trade Receivables – considered doubtful	3.63	2.00
Disputed Trade Receivables considered good	-	-
Disputed Trade Receivables considered doubtful	-	-
TOTAL: TRADE RECEIVABLES	**1,202.77**	**1,671.41**

NOTES No.8.CASH AND CASH EQUIVALENTS:(CURRENT ASSETS-FINANCIAL ASSETS)

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Cash and cash equivalents:		
a Balances with banks;		
In current accounts	496.91	708.73
b Cash on hand	0.37	2.38
	497.27	711.11
c Deposits with Banks maturity more than 3 months but less than 12 months	3,687.02	2,046.61
TOTAL: CASH AND CASH EQUIVALENTS	**4,184.29**	**2,757.72**

NOTES No.9. LOANS (CURRENT ASSETS - FINANCIAL ASSETS) :

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Other loans		
Unsecured, considered good unless stated otherwise:		
a Loans to Employee	11.12	9.90
	11.12	9.90
TOTAL: LOANS	**11.12**	**9.90**

NOTES No.10. CURRENT TAX ASSETS (NET): (CURRENT ASSETS)

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
a Advance Payment of Taxes	474.76	424.36
TOTAL: CURRENT TAX ASSETS (NET)	**474.76**	**424.36**

NOTES No.11. OTHER CURRENT ASSETS: (CURRENT ASSETS)

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Other Current Assets:		
Unsecured, considered good unless stated otherwise:		
a Pre-paid Expense	-	3.29
b Balances with Govt. Authorities	-	-
c Other (Interest Receivable)	-	-
d Other (MEIS Receivable)	-	-
e Advance to suppliers of goods & services.	22.37	8.84
	22.37	**12.12**
TOTAL: OTHER CURRENT ASSETS	**22.37**	**12.12**

NOTES No.12. EQUITY SHARE CAPITAL :

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1 Authorised Shares:authorized;		
1,25,00,000 (Prev.Yr.1,25,00,000) Equity Shares of Rs.10/- each.	1,250.00	1,250.00
	1,250.00	1,250.00
2 Issued, subscribed and fully paid Shares		
1,23,04,636 (Prev.Yr 1,23,04,636) Equity Shares of Rs.10/- each Fully paid up	1,230.46	1,230.46
	1,230.46	1,230.46

3 Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period;

Equity Shares	AS AT 31.03.2026 No. of Shares	AS AT 31.03.2025 No. of Shares
At the beginning of the period	1,23,04,636	1,23,04,636
Issued during the period	-	-
Outstanding at the end of the period	1,23,04,636	1,23,04,636

4 Terms & Right attached to Equity Shares

Equity Shares: The company has only one class of equity shares having a par value of Rs.10/- each. Each shareholder is eligible for one vote per share held. The dividend if any proposed by the Board of Director is subject to approval of the shareholders in the ensuing Annual General Meeting except in case of interim dividend. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the company after distribution of all preferential amounts and payment of preference shareholders, in proportionate to their shareholding.

5 Reconciliation of share capital outstanding at the beginning and at the end of the reporting period;

a) Share Capital at the end of the year 31st March, 2026 **Rs in Lakhs**

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
1,230.46	-	1,230.46	-	1,230.46
(1,23,04,636 Equity Shares of Rs.10/- each Fully paid up)		(1,23,04,636 Equity Shares of Rs.10/- each Fully paid up)		(1,23,04,636 Equity Shares of Rs.10/- each Fully paid up)

b) Share Capital at the end of the year 31st March, 2025 **Rs in Lakhs**

Balance at the beginning of the previous reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the previous reporting period	Changes in equity share capital during the previous year	Balance at the end of the previous reporting period
1,230.46	-	1,230.46	-	1,230.46
(1,23,04,636 Equity Shares of Rs.10/- each Fully paid up)		(1,23,04,636 Equity Shares of Rs.10/- each Fully paid up)		(1,23,04,636 Equity Shares of Rs.10/- each Fully paid up)

6 Shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held

	AS AT 31.03.2026 No. & (%) of Shares Held	**AS AT 31.03.2025 No. & (%) of Shares Held**
a) Equity Shares, fully paid up:		
Jignesh Vallabhbhai Savani	2692440 (21.88%)	2692440 (21.88%)
Falgun Vallabhbhai Savani	2645952 (21.50%)	2645952 (21.50%)
Saritaben Vallabhbhai Savani	2525318 (20.52%)	2520318 (20.48%)
Ghanshyambhai B Savani	802284 (6.52%)	802284 (6.52%)

7 Shares in the company held by each promoter at the end of the year

Sr No	**Promoter Name**	**No. of Shares (%of Total Shares)**	**% Change During the Year**
1	Falgun Vallabhbhai Savani	2645952 (21.5%)	0.00%
2	Jignesh Vallabhbhai Savani	2692440 (21.88%)	0.00%
		5338392 (43.39%)	0.00%

NOTES No.13. OTHER EQUITY :

1) OTHER EQUITY FUNDS AS AT 31.03.2026

Rs in Lakhs

	Reserves and Surplus														
	Share application money pending allotment	Equity component of compound financial instruments	Capital Total Reserve	Securities Premium	General Reserve	Surplus/ (Deficit) in the statement of Profit & Loss	Retained Earnings	Debt instruments through Other Comprehensive Income	Equity Instruments through Other Comprehensive Income	Effective portion of Cash Flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of a foreign operation	Other items of Other Comprehensive Income(specify nature)	Money received against share warrants	Total
Balance at the beging of the current reporting period	-	-	6.86	1,067.26	3.50	7,589.41	-	-	-	-	-	-	-	-	8,667.03
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the current reporting period	-	-	6.86	1,067.26	3.50	7,589.41	-	-	-	-	-	-	-	-	8,667.03
Total Comprehensive Income for the current year															
Profit/(Loss) for the year	-	-	-	-	-	1,310.85	-	-	-	-	-	-	-	-	1,310.85
LESS :															
Interim Dividend to Equity Shareholders	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income-tax Adj. of earlier year	-	-	-	-	-	-9.88	-	-	-	-	-	-	-	-	-9.88
Issue of Bonus Shares	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Any other change (to be specified)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance at the end of the current reporting period	-	-	6.86	1,067.26	3.50	8,890.38	-	-	-	-	-	-	-	-	9,968.00

2) Other Equity Fund as on AS AT 31.3.2025

	Reserves and Surplus														
	Share application money pending allotment	Equity component of compound financial instruments	Capital Total Reserve	Securities Premium	General Reserve	Surplus/ (Deficit) in the statement of Profit & Loss	Retained Earnings	Debt instruments through Other Comprehensive Income	Equity Instruments through Other Comprehensive Income	Effective portion of Cash Flow Hedges	Revaluation Surplus	Exchange differences on translating the financial statements of a foreign operation	Other items of Other Comprehensive Income(specify nature)	Money received against share warrants	Total
Balance at the beging of the current reporting period	-	-	6.86	1,067.26	3.50	6,255.12	-	-	-	-	-	-	-	-	7,332.74
Changes in accounting policy or prior period errors	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restated balance at the beginning of the current reporting period	-	-	6.86	1,067.26	3.50	6,255.12	-	-	-	-	-	-	-	-	7,332.74
Total Comprehensive Income for the current year															
Profit/(Loss) for the year	-	-	-	-	-	1,335.79	-	-	-	-	-	-	-	-	1,335.79
LESS :															
Interim Dividend to Equity Shareholders	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transfer to retained earnings	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income-tax Adj. of earlier year	-	-	-	-	-	-1.50	-	-	-	-	-	-	-	-	-1.50
Issue of Bonus Shares	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Any other change (to be specified)	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Balance at the end of the current reporting period	-	-	6.86	1,067.26	3.50	7,589.41	-	-	-	-	-	-	-	-	8,667.03

NOTES No.14. PROVISIONS (NON-CURRENT - LIABILITIES) :

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1 Provision for employee benefits		
Provision for Gratuity	24.01	26.66
TOTAL: PROVISIONS	**24.01**	**26.66**

NOTES No.15. DEFERRED TAX LIBILITIES (NET) :

	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Deferred Tax Liabilities		
1 Fixed Assets: Impact of difference between Book and Tax Depreciation	326.00	345.00
2 Notional Gain on Mutual Fund	6.00	15.00
Gross Deferred Tax Liabilities	**332.00**	**360.00**
Deferred Tax Assets		
1 C/f. Business & Dep. Loss as per Income-tax	-	-
1 Provision for Gratuity.	7.60	2.00
Gross Deferred Tax Assets	**7.60**	**2.00**
TOTAL: DEFERRED TAX LIBILITIES (NET)	**324.40**	**358.00**

In accordance with accounting standard 22, Accounting for taxes on Income, issued by the Institute of Chartered Accountants India, the Deferred Tax Assets (net of Liabilities) is provided in the books of account as at the end of the year using the rate of taxes that have been enacted.

NOTES No.16. TRADE PAYABLES:- (CURRENT LIABILITIES - FINANCIAL LIABILITIES) :

Trade Payable Aging Schedule	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Particulars		
Outstanding for Less than 1 year		
Undisputed Dues of MSME	80.06	34.49
Undisputed Dues of Others	739.33	1,013.73
Disputed Dues of MSME	-	-
Disputed Dues of Others	-	-
Outstanding for 1 years - 2 years		
Undisputed Dues of MSME	-	-
Undisputed Dues of Others		-
Disputed Dues of MSME	-	-
Disputed Dues of Others	-	-
Outstanding for 2 years - 3 years		
Undisputed Dues of MSME	-	-
Undisputed Dues of Others	-	40.60
Disputed Dues of MSME	-	-
Disputed Dues of Others	-	-
Outstanding for More than 3 years		
Undisputed Dues of MSME	-	-
Undisputed Dues of Others	-	0.32
Disputed Dues of MSME	-	-
Disputed Dues of Others	-	-
TOTAL: TRADE PAYABLES:-	**819.40**	**1,089.14**

NOTES No.17. OTHER CURRENT LIABILITIES :

		AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1	Current maturities of long-term debt	-	-
2	Income received in advance/Advance from Customers	53.58	52.25
3	Unpaid dividends	0.21	0.21
4	Other Payables:		
	Statutory liabilities	5.54	23.47
	Provision for Expense	5.24	4.66
	Remuneration Payable to Director	8.78	7.44
	Salary & Wages Payable	22.56	21.72
		42.11	57.29
TOTAL: OTHER CURRENT LIABILITIES		**95.90**	**109.75**

NOTES No.18. PROVISIONS (CURRENT LIABILITIES) :

		AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
1	Provision for employee benefits		
	Provision for Gratuity	6.17	5.47
		6.17	**5.47**
2	Others:		
	Provision for Taxation.	452.90	452.50
	Proposed Dividend to Equity Shareholders.	-	-
		452.90	**452.50**
	TOTAL: PROVISIONS	**459.07**	**457.97**

NOTES No.19. REVENUE FROM OPERATIONS :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Sales of Products		
Finished Goods Sold during the year:	10,279.85	10,054.60
GST Recovered.	1,262.82	1,241.60
	11,542.67	**11,296.20**
Other Operating Revenue		
Job & Other Work Income.(Bhavnagar)	-	-
Discount, Kasar & Rebate	0.00	-0.00
Duty Drawback & Export License Sale Income	26.31	23.34
Exchange Rate Difference	59.40	19.40
Misc. Income	-	-
	85.71	**42.74**
Revenue From operations (Gross)	**11,628.38**	**11,338.95**
Less : GST	1,262.82	1,241.60
TOTAL: REVENUE FROM OPERATIONS	**10,365.56**	**10,097.35**
FOB Value of Exports	2,804.93	2,531.67

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Details of Sales of Products:		
Magnesium Hydroxide	2,795.95	2,652.66
Alluminium Hydroxide	2,317.64	1,775.88
Sucralfate	-0.67	446.91
Precipitated Silica	3,508.14	3,282.34
Magnesium Trisilicate	370.63	421.10
Magaldrate	435.43	642.44
Magnesium Oxide	186.43	191.61
Allusil (Sodium All. Silicate)	26.55	9.51
Magnesium Alluminium Silicate	465.93	434.43
Magnesium Carbonate	127.56	130.18
Almagate	-	-
Freight	-	-
Others	46.25	67.54
Total	**10,279.85**	**10,054.60**

NOTES No.20. OTHER INCOME :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Interest Income	183.83	104.77
Other non-operating income:		
Insurnace & Other Claim Income	-	-
Dividend Income	8.54	3.32
Donation W/Back Income	-	-
CSR Activity Fund W/Back	-	-
Bad Debt W/Back Income	0.71	0.89
Gain on Investments	206.44	106.05
Profit on Sale of Assets	0.56	-
	216.24	110.27
TOTAL: OTHER INCOME	**400.07**	**215.03**

NOTES No.21. COST OF MATERIALS CONSUMED :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Raw Materials Consumed		
Inventory at the beginning of the year	62.99	38.17
Add: Purchases	4,306.87	3,965.69
	4,369.86	4,003.86
Less: Inventory at the end of the year	-102.81	-62.99
TOTAL:	**4,267.05**	**3,940.86**

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Details of Raw Materials Consumed:		
Sodium Silicate	1,514.97	1,446.89
Caustic Soda Lye	988.06	944.39
Soda Ash	463.15	430.44
Magnesium Oxide (Light)	138.99	164.02
Lime	24.54	52.58
Sulphuric Acid	463.00	234.24
Alluminium Chloride	572.29	507.59
Magnesium Hydroxide (light)	7.41	18.84
Bitern	42.95	42.54
Alluminium Sulphate	9.06	4.75
Magnesium Carbonate (Light)	37.85	69.66
Other Materials including Freight	4.79	24.93
Total	**4,267.05**	**3,940.86**
Value of Raw materials consumed in Percentage:		
Imported	0.17%	0.48%
Indigenous	99.83%	99.52%

NOTES No.22. CHANGES IN INVENTORIES OF FINISHED GOODS, STOCK-IN-TRADE AND WORK-IN-PROGRESS :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Inventories at the end of the year		
Bhavnagar Unit:		
Finished Good	366.39	432.90
Semi-Finished Good	21.19	23.77
	387.58	**456.68**
Inventories at the beginning of the year		
Bhavnagar Unit:		
Finished Good	432.90	309.04
Semi-Finished Good	23.77	19.81
	456.68	**328.85**
TOTAL CHANGE (Net)	**69.09**	**-127.83**

NOTES No.23. EMPLOYEE BENEFITS EXPENSE :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Salaries, Wages & Bonus	546.11	518.23
Contribution to Funds	32.73	31.71
Gratuity Expense	14.59	26.78
Staff welfare expenses	18.59	8.46
TOTAL: EMPLOYEE BENEFITS EXPENSE	**612.01**	**585.18**
Salaries, Wages & bonus includes:		
Remuneration to the Managing Directors & other Whole time Directors:	127.00	167.70

As per Ind AS 19 "Employee benefits", the disclosure defined in the accounting standard are given as below:

During the year salary structure of the employee has been revised and terminal benefits of few employees are also reduced, due to which acturial gain incurred and provision for gratuity has been revised accordingly

Defined Contribution Plan: Contribution paid to the plan recognized as expense for the year as under

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Employer's Contribution to Provident Fund	26.57	25.60
Contribution to Employees Linked Funds	-	-
Re-imb.of Contribution to PF & ESI of Contractors	6.16	6.11

Defined Benefit Plan: The present value of obligation is determined based on actuarial valuation which recognizes each period of service as giving rise to additional unit of employee benefit entitlement and measures, each unit separately to build up the final obligation. Based on it, the contribution has been paid to the plan recognized as expense for the year as under.

Provision for Gratuity	14.59	26.78

NOTES No.24. FINANCE COSTS :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Interest on Long term borrowings to Banks	-	-
Interest on Short term borrowings to Banks	-	-
Interest on Unsecured loans	-	-
Bank charges & Processing Fees	12.73	8.21
TOTAL: FINANCE COSTS	**12.73**	**8.21**
Expenditure in Foreign Exchange		
Bank charges	0.07	-

NOTES No.25. DEPRECIATION AND AMORTIZATION EXPENSE :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Depreciation/Amortization of tangible assets	370.33	364.66
Total Depreciation And Amortization Expense	**370.33**	**364.66**

NOTES No.26. OTHER EXPENSES :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Manufacturing expenses.		
Bhavnagar Unit:		
Freight Octroi & Transportation.	418.35	415.03
Fuel & Fire wood.	1,329.99	1,350.61
Laboratory Expenses.	6.40	18.19
Machinery Repairs & Maintanance.	114.89	105.71
Motive Power.	330.49	356.66
Packing material consumed.	215.05	216.36
Stores & Spares	1.35	0.99
Water, Dranage & Development Charges.	205.03	241.44
Testing Expense	13.98	12.73
Factory Expense.	266.16	246.86
	2,901.70	**2,964.59**
Administrative expenses.		
Bhavnagar Unit:		
Auditor's Remuneration	4.40	4.40
Bad Debts	0.01	0.75
Charity & Donation	0.78	3.49
Communication Expense	4.03	7.07
Director Sitting Fees	3.30	4.95
Insurance Premium	27.85	26.71
Legal & Professional Fees	67.19	72.27
Other Administrative Expenses	44.04	25.36
Rent, Rates & Taxes	30.24	40.36
Sales & Distribution Expenses	568.15	542.95
Vehicle Running & Maint.	14.79	15.03
CSR Activity Fund	35.07	32.00
Traveling & Conveyance Expense	2.72	9.08
	802.56	**784.42**
TOTAL: OTHER EXPENSES	**3,704.26**	**3,749.01**
Payment to auditor includes		
Statutory Audit Fees	2.60	2.60
Other Fees	-	-
Internal Auditor's Fees	1.80	1.80
Expenditure in Foreign Exchange		
Commission Expenses	312.00	384.75
(Included in Sales & Distribution Expenses)		
Value of Stores & Spares Consumed in Percentage		
Imported	0.00%	0.00%
Indigenous	100.00%	100.00%

NOTES No.27. EARNINGS PER EQUITY SHARE (FOR DISCONTINUED & CONTINUING OPERATION) :

	2025-2026 Rs in Lakhs	2024-2025 Rs in Lakhs
Total operations for the year		
Profit/(loss) after tax	1,310.85	1,335.79
Less: Dividends on convertible preference share & tax thereon	-	-
Net profit/(loss) available for equity shareholders	1,310.85	1,335.79
Weighted average number of equity shares in calculating basic EPS	1,23,04,636	1,23,04,636
Weighted average number of equity shares in calculating diluted EPS	1,23,04,636	1,23,04,636
Earning Per Share:		
(1) Basic	10.65	10.86
(2) Diluted	10.65	10.86

NOTES No.28. CONTINGENT LIABILITIES :

Contingent liabilities in respect of:		
1 Claims against the company not acknowledged as debts	-	-
2 Bank Gaurantee issued by bank		-
Kotak Mahindra Bank	10.06	10.06
3 Bills discounted from bank	-	-
4 Letter of credit outstanding	-	-

NOTES NO.29:

29.1 In the opinion of the Board of Directors, the current assets, loans and advances are approximately of the same value if realised in the ordinary courses of business and the provision for all known liabilities is adequately made and not in excess of the amount reasonably consider necessary.

29.2 The figures and groupings of the previous year are re-grouped/reclassified whenever necessary so as to make them comparable with the current year.

29.3 The Company is primarily engaged in manufacturing of API, which constitute single business segment in terms of Ind AS - 108 on "Operating Segments". Accordingly, there are no separate reportable segments as per Ind AS - 108.

29.4 No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries).

29.5 The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

29.6 Paise have been round off to the nearest rupee amount.

NOTES NO.30: RELATED PARTY DISCLOSURES :

Disclosure of Transactions with related parties as required under Ind AS 24 on Related Party Disclosures are given below :

A) The related parties where common control exists :

i) Key Managerial Personnel :

Falgunbhai V Savani	Managing Director
Jignesh V Savani	CEO
Sanket Bhupendrabhai Trivedi	Company Secretary
Chintan Pratapbhai Chauhan	Chief Financial Officer

ii) Relatives of Key Managerial Personnel

Falgunbhai V Savani HUF	HUF of Managing Director
Jignesh V Savani HUF	HUF of CEO

iii) Non-Executive & Independent Directors

Kajal Chitanbhai Vaghani	Independent Director
Krishna Mitulbhai Shah	Independent Director
Pravin Manjibhai Bhayani	Independent Director
Bintal Bhaveshkumar Shah	Independent Director

B) The following transactions were carried out with related parties in the ordinary course of business :

i) Transactions with Key Managerial Personnel :

Name	Nature Of Transcation	AS AT 31.03.2026	AS AT 31.03.2025
		Rs in Lakhs	Rs in Lakhs
Falgunbhai V Savani	Director's Remuneration	51.50	51.50
	Director Sitting Fees	0.50	0.70
	Re-imbursement of Exp.	-	-
	Closing balance-Salary	3.04	2.97
Jignesh V Savani	Director's Remuneration	51.50	51.50
	Director Sitting Fees	0.30	0.40
	Re-imbursement of Exp.	-	-
	Closing balance-Salary a/c	3.19	3.15
Sanket Bhupendrabhai Trivedi	Salary	8.23	7.29
	Closing balance-Salary	0.56	0.52
Chintan Pratapbhai Chauhan	Salary	7.65	6.77
	Closing balance-Salary	0.53	0.48

ii) Transactions with Relatives of key Managerial Personnel during the period:

Name	Nature Of Transcation	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Nil	Nil	Nil	Nil

iv) Transactions with Non-Executive & Independent Directors during the period:

Name	Nature Of Transcation	AS AT 31.03.2026 Rs in Lakhs	AS AT 31.03.2025 Rs in Lakhs
Naynaben J Savani	Director Sitting Fees	-	0.45
Kajal Chitanbhai Vaghani	Director Sitting Fees	0.55	0.65
Krishna Mitulbhai Shah	Director Sitting Fees	0.75	1.00
Pravin Manjibhai Bhayani	Director Sitting Fees	0.75	1.00
	Director's Remuneration	24.00	24.00
Bintal Bhaveshkumar Shah	Director Sitting Fees	0.45	0.45

NOTES NO.31: GOING CONCERN ASSESSMENT :

During the previous financial year, the Board of Directors approved the transfer of the Company's principal business undertaking through a slump sale, along with a strategic plan to diversify into new business segments. As disclosed in earlier periods, the proposed slump sale was expected to provide financial resources for the Company's future operations and strategic initiatives.

During the current financial year, the implementation of the proposed slump sale has been delayed due to regulatory proceedings initiated by the Securities and Exchange Board of India (SEBI). Accordingly, the proposed transaction has not been completed as of the date of approval of these financial statements. The Company is taking appropriate steps in connection with the regulatory proceedings and continues to monitor developments relating to the proposed transaction.

The management has evaluated the impact of the pending regulatory proceedings and the delay in implementation of the proposed restructuring on the Company's financial position and future operations. This assessment included consideration of the Company's current liquidity position, available financial resources, expected cash flows, existing obligations, and alternative business plans.

Based on the above assessment, management believes that the Company has adequate resources to continue its operations and to meet its liabilities as and when they fall due for a period of at least twelve months from the date of approval of these financial statements. Accordingly, these financial statements have been prepared on a going concern basis.

Management will continue to monitor the progress of the regulatory proceedings and evaluate their impact on the Company's operations, financial position, and strategic plans. Any material developments will be appropriately considered and disclosed in future financial reporting periods.

NOTES NO.32: SIGNIFICANT RATIO :

Ratio	2025-26	2024-25	% Change in Ratio
Current Ratio [See Note-1]	4.68	3.31	41.35%
Debt-Equity Ratio	-	-	0.00%
Debt Service Coverage Ratio	-	-	0.00%
Return on Equity Ratio (%) (Before Tax)	15.45%	18.11%	-14.68%
Inventory turnover ratio	19.29	16.54	16.66%
Trade Receivables Turnover Ratio [See Note-2]	0.12	0.17	-29.90%
Trade Payables Turnover Ratio [See Note-3]	0.08	0.11	-26.71%
Net Capital Turnover Ratio	2.05	2.64	-22.29%
Net Profit Ratio (%) (Before Tax)	16.69%	17.75%	-5.96%
Return on Capital Employed	0.15	0.17	-14.04%
Return on Investment (%)	11.71%	13.50%	-13.27%

1 Due to increase in cash and cash equivalents and reduction in Current Liability, Current Ratio has been increased.

2 The outstanding trade receivables as at the year-end have reduced substantially compared to the previous year, indicating effective collection efforts.

3 The Company continued to make timely payments to its suppliers, resulting in a reduction in outstanding trade payables at the year-end.

NOTES NO.33: CORPORATE SOCIAL RESPONSIBILY (CSR) ACTIVITIES:

Particulars	Rs in Lakhs
Amount required to be spent by the company during the year	35.01
Amount of expenditure incurred	35.06
Shortfall at the end of the year, if any	-
Excess expenditure incurred, if any	0.05
Total of previous years shortfall	-
Nature of CSR activities :-	

CSR Project: 1

Name of Project: “PRAGATI PATH”

Focus Area: Promoting education among rural students and livelihood enhancement project.

Project Location: Late Ramajibhai Monabhai Monpara: Kumar Chhatralay, Survey no. 279/4 paiki 1 Near Samaras Hostel, University area, Bhavnagar-364001, Gujarat, India.

Implementing Agency: GOHILWAD LEAUVA PATIDAR KELAVANI MANDAL (Erstwhile GOHILWAD LEAUVA PATEL KELAVANI MANDAL)

Project Cost: Rs. 20 Lacs

Objectives: Construction of 3 hostel room of Rs. 15.5 Lacs and Other structure for room Rs. 4.5 Lacs only

Particulars	Rs in Lakhs
CSR Project: 2 "SWARGA SPARSH" with SOCIETY FOR RESEARCH AND INITIATIVES FOR SUSTAINABLE TECHNOLOGIES AND INSTITUTIONS, (SRISTI) The CSR fund utilized in the Manufacturing and commissioning of SWARGAROHAN Climate-Friendly Cremation System including Supply, Transportation and Installation Total CSR Funding: Rs. 8.56 Lacs	
CSR Project: 3 Name of Project: "GAU SNEH" with SHREE SARVESHWAR GAU DHAM TRUST KOBDI The CSR fund utilized for Cow Feeds and Medical Care of Cows. The adequate nutrition will significantly enhance the health and quality of life of the cows. Elderly and disabled cows will be benefited from a tailored diet that addresses their unique need. 1. Purchase of Cow Feeds Rs. 5.55 Lacs 2. Medical Care of Cows Rs. 0.96 Lacs Total CSR Funding: Rs. 6.51 Lacs	
No any contribution made to a trust controlled by the company in relation to CSR expenditure	

As per our report of even dated.

For, Sarupria Somani & Associates
Firm Regn. No.010674C
Chartered Accountants

Sd/-
Miral Mehta (Partner)
M.No.145361
UDIN -

Bhavnagar, 14th May, 2026

For and on behalf of Board of Directors of
Par Drugs and Chemicals Limited

Sd/-
Mr. Falgun V. Savani
(Chairman & Managing Director)
(DIN - 00198236)

Sd/-
Mr. Jigneshbhai V. Savani
Director & CEO
(DIN - 00198203)

Sd/-
Chintan P Chauhan
(CFO)

Sd/-
Sanket B Trivedi (CS)
(M.No.- F13800)

Bhavnagar, 14th May, 2026

DRUGS AND CHEMICALS LIMITED

Corporate Office

816, Nilamber Triumph,
Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991022

Registered Office

815, Nilamber Triumph,
Gotri Vasna Road,
Vadodara-390007, Gujarat, India
Phone no.: 0265-2991021

Factory Unit

333/1, GIDC, Estate.
Phase-II, Chitra,
Bhavnagar - 364004. Gujarat, India.
+91 - 278 - 244 6342